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Abstract 
 
The thesis involves targeting bacterial and fungal proteins to cure, or prevent life-threatening 
microbial infections. Streptococcus pneumoniae is a leading etiological agent in septicemia, 
pneumonia, bacteraemia, meningitis, otitis media and conjunctivitis. β-lactam antibiotics and 
conjugate vaccines are the mainstay of treating or preventing pneumococcal infections. However, 
there has been a rapid emergence of multi-drug resistant strains in pneumococci in the past two 
decades, which are increasingly untreatable with the existing last line of antibiotics. Therefore, there 
is as urgent need to look for alternative strategies. Targeting pneumococcal virulence factors could 
potentially be one effective strategy to combat S. pneumoniae.  
One such factor is the pneumococcal surface antigen A (PsaA), which is a substrate-binding protein 
(SBP) that functions as a virulence factor, as well as a high-affinity Mn2+-binding protein, 
facilitating acquisition of Mn2+ and transporting it across the bacterial cell membrane. Mn2+ has an 
important role in protecting S. pneumoniae from reactive oxygen species, and hence against 
oxidative stress. Consequently, PsaA is essential for bacterial survival and an important virulence 
factor, which renders it a promising target for antibiotic drug development. Prior to designing novel 
inhibitors targeting PsaA, molecular dynamics simulations were performed to understand the 
conformational flexibility of PsaA and to investigate the molecular movements not captured by the 
static crystal structures of apo- (open state) and metal-bound (closed state) PsaA. These studies 
supported the observations of crystal structures and indicated that the C-terminal domain of PsaA 
undergoes an extensive hinge-bending motion in the apo- (open state) PsaA compared to the metal-
bound (closed state) PsaA, while the N-terminal domain remains nearly static in both open and 
closed states of PsaA. Apart from the conformational flexibility studies of PsaA, novel fragment-
like small molecule inhibitors targeting PsaA were also determined using virtual screening and 
conventional fragment-based drug design approaches. This gave two potent and ligand-efficient 
hits, 15h and 58f, which could potentially be pursued further for hit-to-lead development. 
 
Another major human pathogen is Cryptococcus neoformans, a yeast that can cause fungal 
meningitis and encephalitis in immune compromised humans, especially as secondary infection in 
AIDS patients. It is responsible for an estimated 700,000 deaths from cryptococcal meningitis each 
year. The purine metabolic pathway of C. neoformans has been extensively studied as a potential 
therapeutic target, as it is responsible for the biosynthesis of guanosine triphosphate (GTP) and is 
thereby essential for cell survival and replication. Inosine monophosphate dehydrogenase (IMPDH) 
is a key enzyme in this pathway, involved in the first steps of the GTP biosynthesis and therefore, 
an ideal therapeutic drug target to control C. neoformans persistence. Key differences between 
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fungal and human IMPDH’s have been identified by molecular dynamic simulations, which can 
assist the design and optimisation of fungal-specific IMPDH inhibitors. A high-throughput screen 
(HTS) has identified two hit compounds, MCC_005985 and MCC_006189, with activity against C. 
neoformans IMPDH. In silico structure-activity relationship (SAR) studies have been performed 
with the two hit structures giving valuable information for further optimisation of the hit 
compounds and their optimisation into lead compounds. 
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1.1.   Bacterial and fungal infections 
Microbial infections, such as bacterial and fungal infections, are one of the leading causes of 
morbidity and mortality worldwide, especially for children and elderly population. Bacterial 
infections can be caused by a wide range of bacteria, resulting in mild to life-threatening conditions, 
like bacterial meningitis which requires immediate intervention (1, 2). More importantly, 
hospitalised patients and patients with chronic diseases and compromised immune systems are 
especially at high risk of bacterial infections (3, 4). Some of the most life-threatening bacterial 
infections include upper and lower respiratory tract infections and otitis media, majorly caused by 
Streptococcus pneumoniae, tuberculosis caused by Mycobacterium tuberculosis and gastrointestinal 
infections caused by Campylobacter, Salmonella, Shigella and Helicobacter species (5). Due to its 
high prevalence in both developed and developing world, and rapid emergence of its multi-drug 
resistant strains, Streptococcus pneumoniae is the bacterial pathogen which has garnered lot of 
scientific interest worldwide (5-8). 
Fungal infections, also known as mycoses, have a mortality rate comparable to some of the severe 
bacterial infections such as pneumonia and tuberculosis (9). Furthermore, the prevalence of the 
systemic mycoses is raising with the increased usage of immunosuppressant therapies and incidence 
of HIV/AIDS patients (10). The most commonly infecting fungal pathogens include Candida 
albicans, Apergillus fumigatus and Cryptococcus neoformans. All of these are the leading causative 
agents of life-threatening systemic infections, with Cryptococcus neoformans the most prevalent, 
casuing fungal meningoencephalitis (9).  
 
1.2.   Streptococcus pneumoniae 
Streptococcus pneumoniae, also known as pneumococcus, was first isolated in 1881 by Louis 
Pasteur from the saliva of a patient with rabies and since then, it has been one of the most 
extensively studied microorganisms (11, 12). It is one of the leading causes of morbidity and 
mortality worldwide, reportedly causing more than 1 million deaths per year (7, 13-15). 
Pneumococcal septicaemia caused by S. pneumoniae, is the major cause of infant mortality 
worldwide, especially in the developing countries (13, 14, 16-18). Pneumococcus resides 
asymptomatically in the nasopharynx of healthy individuals, however, if it gains access to the sterile 
parts of the respiratory tract a rapid inflammatory response ensues, which further causes both 
localised and systemic diseases such as pneumonia, bacteraemia, meningitis, otitis media and 
conjunctivitis (7, 19-21). The most common mode of pneumococcus transmission is person-to-
person contact, which involves direct contact with the secretions of infected individuals (7, 19, 20).  
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S. pneumoniae is a Gram-positive bacterium that grows in pairs or short chains. It has three major 
surface layers, which are plasma membrane, cell wall and capsule (22, 23). Of the three, capsule is 
the thickest layer concealing the inner structures as it consists of high-molecular weight 
oligosaccharides (22, 23). The cell wall is mainly composed of peptidoglycan, which is glycan 
chains of alternating N-acetylglucosamine and N-acetylmuramic acid residues, cross-linked to each 
other through peptide side-chains (23-25).   
 
1.2.1. Current treatment and limitations 
β-lactam antibiotics are currently the mainstay of treating life-threatening pneumococcal infection 
(26-28). It is a broad class of antibiotics which consists of the antibiotic agents containing a β-
lactam ring in their molecular structure, such as penicillin, cephalosporin, carbapenem and 
monobactam (26-28). Their mode of action involves inhibiting cell wall biosynthesis in the 
pneumococcus and therefore, is bactericidal in nature (26, 28). In addition to the available antibiotic 
treatment, pneumococcal infection has also been controlled by using available vaccines. There are 
three types of pneumococcal vaccines: (a) 23-valent pneumococcal polysaccharide vaccine 
(PPV23), which is used in adults and immunocompromised children over two years. It contains 
attenuated portions of polysaccharides from 23 serotypes of pneumococcus. (b) 10-valent conjugate 
vaccine (PCV10), which targets 10 pneumococcal serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 
23F), and, (c) 13-valent conjugate vaccine (PCV13), which targets 13 pneumococcal serotypes (the 
PCV10 types plus 3, 6A and 19A) (29-35). The PCV vaccines contain polysaccharides conjugated 
to a protein which is easily recognisable by the naïve immune system of infants and young children 
and is used as well for children under the age of two (11, 35-37). 
Despite the availability of different treatment options to control and cure pneumococcal infections, 
S. pneumoniae continues to remain leading cause of mortality worldwide, with major burden of this 
mortality being shared by the youngest (<5years of age) and the oldest (>60 years of age) segments 
of the population (7, 13, 14). This is due to the rapid emergence of multi-drug resistant (MDR) 
strains of S.pneumoniae within the last two decades, and becoming increasingly unresponsive to 
existing last line antibiotics (11, 38-40). In addition, the current polysaccharide and conjugate 
vaccines provide protection only against up to 23 of the 91 serotypes of S. pneumoniae, highlighting 
the lack of a universal pneumococcal vaccine (7, 11, 37, 41). All these shortcomings have 
highlighted the need to identify new approaches that can combat pneumococcal infections.  
The bactericidal nature of the existing antibiotics puts immense evolutionary pressure on the 
pneumococcus bacterium, and hence is a crucial factor contributing to the rapid emergence of the 
MDR strains (20, 38, 40). Targeting pneumococcal virulence factors is one strategy which puts 
  Chapter 1 
   
4 
 
milder evolutionary pressure on pneumococcus, as they are not essential for the viability of the 
bacteria, but are crucial for establishing and maintaining an infection in host (11, 19, 20). Therefore, 
targeting pneumococcal virulence factors would control the infection and potentially reduce the 
incidence of the resistant strains. 
 
1.2.2.  Virulence factors 
Pneumococcal virulence factors are involved in establishing the infection in the host cells and 
hence, the pathogenicity of pneumococci is attributed to various structures, most of which are found 
on its surface. The capsule, which forms the pneumococcus cell surface, has long been recognised 
as a major virulence factor. It plays a crucial role by reducing the entrapment of pneumococcal cells 
in upper respiratory tract mucous secretions and helping them access the epithelial surfaces (11, 19, 
42). Once at the epithelial surface, another virulence factor comes into play, which is ChoP 
(phosphorylcholine). This factor mediates pneumococcal adherence to the receptor of platelet-
activating factor (rPAF) and helps the bacteria to establish infection in the nasopharyngeal epithelial 
cells (19, 43, 44). Similarly, CbpA (choline-binding protein A), another adhesin, aids the 
attachment of pneumococcal cells to the host epithelial cells (44). The surface-associated 
exoglycosidases, such as NanA (a neuraminidase), BgaA (β-galactosidase) and StrH (a β-N-
acetylglucosaminidase), are another type of virulence factors which are involved in cleaving 
terminal sugars from human glycoconjugates, thereby unmasking receptors for adherence (45). 
Other pneumococcal virulence factors of importance are: Hyaluronidase (Hyl), which ruptures the 
hylaronan-containing extracellular matrix component in the host tissues and helps the bacterial 
spread; Pneumococcal adhesion and virulence A (PavA), which binds to extracellular matrix 
component fibronectin and; Enolase, which binds to extracellular matrix component plasminogen 
(46-49). In addition to the adhesins, Pneumolysin, a cytolytic toxin, also forms an important 
virulence factor for pneumococci. It is released upon the lysis of the pneumococcus cell and forms 
oligomers of the mammalian cells surface, giving rise to transmembrane pores and finally host cell 
lysis (Figure 1.2.2) (50-52). 
Apart from the previously listed factors, substrate-binding proteins (SBPs) have lately been 
considered as another class of pneumococcus virulence factors as they have been shown to be 
essential for pneumococcal virulence (53). 
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Figure 1.2.2: Pictorial representation of virulence factors found in S.pneumoniae.  
 
1.2.3.  Substrate binding proteins (SBPs) as virulence factors 
Some of the prokaryotic SBPs are essential for the colonisation and pathogenesis of pneumococcus 
as their absence or loss has been found to attenuate the virulence of S. pneumoniae (54-56). In 
addition to this, SBPs are integral components of ATP-binding cassette (ABC) transporter complex, 
also known as ABC permease, which is involved in the transport of essential substrates and metal 
ions across the bacterial cell membrane (57, 58). In Gram-positive bacteria such as S. pneumoniae, 
the SBPs are attached to the microbe’s cell wall by an N-terminal lipid moiety, whereas in Gram-
negative bacteria, SBPs are found in the periplasmic space (59-61).  
 
The SBPs are classified into 6 different clusters (A-F) based on their structural similarity (62). They 
are: 
Cluster A- This cluster includes SBPs mainly involved in metal binding. The SBPs in this cluster 
have a distinguished α-helix which serves as a hinge between the two domains and ensures an 
overall rigid structure of the protein. This cluster is further subdivided into two sub-clusters, A-I 
and A-II, based on the cognate substrate involved. The cluster A-I SBPs bind to the metal ions such 
as Zn2+, Mn2+ or Fe2+ via direct interactions with the metal ions, whereas, cluster A-II SBPs bind to 
chelated metals by siderophores such as eneterobactin, catecholate and hydroxamate (Table 1.2.3.1, 
Figure 1.2.3, panel A) (62). 
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Cluster B- This cluster includes SBPs binding mainly to carbohydrates, amino acids and natriuretic 
peptides. Structurally, these SBPs have three hinges between two domains and with N- and C-
terminal found within the same domain (Table 1.2.3.1, Figure 1.2.3, panel B) (62). 
 
Cluster C- The SBP-C bind to different ligands such as di- and oligo peptides, arginine, nickel ions 
and cellobiose. They also are larger in size and have an extra domain compared to other SBPs 
(Table 1.2.3.1, Figure 1.2.3, panel C) (62). 
 
Cluster D- This cluster consists of SBPs which bind to a variety of substrates such as 
carbohydrates, thiamine, oxyanion and ferric or ferrous iron. They have a distinguishing hinge 
region which consists of two short strands, 4-5 amino acids long (Table 1.2.3.1, Figure 1.2.3, panel 
D) (62). 
 
Cluster E- The SBP-E belong to TRAP (tripartite ATP-independent periplasmic) transporter family 
and they use an electrochemical gradient to fuel the uphill translocation of substrates. The 
characteristic feature of this cluster is that all SBPs have a large single β-strand and a long helix, 
both of which form an integral component of the structural stability (Table 1.2.3.1, Figure 1.2.3, 
panel E) (62). 
 
Cluster F- The SBP-F bind a wide variety of substrates such as trigonal planar anions, amino acids 
and glycine betaine. They have a characteristic hinge in their structure, which contains two 
segments connecting the two domains. These two longer segments impart flexibility to the open and 
closed conformations of the Cluster F SBPs (Table 1.2.3.1, Figure 1.2.3, panel F) (62). 
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Table 1.2.3.1: Overview of the prokaryotic substrate binding proteins (SBPs) associated with the membrane protein complexes (Reproduced with permission from Elsevier) (62). 
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Table 1.2.3.1: (continued). 
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Table 1.2.3.1: (continued). 
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Figure 1.2.3: Schematic representation of SBP-membrane protein complexes showing different SBP clusters. (A) 
ABC- transporter complex with a lipid-anchored SBP (in Gram-positive bacteria) or periplasmic SBP (in Gram-
negative bacteria. The nucleotide–binding domains help transport substrate across the membrane via ATP hydrolysis. 
(B) SBP is fused to the transmembrane domain (TMD) of ABC-transporter, yielding two SBDs per transporter 
complex. (C) Cluster E includes TRAP transporter that can either have lipid-anchored or periplasmic SBP. (D) 
Guanylate cyclase-atrial natriuretic peptide receptor is a dimeric structure with a SBD, a single transmembrane helix 
and an intracellular domain (ICD). (E) Ligand-gated ion channel, with ATD domains at the top and involved in 
oligomerisation of the protein. (F) Cluster F includes GPCRs with a cytoplasmic domain. (Reproduced with permission 
from Elsevier) (62) 
 
In case of S. pneumoniae, PsaA and AdcA, two SBPs from the A-I subcluster are involved in 
crucial metal-binding processes (62, 63). They capture Mn2+ and Zn2+ ions and transport them 
across the bacterial cell membrane using the ABC transporter complex (63, 64). These metal ions 
are crucial for the pneumococcus survival as they protect it from the oxidative stress (63, 64) and 
thereby the virulence or severity of the pneumococcal infection. This work focuses on PsaA, 
investigating the potential to inhibit its function and understanding its conformational flexibility. 
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1.2.4.  Targeting Pneumococcal surface antigen A (PsaA)  
PsaA is a surface exposed lipoprotein, which is expressed in all known pneumococcal serotypes 
(65, 66). The protein has been found to be required for colonisation and pathogenicity of the 
bacterium, as the loss or absence of PsaA perturbs growth and attenuates the in vivo virulence of S. 
pneumoniae in murine models (54, 55). PsaA is an integral part of an ATP-binding cassette (ABC) 
transporter protein complex, also known as PsaBCA permease. This permease complex works by 
extracellular PsaA capturing Mn2+ ions and transferring them to PsaB. Both transmembrane protein 
PsaB and cytosolic PsaC undergo a series of conformational changes, induced by ATP binding and 
hydrolysis, finally transporting Mn2+ into the cytoplasm (Figure 1.2.4, panel a) (63, 67, 68). Mn2+ 
ion serves as essential trace element for the pneumococcus as it protects the bacteria from oxidative 
stress. The ion serves as a cofactor for the superoxide dismutase (SOD) which catalyses the 
dismutation of superoxide to oxygen and hydrogen peroxide (63, 67-69). PsaA is thereby a 
promising drug target for anti-microbial therapies against S. pneumoniae.  
The three-dimensional structure of PsaA contains two lobes, with N- and C-terminal domains linked 
together by a rigid helix (70-72). The crystal structure (pdb: 3ZTT) revealed that the Mn2+-binding 
site is formed by the side-chains of residues His67, His139, Glu205 and Asp280 forming a 
tetrahedral coordination geometry for the ion (70-72). His67 and His139 interact with the metal ion 
via their Nε2 nitrogen atoms of their imidazole side-chain, whereas, the carboxylate side-chains of 
Glu205 and Asp280 interact with the metal ion via their Oε1 and Oδ2 atoms, respectively (Figure 
1.2.4, panel b) (70-72). Hence, targeting the metal-binding pocket of PsaA could result in 
preventing Mn2+ uptake and inhibiting pneumococcal growth. 
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Figure 1.2.4: (a) Schematic view of PsaABC permease. (b) Cartoon representation of Mn2+-bound PsaA (pdb: 3ZTT), 
showing N- and C-terminal domains connected by the linking helix. Metal-coordinating residues are shown in stick 
representation with the following color scheme: carbon,orange; nitrogen, blue and oxygen, red. Mn2+ ion is shown as a 
sphere. 
 
 
1.3.  Cryptococcus neoformans 
C. neoformans is encapsulated yeast, which belongs to the basidiomycota phylum and is commonly 
found in pigeon guano (73). Its spores, upon inhalation, cause localised and systemic infection in 
the lungs and other parts of the body such as central nervous system (CNS) leading to meningitis 
and meningoencephalitis (74, 75). Cryptococcal meningitis, caused by C. neoformans, has been 
found to be one of the leading causes of mortality in immune-compromised individuals, such as 
HIV-infected and transplant patients (76).   
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1.3.1.  Current treatment and limitations 
 
Due to the close similarity between fungal and human physiology, fungal infections have always 
been difficult to treat (75). At present, there are only 3 marketed drugs which have the potential to 
cure systemic cryptococcal infections: amphotericin B, flucytosine and fluconazole. Amphotericin 
B binds to the ergosterol, which is a sterol found in fungal cell membranes, and induces a 
transmembrane channel causing membrane leakage and eventually cell death. Fluconazole inhibits 
ergosterol synthesis itself, causing cell membrane instability, and flucytosine inhibits protein and 
DNA synthesis in a fungal cell (77). These drugs are often used as a combination therapy depending 
upon the site of infection and the patient’s immunological condition (78-81). 
However, there are some major limitations of this current antifungal treatment targeting C. 
neoformans, which primarily includes toxicity of the drugs and high cost. Amphotericin B is well 
known for its toxic and severe lethal side effects. It is a bigger problem in developing countries due 
to the lack of resources to monitor its administration (82). Flucytosine has also been found to be 
highly toxic leading to liver and renal dysfunction, skin reactions and adverse effects on CNS. In 
addition, due to its high cost it is usually unavailable in developing countries (83). This leaves us 
with fluconazole as the only available treatment for many patients (84, 85). However, fluconazole 
has been found to be ineffective at clearing cryptococcal meningoencephalitis and the emergence of 
resistance against the drug has been reported, further reducing its effectiveness (86-88). Given this 
limitiation of currently available treatment to cure systemic fungal infections, there is an urgent 
need to look for novel, affordable and non-toxic antifungal drugs. 
 
1.3.2.  Exploring new antifungal drug targets 
 
The similarity of fungal and human physiology has been one of the major limiting factors in 
exploring new antifungal drug targets (89). Therefore, researchers have come up with a newer 
approach to tackle this, which is to target proteins that are pivotal for both humans and fungi, but 
exploiting the differences between the two in the drug design process (90). An example of this 
approach is sordarins, which is a class of antifungals currently under development. Despite the 
sequence and structural similarity between fungal and human elongation factor 2, sordarins interact 
with fungal elongation factor 2 leading to the inhibition of a fungal protein synthesis suggesting that 
this interaction is highly specific(91-93).  This suggests that other conserved proteins could also be 
targeted to design novel, potent and selective antifungal inhibitors. 
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1.3.3.  Purine metabolic pathway 
 
The purine metabolic pathway is highly conserved across all species and organisms, primarily 
because it is responsible for the biosynthesis of adenosine triphosphate (ATP) and guanosine 
triphosphate (GTP) (94). Both ATP and GTP are essential for cell survival and replication, and can 
be synthesised in most organisms by two routes: a de novo and a salvage route (95). In the de novo 
route, the purine ring is synthesised from 5-phosphoribosyl-1-pyrophosphate, whereas in the 
salvage route, purine is taken up from the environment. During a fungal infection, the salvage route 
becomes ineffective due to the low concentration of purines in the extracellular fluids of the host 
(96-98). Therefore, fungal pathogens have to rely on the de novo route to survive, making the de 
novo ATP and GTP biosynthesis essential for fungal survival and pathogenesis. This makes 
enzymes involved in the de novo pathway potential drug targets for controlling fungal infection, 
such as cryptococcal meningitis caused by C. neoformans (90, 97, 99, 100). One key step in the de 
novo GTP biosynthesis pathway is the conversion of inosine monophosphate (IMP) to xanthosine 
monophosphate (XMP) by inosine monophosphate dehydrogenase (IMPDH) (Figure 1.3.3). 
 
 
Figure 1.3.3: The de novo GTP biosynthesis (purine metabolic) pathway. IMPDH is highlighted in red (90). 
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1.3.4.  Targeting inosine monophosphate dehydrogenase (IMPDH)  
 
IMPDH is involved in de novo GTP synthesis and has been found to be conserved in many 
organisms. It catalyzes the conversion of inosine monophosphate (IMP) to xanthosine 
monophosphate (XMP) via an oxidation and a hydrolysis reaction using NAD+ as a cofactor (Figure 
1.3.4.1) (101, 102). 
 
Figure 1.3.4.1: Conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP) is catalyzed by 
IMPDH. It also utilises NAD+, which is reduced to NADH during the process. 
 
The active site of IMPDH has two binding sites, a substrate-binding site for IMP and a cofactor-
binding site for NAD+ (90). When both IMP and NAD+ are in their respective binding site, a 
cysteine residue present in the active site loop binds to the 2nd position of IMP head group, forming 
a covalent bond between the enzyme and IMP (E-IMP) (103, 104). The oxidation of the E-IMP 
complex leads to its conversion into E-XMP complex and releases a H+, which is captured by 
cofactor NAD+ reducing it to NADH (103, 104). This causes NADH to dissociate from its binding 
site leading to extensive conformational changes in the enzyme from an open to a closed state as the 
active site flap folds and occupies the cofactor binding site. Once the active site flap is in the 
cofactor site, an arginine residue on the flap activates a water molecule, which then hydrolyses the 
E-XMP bond releasing XMP as the product (Figure 1.3.4.2, panel a) (104). Following this, XMP is 
converted into GMP (guanosine monophosphate) in a reaction catalyzed by GMP synthase (102, 
105). 
The biologically active conformation for an IMPDH enzyme is a homotetramer, with each 
monomer containing an eight-stranded α/β barrel catalytic domain and two cystathionine-β-synthase 
(CBS) domains (Figure 1.3.4.2, panel b) (106, 107). The catalytic domain contains the active site 
flap, active site loop and the catalytic cysteine residue, all of which are needed to perform oxidation 
and hydrolysis reactions for IMP to XMP conversion. The catalytic domain also has the two 
binding sites, for IMP and NAD+ (Figure 1.3.4.2, panel c) (108, 109). Attenuation or loss of 
IMPDH in C. neoformans has been found to cause guanine auxotrophy, and supplementing guanine 
from external sources into the growth media still shows slow growth and reduced expression of 
virulence factors in the knock-out mutants (90). Lack of virulence of the IMPDH mutants in mice 
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and nematode infection models suggests that IMPDH is a potential therapeutic target in this fungal 
pathogen (90). In addition, inhibition of IMPDH drastically reduces cellular levels of all the 
downstream substrates in the purine metabolic pathway, which are essential for important cell 
processes such as DNA and RNA synthesis and the function of G-coupled protein receptors (101).  
Given its high expression in rapidly proliferating lymphocytes, cancerous cells and microbial 
pathogens, IMPDH is considered as a therapeutic target for a wide variety of diseases (110). 
Currently, there are four drugs on the market with inhibitory effect against human IMPDH: the 
immunosuppressants mycophenolic acid (MPA) and mizoribine, the antiviral drug ribavirin and the 
anticancer drug tiazofurin (102). Out of these, MPA and mizoribine have also shown activity 
against fungal IMPDH, however, they cannot be used for treatment of fungal infections due to their 
immunosuppressant activity (90, 111, 112) which would be counterproductive in the case of a 
fungal infection. Apart from these drugs, several inhibitors targeting human, bacterial and parasitic 
IMPDH are currently under investigation or in development (113-120). In conclusion, one of the 
major challenges is to design and develop inhibitors selective for C. neoformans IMPDH, which do 
not inhibit both human IMPDH isoforms, type I and type II.  
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Figure 1.3.4.2: (a) Schematic view of the enzymatic reaction mechanism of IMPDH, highlighting key conformational 
changes during catalysis, based on (121). (b) Cartoon representation of the biologically active homotetramer of 
Cryptococcus neoformans IMPDH (pdb: 4AF0). Each monomer is represented with a different color (90). (c) Cartoon 
representation of the IMP and NAD binding site in the Cryptococcus neoformans IMPDH (pdb: 4AF0). IMP, bound to 
the IMP-binding site and MPA, bound to the NAD binding site, are shown in stick representation. Residues forming the 
binding sites are also shown in stick representation with the following atom colors: carbon, green; nitrogen, blue; and 
oxygen, red.   
 
 
1.4.  Thesis aims 
 
This thesis aims to:  
1. Investigate the conformational flexibility of PsaA using molecular dynamics (MD) 
simulations to gain further insights into the metal-binding process in cluster A-I SBPs. 
Crystal structures are static representations of protein structures at low temperature and their 
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conformations sometimes restricted by crystal packing. MD simulation can help to analyse 
the dynamic behavior of proteins and their conformational flexibility, by both raising the 
temperature and simulating the protein in solution. MD simulations are thereby able to 
investigate the flexibility of different domains and stability of secondary structures elements 
of proteins, as well as analysis the dynamic behavior under different conditions, like 
different pH.  
2. Identify novel small molecule inhibitors of PsaA that could potentially be pursued further to 
develop lead compounds. 
3. Develop strategies to design selective antifungal inhibitors using sequence and structural 
comparisons between C. neoformans and human IMPDHs. 
4. Build and investigate homotetrameric conformations of C. neoformans IMPDH and human 
IMPDH using homology modelling and MD simulation techniques, to come up with a 
biologically relevant conformation of fungal IMPDH which could be useful to design 
selective antifungal IMPDH inhibitors.  
5. Design structure-activity relationships (SAR) around the experimentally identified 
antifungal hits, to improve their potency and selectivity in the process of hit-to-lead 
development.        
 
In short, the thesis involves using molecular modelling and MD simulation techniques to work on 
two microbial targets, a bacterial virulence factor (PsaA) and a fungal protein target (IMPDH). 
Chapter 2 involves investigation and understanding of the overall conformational flexibility of PsaA 
structure. Chapter 3 involves identification of the novel fragment-like small molecule inhibitors 
targeting PsaA metal binding pocket. Finally, chapter 4 uses homology modelling and MD 
simulation techniques to identify bioactive conformations C. neoformans and human IMPDH, 
which could be used further to design effective SAR around the already identified novel anti-fungal 
hits. 
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2.1. Introduction 
Rapid emergence of multi-drug resistant bacteria in the past two decades against traditional 
antibiotics has shifted the focus to look for alternative strategies to combat bacterial infections 
(1). As illustrated in chapter 1, one such strategy is targeting Pneumococcal surface antigen A 
(PsaA), part of Cluster A-1 SBP family (2). It plays an important role in pneumococcal 
adherence to human nasopharyngeal epithelial cells and transport of manganese (Mn2+) across 
the bacterial cell membrane (3-5). The 3-D structure of PsaA comprises of a N- and a C-terminal 
domain linked together by a rigid α-helix forming a metal ion binding site at the intersection of 
the two domains (6-8). A metal ion, such as Mn2+ (pdb: 3ZTT),  Zn2+ (pdb: 1PSZ) or Cd2+ (pdb: 
4UTP), is coordinated by two side chain N atoms from His67 and His139 and two O atoms, one 
from each side chain of residues Glu205 and Asp280 (6, 7). The structure of the metal-free (apo) 
PsaA (pdb: 3ZK7) has an open conformation with the metal-binding site exposed to the solvent. 
The transition from the closed metal-bound structure (pdb: 3ZTT) to the open metal-free 
conformation (pdb: 3ZK7) is achieved by a rigid-body movement of the C-terminal domain with 
a hinge-bending angle between N- and C-terminal domains of 13° (8). The mechanism of metal 
binding to PsaA has been identified as a ‘spring-hammer’ mechanism, where mobile metal 
binding residue (Glu205, ‘the hammer’), found on the C-terminal domain, captures interactions 
with the metal ion and pushes onto the static metal-binding site (His67, His139 and Asp280, ‘the 
anvil’) (8). Molecular dynamics (MD) simulations have further helped to analyse the stability of 
the open state and to understand the dynamic transition from the closed to open state (8). All 
these finding are reported in the following manuscript that has been published in Nature 
Chemical Biology “R.M. Couñago, M.P. Ween, S.L. Begg, M. Bajaj, J. Zuegg, M.L. O’Mara, 
M.A. Cooper, A.G. McEwan, J.C. Paton, B. Kobe and C.A. McDevitt. Imperfect coordination 
chemistry facilitates metal ion release in the PsaA permease. Nature Chemical Biology 10, 35–
41 (2014)| doi:10.1038/nchembio.1382”. This publication forms section 2.2 of chapter 2. 
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Manganese is an essential trace element required for almost all forms of life1. The requirement for manganese by pathogenic bacteria necessitates the acquisition of 
this metal ion from the host environment. As a consequence, the 
transport components for manganese uptake are known virulence 
determinants for a range of human pathogens, including Bacillus 
anthracis2, Streptococcus pneumoniae3,4, Streptococcus pyogenes5 and 
Staphylococcus aureus6. In many bacterial pathogens, manganese 
has a prominent role in defense against innate or host-mediated oxi-
dative stress. Manganese principally serves as a prosthetic group in 
superoxide dismutase1,7 but is also able to provide direct protection 
against oxidative stress, as exemplified by Lactobacillus plantarum, 
which does not produce a superoxide dismutase8, and ‘indirect’ 
protection, by substituting for ferrous iron in non-redox meta-
bolic enzymes9. In addition, manganese also serves as a cofactor in 
enzymes involved in primary metabolism and DNA synthesis10–13.
Manganese acquisition in the human pathogen S. pneumoniae 
is facilitated by PsaA, a high-affinity, Mn-specific cluster A-I sub-
strate-binding protein (SBP) that is associated with an ATP-binding 
cassette (ABC) transporter (PsaBC), which mediates active manga-
nese import across the bacterial cell membrane14. Lack of any com-
ponent of the PsaBCA permease attenuates the in vivo virulence of 
S. pneumoniae3,15,16. Furthermore, direct inhibition of PsaA-mediated 
Mn2+ transport by zinc ions has recently been implicated as part of 
the host innate immune response against bacterial colonization17.
High-resolution structures of PsaA in the metal-bound state show 
that it has a two-lobed organization with N- and C-terminal (β/α)4 
domains bisected by a protein surface cleft in which the ligand binds 
and that is completely occluded in the ligand-bound form17,18. The 
two (β/α)4 domains in PsaA are linked by a rigid helix. This fold is 
conserved among cluster A SBPs19 that interact directly with metal 
ions (for example, PsaA17), those that bind chelated metals (for 
example, HmuT, the SBP of the heme ABC importer from Yersinia 
pestis20) or vitamins (for example, BtuF, the SBP of the vitamin B12 
ABC importer from Escherichia coli21). The open and ligand-free as 
well as the closed and ligand-bound structures of SBPs belonging 
to other clusters have shown that the flexible linker between their 
N- and C-terminal lobes allows them to function via N- and 
C-terminal domain movements referred to as a ‘Venus flytrap’ 
mechanism22–24. By contrast, determining the structure of the open, 
ligand-free cluster A-I SBPs has, to date, proved to be challenging. 
Ligand-free structures of proteins belonging to this subgroup show 
only minor differences in their conformations in comparison to 
metal-bound structures, suggesting that the closed state is the most 
stable form of the protein under crystallographic conditions25–29. 
This may be attributable to the longer and more rigid α-helical linker 
present in cluster A-I SBPs, and consequently the way in which they 
open and close to recruit metal ions from the extra cellular environ-
ment has remained unknown17,18.
Metal ion discrimination in biological systems is generally thought 
to involve an interplay between the prevailing metal ion availability, 
the nature of coordinating ligands30–32 and the effect of the Irving-
Williams stability series (where affinity in order of increasing atomic 
number can be represented as Mg2+/Ca2+ < Mn2+ < Fe2+ < Co2+ < Ni2+ 
< Cu2+ > Zn2+, with ‘>’ indicating higher affinity) on protein-metal 
ion affinity33. Both manganese and zinc are d-block elements that 
have zero crystal field stabilization energy, but zinc has a smaller 
ionic radius, which leads to a general increase in metal complex 
stability. In addition, manganese and zinc have different preferences 
for ligands; manganese is a relatively hard acid and forms complexes 
with N and O ligands, whereas zinc is a softer acid and forms com-
plexes primarily with N and S ligands, although it can also bind O 
ligands. The metal-binding site of PsaA is coordinated by two side 
chain nitrogen atoms from His67 and His139 and two O atoms, one 
from each side chain of residues Glu205 and Asp280; the same num-
ber of N and O ligands is seen in other SBPs associated with Mn2+-
specific ATP permeases18. Carboxylate groups can provide either one 
(monodentate) or two (bidentate)  metal-coordinating atoms, and 
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Imperfect coordination chemistry facilitates metal 
ion release in the psa permease
rafael M Couñago1,2,5, Miranda p Ween3,5, stephanie L Begg3, Megha Bajaj2, Johannes Zuegg2,  
Megan L O’Mara1,4, Matthew a Cooper2, alastair G Mcewan1, James C paton3, Bostjan Kobe1,2* & 
Christopher a Mcdevitt3*
The relative stability of divalent first-row transition metal ion complexes, as defined by the Irving-Williams series, poses a 
fundamental chemical challenge for selectivity in bacterial metal ion acquisition. Here we show that although the substrate-
binding protein of Streptococcus pneumoniae, PsaA, is finely attuned to bind its physiological substrate manganese, it can also 
bind a broad range of other divalent transition metal cations. By combining high-resolution structural data, metal-binding 
assays and mutational analyses, we show that the inability of open-state PsaA to satisfy the preferred coordination chemistry 
of manganese enables the protein to undergo the conformational changes required for cargo release to the Psa permease. This 
is specific for manganese ions, whereas zinc ions remain bound to PsaA. Collectively, these findings suggest a new ligand bind-
ing and release mechanism for PsaA and related substrate-binding proteins that facilitate specificity for divalent cations during 
competition from zinc ions, which are more abundant in biological systems. 
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so the metal-binding site of PsaA could, theoretically, accommo-
date both tetrahedral (coordination number n = 4) and octahedral 
(n = 6) geometries34. Unexpectedly, Mn2+- and Zn2+-bound PsaA 
have indistinguishable overall structures and identical tetrahedral 
(n = 4) coordination geometries17,18. Thus, it is not readily apparent 
from these metal-bound structures how PsaA functions as a compo-
nent of the Mn-specific Psa permease.
Here we used a combination of in vitro, in vivo and structural 
analyses to investigate how PsaA interacts with d-block elements. 
In this study, we show that the coordination chemistry of the metal-
binding site is dictated by a combination of the metal-binding site 
residues and the extent to which the C-terminal region of the link-
ing helix of PsaA is distorted during interaction with d-block metal 
ions. Although both Mn2+ and Zn2+ are able to interact with the 
metal-coordinating ligands at the metal-binding site of the protein, 
the inability of PsaA to optimally coordinate manganese permits 
reversible binding of the metal ion. By contrast, satisfaction of the 
preferred tetrahedral metal ion coordination geometry, as occurs 
with zinc, results in greater distortion of the linking helix of PsaA, 
locking the protein in a closed conformation. Collectively, these 
findings provide a new mechanistic basis for how cluster A-I SBPs 
can achieve selection in the acquisition of metal ions at the lower 
end of the Irving-Williams series.
reSulTS
PsaA interacts with various d-block elements in vitro
Our prior studies show that the binding site of PsaA has the capacity 
to accommodate both Zn2+ and Mn2+ (refs. 17,18) and thus suggest 
that PsaA can also interact with other d-block elements that employ 
tetrahedral and octahedral coordination chemistries. Using ther-
mal shift assays (TSAs) and metal-binding experiments, we found 
that apo-PsaA bound various d-block elements and that the metal-
 induced stabilization of the protein was not restricted to its cognate 
physiological transition metal ion (Table 1 and Fig. 1a). Remarkably, 
the extent to which PsaA thermostability varied was dependent upon 
the metal ion bound, and, with the notable exception of the cog-
nate ligand Mn2+, the observed shifts in the melting temperature of 
PsaA and the ethylenediaminetetraacetic acid (EDTA) reversibility 
of binding were essentially consistent with the Irving-Williams 
series33; that is, Fe2+ < Co2+ < Ni2+ < Cu2+ > Zn2+. Nevertheless, accu-
mulation of d-block elements other than Mn2+ in the pneumococcus 
was not negatively affected by the loss of PsaBCA function, whether 
by isogenic deletion of the psaA gene (ΔpsaA; 1 μM Mn2+; 
P = 0.0051) or through disruption by competitive Zn2+ concentrations 
(100 μM Zn2+ and 1 μM Mn2+; P < 0.0001)17 (Fig. 1b). This indi-
cated that the Psa permease was not a primary transporter of other 
d-block elements and supports the established role of PsaA in Mn2+ 
acquisition14,15,17. However, given the apparent contrast between the 
in vivo role of PsaA and the in vitro interaction of the protein with 
other metal ions, we sought to ascertain how the paradox of func-
tional Mn2+ selectivity by PsaA could be achieved.
Zn2+ locks PsaA in the closed state
We have previously shown that the Zn2+-mediated inhibition of 
pneumococcal growth in vitro is linked to this metal ion’s ability 
to stabilize PsaA to a greater extent than Mn2+, despite Mn2+ being 
its physiological ligand17. Thus, we postulated that Zn2+ binding 
locks the protein in a closed conformation and prevents opening 
of the metal-binding site and cargo delivery to the Psa permease. 
We assessed the solvent accessibility of the metal-binding site of 
PsaA by the ability of the chelating agent EDTA to extract metal 
ions from Zn2+- or Mn2+-loaded protein. Chelation by a 100-fold 
excess of EDTA did not significantly (P = 0.1272) remove Zn2+ 
from Zn2+-loaded PsaA, whereas EDTA completely extracted 
Table 1 | effect of various transition row metals on the melting 
temperature shift of apo-PsaA
sample Tm (°C)a ΔTm (°C) Coordination number (n)b
apo-Psaa 52.70 ± 1.57 — —
Psaa 10:1 Mn2+ 63.97 ± 1.94 +11.27 6
Psaa 10:1 Fe2+ 58.58 ± 0.06 +5.88 6
Psaa 10:1 Fe3+ 56.30 ± 2.04 +3.59 6
Psaa 10:1 Co2+ 61.24 ± 7.45 +8.53 6
Psaa 10:1 ni2+ 64.06 ± 0.28 +11.36 6
Psaa 10:1 Cu2+ 64.37 ± 1.66 +11.67 4
Psaa 10:1 Zn2+ 70.86 ± 2.06 +18.16 4
avalues shown represent the mean ± s.d. from at least three independent measurements. 
bPreferred coordination number34.
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Figure 1 | metal ion interaction with PsaA and accumulation by S. pneumoniae. (a) Metal-binding experiments of apo-Psaa with divalent metal ions 
as indicated. Columns correspond to apo-Psaa (black), metal-loaded Psaa (light gray) and EDTa-treated Psaa (dark gray) analyzed by ICP-MS. The 
metal ion/protein molar ratio was determined, and data correspond to mean values ± s.d. of at least four independent biological experiments. (b) In vitro 
metal accumulation of wild-type S. pneumoniae D39 (black) or ΔpsaA (light gray) grown in cation-defined medium (CDM) and wild-type S. pneumoniae 
D39 grown in CDM with 100 μM Zn2+ and 1 μM Mn2+ (dark gray). Total cellular accumulation of metal ions was assessed by ICP-MS. Data correspond to 
mean ± s.d. μg metal per g dry cell weight from duplicate measurements of at least four independent biological experiments. Statistical significance was 
determined by a two-tailed unpaired Student’s t-test. **P < 0.01, ***P < 0.001 and ****P < 0.0001. (c,d) Metal-binding experiments of apo-Psaa variants 
PsaaE205Q (c) and PsaaD280n (d) with divalent metal ions as indicated. Columns correspond to apo-Psaa protein (black), metal-loaded protein (light gray) 
and EDTa-treated protein (dark gray) analyzed by ICP-MS. The metal ion/protein molar ratio was determined, and data correspond to mean values ± s.d. 
of at least four independent biological experiments.
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Mn2+ from the protein (Fig. 1a). These results showed that Zn2+, 
but not Mn2+, could lock PsaA in a closed conformation, consistent 
with the greater thermostabilization of Zn2+-PsaA observed by the 
TSA (Table 1).
Coordination chemistry affects binding-site dynamics
Among other factors, the specificity and strength of metal-protein 
ionic bonds depend on the coordination chemistry35,36. PsaA binds 
Zn2+ and Mn2+ with identical tetrahedral coordination, facili-
tated by two N and two carboxyl O atoms17,18. This configuration 
of the metal-binding site of PsaA is likely to favor stronger ionic 
bonds to Zn2+, which prefers tetrahedral coordination (n = 4, bond 
lengths < 2.1 Å) than to Mn2+, which prefers symmetrical octahedral 
coordination (n = 6, bond lengths < 2.2 Å)34. We tested the relevance 
of the protein-metal coordination chemistry for the stabilization of 
the closed state of PsaA by individually replacing the carboxylate 
groups from residues Glu205 and Asp280 in the metal-binding site 
of the protein with their isosteric neutral polar amide analogs.
Both E205Q and D280N mutations had no effect on Zn2+ 
loading but substantially reduced the ability of these mutant pro-
teins to retain the metal ion (Fig. 1c,d). TSAs further revealed 
that Asp280 had a greater influence on the Zn2+-mediated stabi-
lization of the closed state of PsaA than Glu205 (Supplementary 
Results, Supplementary Table 1). Analogous experiments with 
Mn2+-loaded mutant proteins similarly indicated that Asp280 was 
more important than Glu205 in PsaA binding to Mn2+ (Fig. 1c,d 
and Supplementary Table 1). These findings suggested that metal 
coordination was important for the stability of closed-state PsaA 
and that the metal ion coordination by Asp280 at the bottom of the 
metal-binding site of PsaA was more important for metal binding 
and retention than metal ion coordination by Glu205.
Although Mn2+- and Zn2+-bound PsaA structures display virtu-
ally identical closed conformations17,18, our results so far showed 
that the nature of the metal ion directly affected the opening and 
closing of the metal-binding site of PsaA. Consequently, we sought 
to structurally characterize the open, metal-free state of PsaA to 
further investigate the mechanism underlying metal binding.
The structure of open-state, metal-free PsaA
The high-resolution crystal structure of metal-free (apo) wild-type 
PsaA (Supplementary Table 2) revealed an open conformation 
with the metal-binding site completely exposed to the solvent. The 
metal-binding site was situated ~15 Å from the protein’s molecular 
surface at the bottom of a deep, negatively charged crevice between 
the N- and C-terminal lobes. The opening was relatively large 
(~350 Å3) when compared with the small size of the cognate ligand 
(~1.4 Å and ~11.5 Å3 atomic radius and volume, respectively) of 
PsaA (Fig. 2a,b and Supplementary Fig. 1). Opening of the metal-
binding site reduced the extent of the solvent-accessible area buried 
by the interdomain interface by ~15% (2,500 Å2 to 2,200 Å2) but dis-
rupted only four interdomain hydrogen bonds. The small number 
of contacts broken upon opening of PsaA suggested that the metal-
protein ionic bonds provided most of the stabilization for the closed 
state of the protein.
Opening of the structure occurred via a rigid-body movement of 
the C-terminal (β/α)4 domain, with a hinge-bending angle between 
the N- and C-terminal domains of ~13°, in a plane orthogonal to the 
linking helix. This movement pivoted on residues 190–194, which in 
the open state formed an extra helical turn at the C-terminal end of 
the interdomain helix not present in the metal-bound structures17,18 
(Fig. 2c). The N-terminal portion of the linking helix remained 
undisturbed in both metal-bound and metal-free states as it was 
tightly packed against the preceding helix (up until residue 180) 
from the N-terminal lobe.
Independently superimposing the N- and C-terminal domains 
of the open- and closed-state crystal structures yielded Cα r.m.s. 
deviations of only 0.5 Å and 0.7 Å, respectively. Thus, the overall 
organization of individual secondary structure elements in open-
state PsaA were unchanged from the closed, metal-bound struc-
tures (Supplementary Fig. 2a,b). The rigid-body movement of the 
PsaA C-terminal domain displaced the metal-coordinating residue 
Glu205 ~2.4 Å (Cα displacement) away from its position in the 
metal-bound state. By contrast, in both the open and closed states 
of PsaA, the relative positions of the other three metal-binding resi-
dues (His67, His139 and Asp280) were very similar (Cα r.m.s. devia-
tion <0.4 Å; Fig. 2d). Consequently, the metal-binding site of PsaA 
was nearly preformed in the open state.
Molecular dynamics (MD) simulations were performed to ana-
lyze the stability of the open state and to characterize the dynamic 
transition from the closed to the open state. Following MD simu-
lations (50 ns) of open-state PsaA, the average interdomain angle 
increased to 23 ± 8° (mean ± s.d.; details are in Online Methods) 
(Supplementary Fig. 3a), and the Cα r.m.s. deviation values of the 
N- (residues 32–189) and C-terminal (residues 194–221 and 248–
309) domains were only 2.3 ± 0.4 Å and 2.0 ± 0.5 Å, respectively 
(Supplementary Fig. 3b–e). In the metal-binding site of PsaA, the 
distance between the Cβs of His139 and Asp280 remained within 
0.3 ± 1.4 Å of the crystal structure, whereas there was a distance 
d
ba N lobe C lobe
Linking helix
c
His67
Asp280
Glu205
~13°
184
194 His139
Figure 2 | The structure of open, metal-free PsaA reveals an open  
metal-binding site. (a) Cartoon representation of apo-Psaa (PDB code 
3ZK7), determined in this study, showing n- and C-terminal lobes 
connected by the linking helix. Metal-coordinating residues are shown  
in stick representation. (b) Cross-section view of the molecular  
surface in apo-Psaa showing that the metal-binding site is exposed to the 
solvent. The position of the metal ion, as in the Zn2+-bound protein  
(PDB code 1PSZ), is shown as a dotted sphere. Protein backbone is  
shown in green cartoon representation. Molecular surfaces shown are  
colored by electrostatic potential (blue, positive; red, negative).  
(c) Superposition of open, metal-free (green) and closed metal-bound 
(purple) Psaa structures (Cα atoms, residues 32–163, were used for the 
superposition). The linking helix (residues 164–194) is shown in cartoon 
representation, and all of the other helices are shown as cylinders. For 
the open structure, backbone atoms in the flexible region of the linking 
helix (residues 184–194) are shown in stick representation, and hydrogen 
bonds between backbone atoms are shown as dashed lines. residues in 
the metal-binding site are shown in stick representation. The metal ion is 
shown (Zn2+, gray sphere) for the closed protein. The hinge angle  
between C-terminal domains from open and closed structures is noted. 
(d) The metal-binding site of Psaa in the presence (purple) and absence 
(green) of ligand (Zn2+, gray sphere). Metal-coordinating residues are 
shown in stick representation. Metal ion coordination is shown as dashed 
lines and conforms to a tetrahedral geometry.np
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increase between residues Glu205 and His67 of 6.0 ± 1.8 Å (with 
respect to the closed-state structure). Simulations of PsaA tran-
sitioning from the closed to the open state upon removal of Zn2+ 
indicated that the distance between Glu205 and His67 increased by 
4.0 ± 1.1 Å after 50 ns of simulation, whereas the distance between 
His139 and Asp280 increased by only 2.6 ± 0.9 Å. Collectively, these 
MD analyses supported the hinge-bending motion of the C-terminal 
domain, the structural integrity of the N- and C-terminal lobes and 
the displacement of metal-binding residues suggested by crystallo-
graphy during ligand binding.
High-resolution apo structures of both carboxylate mutants were 
also captured in the same open conformation observed for wild-type 
apo-PsaA and displayed a similar arrangement of the metal-binding 
residues (Supplementary Table 2 and Supplementary Fig. 4).
metal binding is linked to occlusion of the binding site
To further investigate the metal-binding mechanism of PsaA, Mn2+ 
and Zn2+ were soaked into the crystals of metal-free wild-type PsaA 
and the carboxylate mutants. In all but one case, metal ion treatment 
damaged the crystals. The only exception was PsaAD280N soaked 
with Mn2+, which, in the TSA (Supplementary Table 1) and metal- 
stripping experiments (Fig. 1d), had shown the weakest interaction 
with Mn2+. The stronger binding interactions observed for all of the 
PsaA variants with Zn2+ and both wild-type PsaA and PsaAE205Q with 
Mn2+ appeared to induce considerable damage of the crystalline 
lattices, most likely owing to metal-induced protein closure.
Electron density was clearly observed for a manganese ion at 
the metal-binding site in the Mn2+-soaked PsaAD280N crystals. Three 
solvent molecules, the Nε2 atom from His139 and two carboxyl O 
atoms from Glu205 loosely coordinated the metal ion in a distorted 
octahedral geometry (n = 6), and the metal ion was closer (~1.5 Å) 
to the molecular surface than in the Mn2+-bound, closed structure17 
(Fig. 3). These observations were in excellent agreement with our 
biochemical data that suggested that metal ion coordination by 
Asp280 at the bottom of the metal-binding site was critical for Mn2+ 
and Zn2+ binding by PsaA. The interaction between Glu205 and 
Mn2+ introduced small deviations in the flexible portion of the link-
ing helix (residues 188–194), breaking the hydrogen bond between 
main-chain N and O atoms from residues 189 and 193 seen in the 
metal-free wild-type structure. As a consequence, the Mn2+-soaked 
structure displayed a slight closing of the metal-binding site with a 
hinge-bending angle between the domains of ~10° (versus ~13° in 
the metal-free structure; Fig. 3a).
linking-helix flexibility affects binding-site dynamics
To directly test the relevance of the flexible region of the linking helix 
to PsaA’s ability to bind and release metal ions, we engineered two 
disulfide bonds in this region of the protein (Cys-PsaA) (Fig. 4a and 
Supplementary Fig. 5a). We selected residues Ile190 and Leu194 
for mutagenesis owing to their location within the flexible region 
of the linking helix and their proximity to residues Ala304 and 
Ala308, located in the C-terminal helix of the protein. MD simula-
tions showed that in the absence of a bound metal ion, the distances 
between the Cα atoms of the residue pairs 190-304 and 194-308 were 
less than 10.0 Å and were consistent with the formation of a disul-
fide bond in the presence of an oxidizing agent (Supplementary 
Fig. 5b,c). We predicted that cross-linking would restrict the flex-
ibility of the C-terminal region of the linking helix by tethering it to 
the C-terminal helix of the protein and thereby affect the ability of 
Cys-PsaA to bind and release metal ions.
Under reducing conditions, metal ion binding by Cys-PsaA was 
unaffected. Chelation-mediated release of Mn2+ from Cys-PsaA was 
also unaffected, but, in contrast to the wild-type protein, ~27% of the 
bound Zn2+ could be extracted from reduced Cys-PsaA (Fig. 4b,c). 
This finding was also consistent with TSA results of the reduced 
Cys-PsaA variant (Supplementary Table 3), which indicated that 
a ~3°
184
194
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b
Figure 3 | Closing of PsaA is initiated by the interaction between Asp280 
and manganese. (a) Superposition of open, metal-free (green, PDB code 
3ZK7, determined in the current study) and open, Mn-bound (pink, PDB 
code 3ZKa, determined in the current study) Psaa structures (protein 
superposition as in Fig. 2). The linking helix (residues 164–194) is shown in 
cartoon representation, and all of the other helices are shown as cylinders. 
Backbone atoms making up the flexible coil helical turn (residues 184–194) 
and residues in the metal-binding site are shown in stick representation. 
Manganese is shown as a pink sphere. The hinge angle between C-terminal 
domains of open, metal-free and closed, Mn-bound structures is noted. 
(b) Details of the metal-binding site of Psaa in the presence (pink) 
and absence (green) of Mn2+ (pink sphere). Metal ion coordination in 
the metal-bound protein is shown as dashed lines and conforms to a 
distorted octahedral geometry. Solvent molecules taking part in metal ion 
coordination are shown as light blue spheres.
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Figure 4 | location of introduced cysteine residues in Cys-PsaA and 
metal ion binding by the Cys-PsaA protein. (a) location and expected 
organization of the introduced cysteine residues in metal-free (green,  
PDB code 3ZK7, determined in the current study) and Zn2+-bound (purple, 
PDB code 1PSZ) Psaa structures. Structures were superimposed using 
residues from the C-terminal lobe. Metal-coordinating residues are shown 
in stick representation. (b,c) Metal-binding experiments of apo-Psaa,  
apo-Cys-Psaaox and apo-Cys-Psaared with Mn2+ (b) and Zn2+ (c) analyzed 
by ICP-MS. The metal ion/protein molar ratio was determined. Data 
represent mean values ± s.d. of at least four independent biological 
samples. Statistical significance between the means was determined by a 
two-tailed unpaired Student’s t-test. WT, wild type; nS, not significant;  
*P < 0.05; **P < 0.01; ****P < 0.0001.
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the introduction of cysteine residues, though not having altered the 
metal-binding properties of PsaA, had resulted in a decrease in the 
overall stability of the Zn2+-bound state. This was most likely due 
to the rigidifying effect of the cysteine residues on the C-terminal 
region of the linking helix, preventing the Zn2+-binding event from 
completely locking the protein in a closed conformation. Under 
oxidizing conditions, the cross-linking resulted in a significant 
(P = 0.0006) reduction (~20%) in the binding capacity of Cys-PsaA 
for both Mn2+ and Zn2+. Taken together, these data directly link 
closure of the metal-binding site with the ability of the C-terminal 
region of the linking helix to distort upon metal binding and 
support a role for the extent of this distortion in determining the 
stability of the metal-bound complex.
Proposed binding and release mechanism for PsaA
Collectively, the biochemical and structural data presented here 
with the available Zn2+- and Mn2+-bound structures of PsaA sug-
gest a hitherto undescribed mechanism for metal binding and 
release in PsaA (Fig. 5a). In the apo-PsaA structure, the metal-
binding site was exposed to the solvent, and residues 188–194 
were part of a helical turn in the C-terminal region of the protein 
linking helix (Fig. 5b). As seen in the PsaAD280N Mn2+-bound open 
structure, interactions between residue 205 and the metal ion ini-
tiated closing of the metal-binding site and caused a slight dis-
tortion in the helical turn formed by residues 188–194 (Fig. 5c). 
As binding progressed, residues Asp280 and His139 replaced sol-
vent molecules to coordinate the metal ion at the bottom of the 
metal-binding site, with the side chain group of His67 closing 
over the metal ion at the final stages of protein closure. As seen 
in the Mn2+- and Zn2+-bound closed PsaA structures, the identity 
of the ligand and its coordination chemistry in the metal-binding 
site of the protein directly influenced the extent of distortion in 
the helical turn formed by residues 188–194 (Fig. 5d,e), whereas, 
concomitantly, these factors also dictated the ability of PsaA to 
release the bound metal ion (Fig. 1a,c,d). This mode of ligand bind-
ing is distinct from the Venus flytrap mechanism found in SBPs that 
contain a flexible linker. By contrast, the mechanism used by PsaA 
is more akin to a ‘spring-hammer’, in which the protein confor-
mational changes can be summarized as a swinging metal-binding 
residue (Glu205, ‘the hammer’) that pushes onto or pulls away from 
(a mostly) static metal-binding site (His67, His139 and Glu280, 
‘the anvil’) according to the integrity of a helical turn in the  protein 
linking helix (residues 188–194, ‘the spring’) (Fig. 5a–e and 
Supplementary Movie 1).
DISCuSSIoN
Extracellular metal ion receptors face the challenge of binding the 
correct metal ion in an environment of low abundance or avail-
ability17. Achieving selectivity for Mn2+ over harder acids such as 
Mg2+ is easily achieved by increasing the number of N ligands in 
the metal-binding site, and this is observed for PsaA. However, the 
incorporation of N ligands into the active site opens the way for 
the binding of metal ions at the higher end of the Irving-Williams 
stability series, such as Zn2+. Consistent with this expectation, the 
TSA and in vitro metal-binding experiments revealed that PsaA 
interacted with most d-block divalent cations. Although both Zn2+ 
and Mn2+ can interact with N and O ligands, Zn2+ is not often 
thought to compete for Mn2+-binding sites, owing to the presence 
of proteins and peptides, such as glutathione, that contain solvent- 
exposed S ligands and facilitate intracellular Zn2+ buffering. However, 
although this pattern of metal ion selectivity applies in the reducing 
environment of the cytoplasm, it cannot apply in the more oxidizing 
environment outside the cell, where cysteine thiols form disulfide 
bonds. Consistent with this inference, inductively coupled plasma 
(ICP)-MS analysis of S. pneumoniae showed that extracellular Zn2+ 
could reduce Mn2+ uptake, similar to a ΔpsaA mutant strain, with only 
a minor, but significant, increase in Zn2+ accumulation (P = 0.01). 
The increased zinc associated with S. pneumoniae under these con-
ditions would also be consistent with Zn2+ competition for PsaA, 
the expression of which is highly upregulated during growth under 
Mn2+-limiting conditions17. The ΔpsaA strain also showed a small 
significant increase in Fe accumulation (P = 0.0002). However, as 
no significant changes occurred in the wild-type strain (P = 0.7214) 
in the presence or absence of Zn2+ stress, these data may suggest that 
low Mn2+ is associated with a change in regulation of iron uptake 
pathways, but this is then further perturbed in the presence of high 
Zn2+ concentrations. Consequently, Zn2+ can inhibit Mn2+ uptake by 
competing for binding to PsaA, and this may have a role in host-
pathogen interaction as, in vivo, Zn2+ release occurs in response to 
S. pneumoniae infection17.
We show here that Zn2+ binding locks PsaA in a closed state. 
This result highlights the fact that in transport proteins, adaptations 
toward increased ligand specificity must also preserve the ability of 
the protein to release its cargo. The reversible binding of Mn2+ to 
PsaA is likely to arise from the asymmetrical distribution of metal-
coordinating atoms in the protein, which do not support the pref-
erence of manganese for symmetrical octahedral coordination. A 
similar distribution of metal-coordinating residues is observed in 
the structures of related bacterial SBPs involved in the acquisition of 
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Figure 5 | Proposed metal-binding mechanism for PsaA. (a) Superposition of open, metal-free (green, PDB code 3ZK7, determined in the current study); 
open, Mn-bound (pink, PDB code 3ZKa, determined in the current study); closed, Mn-bound (yellow, PDB code 3ZTT); and closed Zn-bound  
(purple, PDB code 1PSZ) Psaa structures (protein superposition as in Fig. 2). Dashed lines indicate the ‘static’ metal-binding residues His67, His139 and  
asp280 (black); the ‘mobile’ metal-binding residue Glu205 (blue); and the ‘flexible’ region of the linking helix (residues 184–194) (red). The molecular 
surface contour is shown for the open, metal-free structure. The protein backbone is shown in cartoon representation highlighting regions adjacent to  
the metal-binding site. (b–e) The static, mobile and flexible regions for the open, metal-free (b); open, Mn-bound (c); closed, Mn-bound (d); and closed,  
Zn-bound (e) structures of Psaa shown in a. Backbone atoms of residues in the flexible helical turn (residues 184–194) are shown in stick representation, 
and hydrogen bonds between backbone atoms within this region are shown as dotted lines. Boxes represent the extent of distortion of the flexible  
helical turn (residues 184–194) in the various Psaa structures in a gradient from blue (no distortion or breakage of backbone hydrogen bonds) to red 
(distortion and breakage of backbone hydrogen bonds). Wild-type residues are shown for all of the structures. The pink (in d) and yellow (in e) lines 
represent ideal tetrahedral and octahedral geometries, respectively.
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Fe2+ and Mn2+ (MtsA37 and MntC38, respectively). In contrast, PsaA 
binds zinc in a close-to-ideal tetrahedral coordination via two N 
and two O atoms, creating a strong metal ion-protein interaction 
that is directly responsible for the observed Zn2+-induced Mn2+-
starvation of pneumococci when challenged with an excess of zinc 
over manganese17. The bacterial cluster A-I SBPs that facilitate 
the transport of zinc may avoid a harmfully strong interaction with 
their ligand by employing different metal-coordinating atoms, 
which in some cases are located at mobile regions of the protein26 
or recruited from the solvent27,39. Our TSA results also indicate that 
binding of Mn2+ to PsaA is more favored than would be expected 
from considerations of metal ion coordination chemistry alone. The 
greater thermostabilization of PsaA by Mn2+ compared to Fe2+ and 
Co2+, which are situated above manganese in the Irving-Williams 
series, may be partly due to the larger atomic radius of Mn2+ (0.83 Å), 
which enables it to achieve a better, although still suboptimal, 
octahedral coordination than either Fe2+ or Co2+. By contrast, the 
smaller atomic radii of Fe2+ (0.78 Å) and Co2+ (0.74 Å) may impose 
additional steric issues with respect to achieving a suitable metal-
coordination sphere at the binding site of PsaA. Thus, our findings 
for PsaA and the available structural and biochemical information 
for other metal-binding SBPs suggest that preventing a strong metal 
ion-protein interaction is a conserved trend within this family of 
metal ion receptors.
Metal-specific allosteric changes can couple binding of the 
appropriate metal ion to the protein’s biological function. The best 
known examples involve transcription factors, where DNA-binding 
or conformational changes are only triggered by satisfying a specific 
protein-metal ion coordination chemistry40–45. Our data suggest 
that a similar mechanism is present in PsaA. However, in the case 
of PsaA, it is the inability of the protein to strongly interact with 
Mn2+ that facilitates the conformational changes required for the 
proper in vivo functioning of PsaA in metal acquisition. Although 
Mn2+- and Zn2+-bound PsaA display almost identical closed 
conformations17,18, only the Mn2+-bound protein seems to exist in 
a metal ion–loaded open conformation that allows stripping of the 
metal ion by EDTA and, potentially, transference of the ligand to the 
PsaA-associated permease (PsaBC). Opening of the metal-binding 
site in PsaA requires the C-terminal region of the linking helix to 
refold, which does not appear to occur in the Zn-bound protein. The 
equivalent regions in the closed Fe-bound structure of S. pyogenes  
MtsA37 and the closed Mn2+-bound structure of Synechocystis MntC38 
are found distorted in much the same way as that observed for the 
closed structures of metal-bound PsaA. Although these structural 
observations suggest that these proteins also employ a similar mecha-
nism for metal binding and release, the effects of Zn2+ on the stabili-
zation of the closed states of these proteins and on the ability of their 
source organism to acquire Fe2+ or Mn2+ remain to be established. 
By contrast, the linking helices of Zn2+-binding SBPs in both metal-
free and metal-bound states are very similar and closely resemble the 
linking helix of open PsaA. The metal-free structure of ZnuA suggests 
that cargo release in this protein is accomplished by large movements 
of specific secondary-structure elements from the C-terminal lobe 
(and not the entire domain)28, whereas the open PsaA structure sug-
gests that most of the C-terminal lobe behaves as a rigid body upon 
metal ion release. Thus, Zn-binding SBPs seem to employ a slightly 
different cargo-release mechanism than the mechanism proposed 
here for PsaA and other SBPs associated with the transport of metal 
ions at the lower end of the Irving-Williams series. These mechanistic 
differences are also likely to be associated with the different metal-
coordinating residues at the binding sites of Zn2+-binding cluster A-I 
SBPs (typically three histidines and one carboxylate residue) and the 
resultant metal coordination geometries that these residues permit.
The structural data presented here for PsaA are also in excellent 
agreement with our current knowledge of the interaction between 
bacterial SBPs and their ABC transporters. Recent structures of 
 bacterial translocation machineries for heme20 and vitamin B12 
(ref. 21) have suggested a conserved docking mode of the SBP onto 
the permease. Both heme (HmuT) and vitamin B12 (BtuF) receptors 
are structurally related to PsaA, belonging to the cluster A-II subfam-
ily of SBPs and have two (β/α)4 lobes connected by a long linking 
helix. Docking of these SBPs occurs via two acidic residues on the 
SBP, Glu74 and Glu202 in BtuF and Glu77 and Glu206 in HmuT, 
which align their cargo-binding sites to the translocation cavity of 
the permease. The corresponding conserved acidic residues in PsaA 
(Glu75 and Glu241) are also present, and the open-state structure 
revealed that only Glu241 moves substantially during the transition 
to the loaded structure. It is tempting to speculate that this struc-
tural movement optimally positions the acidic residue from the SBP’s 
C-terminal lobe for docking onto the ABC transporter and represents 
a plausible mechanism by which the permease discriminates between 
the apo and metal-loaded conformations of the SBPs or, alternatively, 
aids in the release of the SBP after the completion of the translocation 
cycle. Although no information is currently available for the open 
state of HmuT, the structure of BtuF in complex with its cognate 
permease captured the SBP in an open conformation. This structure 
revealed a rigid-body rotation of the C-terminal lobe (~8°) around 
a hinge located at the end of the linking helix in a fashion similar to 
what is reported here for PsaA. Despite the substantial differences in 
cargo size between PsaA and BtuF, the similarities between the open 
state of PsaA and that of BtuF suggest a conserved mode for cargo 
release for cluster A SBPs into their cognate permeases.
In conclusion, this work presents a new spring-hammer mecha-
nism for metal binding and release in cluster A-I SBPs that mediate 
the acquisition of divalent cations at the lower end of the Irving-
William series. Our findings underscore how the binding sites of 
these proteins combine increased metal specificity with protein-
metal interactions to facilitate the conformational changes required 
for cargo release. The combination of these factors provides the basis 
for in vivo acquisition of Mn2+, a poorly abundant d-block metal ion 
in many host tissues that is essential for pneumococcal coloniza-
tion and disease, despite the presence of more abundant d-block ele-
ments, such as Zn2+, in the host environment. 
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Methods and any associated references are available in the online 
version of the paper.
Accession codes. Protein Data Bank (PDB). The data for the follow-
ing structures are deposited under the accession codes in parenthe-
ses: metal-free, wild-type PsaA (3ZK7); metal-free PsaAE205Q (3ZK8); 
metal-free PsaAD280N (3ZK9); and Mn-bound PsaAD280N (3ZKA).
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oNlINe meTHoDS
Whole-cell metal accumulation. S. pneumoniae D39 and the ΔpsaA mutant 
strain were grown in CDM, which is C + Y medium supplemented with 1 μM 
MnSO4 (ref. 17). Zinc stress conditions used CDM supplemented with 1 μM 
MnSO4 and 100 μM ZnSO4. All of the chemicals used were purchased from 
Sigma-Aldrich unless otherwise specified. Metal concentrations of the CDM 
were ascertained by ICP-MS. S. pneumoniae was grown to an OD600 of 0.3 in 5% 
CO2 at 310 K. The bacteria were then washed, by resuspension and centrifuga-
tion at 8,000g for 10 min, three times with PBS containing 5 mM EDTA and 
then twice with PBS. Bacterial pellets were desiccated at 370 K overnight. The 
dry cell weight was measured, and the pellets were resuspended in 35% HNO3. 
Samples were diluted to a final concentration of 3.5% HNO3 and analyzed 
by ICP-MS on an Agilent 7500cx ICP-MS (Adelaide Microscopy, University 
of Adelaide).
Statistical analyses. Statistical significance of the differences between experi-
mental means was analyzed by two-tailed unpaired Student’s t-tests using 
Graphpad Prism version 5.0b (Graphpad Software). All of the experiments 
used at least three independent biological samples.
Expression and purification of PsaA and mutant variants. Recombinant 
PsaA was generated by PCR amplification of S. pneumoniae D39 psaA and 
by using ligation-independent cloning to insert the gene into a C-terminal 
His10-containing vector, pCAMcLIC01, to generate pCAMcLIC01-PsaA. Site-
directed mutagenesis (Quickchange Lightning, Agilent Technologies) was used 
to introduce specific mutations in the coding sequence of pCAMcLIC01-PsaA 
(all of the primers are listed in Supplementary Table 4), whereas the Cys-PsaA 
variant (L190C, I194C, A304C, A308C) was synthesized (Genscript). Protein 
expression was performed in E. coli LEMO21(DE3) by growing the cells in an 
autoinducing TB medium (Overnight Express, Merck) for 18 h at 303 K. Cells 
were harvested and disrupted at 30 kPSI by a Constant Systems cell disruptor, 
and the soluble supernatant was isolated by centrifugation at 277 K for 60 min 
at 120,000g. PsaA was isolated in a Histrap HP column (GE Healthcare) on an 
AKTA Purifier (GE Healthcare) and was further purified on a Superdex 200 
10/300 gel filtration column (GE Healthcare). The His10 tag was removed by 
enzymatic digestion by the human rhinovirus 3C protease, and the protein was 
purified further on a Histrap HP column.
Apo-PsaA generation. Purified apo-PsaA and mutant variants were prepared 
by dialyzing the polyhistidine tag–cleaved protein (10 ml) in a membrane with 
a 20 kDa molecular weight cutoff (Slide-A-Lyzer, Pierce) against 4 l of sodium 
acetate buffer, pH 3.7, with 20 mM EDTA at 300 K. The sample was then dia-
lyzed against 4 l of 20 mM Tris-HCl, pH 7.2, 100 mM NaCl, at 277 K and cen-
trifuged at 18,000g for 10 min to remove any insoluble material. The Cys-PsaA 
variant was purified using essentially the same procedure with 5 mM DTT 
included in all buffers before final treatment. The Cys-PsaA variant was then 
desalted using a PD10 column and treated with either 20 mM Tris-HCl, pH 7.2, 
100 mM NaCl, 5 mM H2O2 for 60 min to generate Cys-PsaAOx or 20 mM Tris-
HCl, pH 7.2, 100 mM NaCl, 5 mM TCEP for 60 min to generate Cys-PsaARed. 
Quantification of thiol groups in Cys-PsaA in the reduced and oxidized states 
was performed, before metal-loading experiments, using a fluorometric assay 
procedure (Cayman Biochemicals), according to the manufacturer’s instruc-
tions. Protein samples were analyzed for metal content by heating 10 μM 
protein at 370 K for 30 min in 3.5% HNO3, and the metal ion content was 
measured by ICP-MS.
TSAs. Assays were performed with 10 μM of protein in 100 mM 
4-morpholinepropanesulfonic acid (MOPS), pH 7.2, 150 mM NaCl, 5× 
SYPRO Orange (Life Technologies) incubated in the presence of 100 μM 
metal ion and then were analyzed on a Roche LC480 Real-Time Cycler (Roche 
Applied Sciences). The samples were preincubated for 10 min with the metal 
ion and then subjected to thermal unfolding from 310 K to 370 K at a heat-
ing rate of 1 K per min. Fluorescence data were also collected for buffer only, 
protein without metal ions and for each of the metal ions without protein. 
The fluorescence data were collected by excitation at 470 nm and emission at 
570 nm. After subtraction of the background fluorescence from the buffer, the 
first derivative of the fluorescence data was determined and analyzed using 
Graphpad Prism to determine the inflection point of the melting transition 
(Tm). Data from at least three independent TSA experiments were used to 
determine the mean Tm (± s.d.) of wild-type PsaA and the mutant variants.
Protein assays. Metal loading assays were performed on purified apo-PsaA 
variants (30 μM) by mixing with tenfold Mn2+ or Zn2+ (300 μM MnSO4 or 
ZnSO4) in a total volume of 2 ml into the assay buffer (20 mM MOPS, pH 7.2, 
100 mM NaCl) for 60 min at 277 K. The sample was desalted on a PD10 col-
umn (GE Healthcare) into the assay buffer, and the protein was concentration 
quantified. Protein was then either kept for ICP-MS analysis or mixed with 
3 mM EDTA in a total volume of 2 ml for 60 min at 277 K. Samples were then 
desalted on a PD10 column as before. The length of incubation for chelation of 
the metal ions was calibrated by observing that maximum extraction of Mn2+ 
from Mn2+-PsaA occurred within 60 min, whereas negligible extraction of Zn2+ 
from Zn2+-PsaA was achieved over this time. Longer incubations (up to 4 h) 
of Zn2+-PsaA with EDTA did not achieve any significant (P = 0.2) extraction 
of Zn2+ (Supplementary Fig. 6). Reversing the order of addition of the chelat-
ing agent and Zn2+ (EDTA-Zn2+) confirmed that the concentration of EDTA 
used was sufficient for complete chelation of Zn2+ (Supplementary Fig. 6). 
Solutions (5–10 μM) of control, metal-loaded and EDTA-treated protein were 
prepared in 3.5% HNO3 and boiled for 15 min at 370 K. Samples were then 
cooled and centrifuged for 20 min at 14,000g. The supernatant was then ana-
lyzed by ICP-MS, and the protein/metal ratio was determined.
Protein crystallization, structure determination and analysis. All of the 
protein samples were further purified by gel filtration using a HiLoad 26/60 
column (GE Healthcare), equilibrated with 25 mM Tris-HCl pH 8.0, 5.0% 
(v/v) glycerol, 150 mM NaCl, before crystallization experiments. Eluted PsaA 
was concentrated to 10 mg ml−1 using Amicon Ultra-4 centrifugal devices 
(Millipore). Following optimization, large crystals (200 μm × 100 μm × 100 μm) 
were obtained, after 7–10 d at 293 K from streak-seeded pre-equilibrated 
(24 h) drops, in 12.5% (w/v) PEG 1000, 12.5% (w/v) PEG 3350, 12.5% (v/v) 
MPD, 0.1 M Trizma-Bicine, pH 8.7. Prior to data collection, crystals were 
flash-cooled by rapid immersion in liquid nitrogen. For Mn2+-containing 
PsaA structures, crystals were grown as described above and transferred into 
pre-equilibrated protein crystallization drops containing MnSO4 (100 mM in 
reservoir solution) and allowed to equilibrate for at least 10 min before flash-
cooling as described above. Diffraction data were collected on single crystals 
at the wavelength of 0.95 Å at the Australian Synchrotron. All of the structures 
were solved by molecular replacement using the automated molecular replace-
ment pipeline Balbes46 followed by automatic model building in Arp/wArp47,48. 
Structure refinement was performed using Buster (Global Phasing) iteratively 
with manual model building in Coot49. All of the crystals had two protein mol-
ecules per asymmetric unit (r.m.s. deviation < 0.5 Å over 278 Cα atoms from 
each protein chain). Protein superpositions used ‘chain A’ and were performed 
using Superpose within CCP4 (ref. 47). Statistics for data processing and struc-
tural refinement can be found in Supplementary Table 2. Morphing of atomic 
coordinates was performed with the University of California–San Francisco 
Chimera package. Chimera is developed by the Resource for Biocomputing, 
Visualization, and Informatics at the University of California–San Francisco 
(supported by NIGMS P41-GM103311)50.
Molecular dynamics simulations of PsaA. All of the MD simulations were per-
formed using the GROMACS (Groningen Machine for Chemical Simulation) 
engine51 in conjunction with the GROMOS 54a7 forcefield52 for proteins using 
the three initial conformations of the protein described below. The crystallo-
graphic water molecules were retained. Water was described using the simple 
point charge (SPC) water model. All of the simulations were performed under 
periodic boundary conditions using either a dodecahedron or rectangular 
box. The dimensions of the box were chosen such that the minimum distance 
between the protein and the box wall was at least 1.2 nm. The nonbonded 
interactions were evaluated using a twin-range method. Interactions within 
the short-range cutoff of 0.9 nm were updated every step. Interactions within 
the long-range cutoff of 1.4 nm were updated every three steps together with 
the pair list. To minimize the effect of truncating the electrostatic interactions 
beyond the 1.4-nm long-range cutoff, a reaction-field correction was applied 
using a relative dielectric constant of εr = 78.5 (ref. 53). The SHAKE algorithm54 
was used to constrain the lengths of the covalent bonds. The SETTLE algo-
rithm55 was used to constrain the geometry of the water molecules. To extend 
the timescale that could be simulated, explicit hydrogen atoms in the protein 
were replaced with dummy atoms, the positions of which were calculated in 
each step on the basis of the positions of the heavy atoms to which they were 
attached. Doing so eliminated high-frequency degrees of freedom associated 
with the bond angle vibrations involving hydrogens, allowing a time step of 
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Maiorov and Crippin59 after first fitting the trajectory frames to a reference 
structure or domain.
Interdomain angles: To identify the domain motion associated with the 
change in angle between the C-terminal and N-terminal domain associated 
with the bending of the hinge residues, the angle between the Cα atoms of 
His67, His139 and Glu205 was calculated.
Inter-residue distances: To determine the flexibility of the PsaA metal- 
binding site, the distance between the center of mass of the Cβ atoms of 
residues His67 and Glu205, and the center of mass of the Cβ atoms of residues 
His139 and Asp280 was measured.
4 fs to be used to integrate the equations of motion without affecting thermo-
dynamic properties of the system56. The simulations were carried out in the 
NPT ensemble at T = 300 K and P = 1 bar. The pressure coupling was isotropic. 
The temperature and pressure were maintained close to the reference values by 
weakly coupling the system to an external temperature and pressure bath using 
a relaxation time constant of 0.1 ps57 and 0.5 ps, respectively. The compress-
ibility was 4.5 × 10−5 bar. Configurations were saved every 40 ps for analysis. 
Images were produced using VMD58.
To investigate the conformational flexibility of PsaA without a metal ligand, 
two sets of coordinates were used as initial models, the Zn2+-bound PsaA struc-
ture (PBD code 1PSZ) with the Zn2+ ligand removed and the metal-free PsaA 
structure (PDB code 3ZK7). Metal binding by PsaA is a pH-dependent process1, 
and metal-bound structures have been crystallized at pH 4.0 (Mn2+)17 and 7.5 
(Zn2+)18. As the pKa of the imidazole side chain of histidine is approximately 6.5, 
these pH differences will affect the protonation state of the two histidine residues 
involved in the metal-binding site. To take into account the effect of pH on the 
structural stability of apo-PsaA, simulations were performed under three differ-
ent initial conformations of PsaA. First, to assess the stability of apo-PsaA, the 
two histidine residues from the metal-binding site were assigned single protona-
tion states (metal-free PsaA (PDB code 3ZK7)) with His67 (HisB) and His139 
(HisA)). Second, to assess the stability of the apo structure as the pH was lowered, 
the binding site histidines, His67 and His139, were doubly protonated (metal-
free PsaA (PDB code 3ZK7) with His67 (HisH) and His139 (HisH)). Finally, 
to examine the conformational change that could be involved in opening the 
protein on the release of metal ion, His67 and His139 of Zn2+-bound PsaA were 
doubly protonated, and the metal ion was removed from the binding site before 
MD simulations (closed-state, Zn-removed PsaA (PDB code 1PSZ) with His67 
(HisH) and His139 (HisH)). The HisA, HisB and HisH nomenclature is consist-
ent with that used in the GROMOS 54a7 ff, implemented in GROMACS.
The system was equilibrated as follows: 500 steps of steepest descent energy 
minimization were performed to relax the solvent atoms with the initial pro-
tein conformation restrained using a harmonic potential with a force constant 
of 1,000 kJ mol−1 nm−1. Then, a series of 1-ns simulations was performed, in 
which the force constant was progressively relaxed from 1,000 kJ mol−1 nm−1 
to 10 kJ mol−1 nm−1 over a 10-ns equilibration period. New velocities were then 
assigned, and each system was simulated for 50 ns without restraints. Three 
independent simulations with different sets of starting velocities were per-
formed. In all MD simulations, the error is the standard deviation calculated 
from the last frames of the simulations.
MD analysis. R.m.s. deviation. To compare the relative difference between tra-
jectories or clusters, the r.m.s. deviation was calculated using the method of 
46. Long, F., Vagin, A.A., Young, P. & Murshudov, G.N. BALBES: a molecular-
replacement pipeline. Acta Crystallogr. D Biol. Crystallogr. 64, 125–132 (2008).
47. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. 
D Biol. Crystallogr. 50, 760–763 (1994).
48. Langer, G., Cohen, S.X., Lamzin, V.S. & Perrakis, A. Automated 
macromolecular model building for X-ray crystallography using ARP/wARP 
version 7. Nat. Protoc. 3, 1171–1179 (2008).
49. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development 
of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
50. Pettersen, E.F. et al. UCSF Chimera—a visualization system for exploratory 
research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
51. Lindahl, E., Hess, B. & Van Der Spoel, D. GROMACS 3.0: a package for 
molecular simulation and trajectory analysis. J. Mol. Model. 7, 306–317 
(2001).
52. Schmid, N. et al. Definition and testing of the GROMOS force-field versions 
54A7 and 54B7. Eur. Biophys. J. 40, 843–856 (2011).
53. Tironi, I.G., Sperb, R., Smith, P.E. & Vangunsteren, W.F. A generalized 
reaction field method for molecular-dynamics simulations. J. Chem. Phys. 
102, 5451–5459 (1995).
54. Hess, B., Bekker, H., Berendsen, H.J.C. & Fraaije, J.G.E.M. LINCS: a linear 
constraint solver for molecular simulations. J. Comput. Chem. 18, 1463–1472 
(1997).
55. Miyamoto, S. & Kollman, P.A. Settle—an analytical version of the shake and 
rattle algorithm for rigid water models. J. Comput. Chem. 13, 952–962 (1992).
56. Feenstra, K.A., Hess, B. & Berendsen, H.J.C. Improving efficiency of large 
time-scale molecular dynamics simulations of hydrogen-rich systems.  
J. Comput. Chem. 20, 786–798 (1999).
57. Berendsen, H.J.C., Postma, J.P.M., Vangunsteren, W.F., Dinola, A. &  
Haak, J.R. Molecular-dynamics with coupling to an external bath. J. Chem. 
Phys. 81, 3684–3690 (1984).
58. Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics.  
J. Mol. Graph. 14, 33–38 (1996).
59. Maiorov, V.N. & Crippin, G.M. Significance of root-mean-square deviation in 
comparing three-dimensional structures of globular proteins. J. Mol. Biol. 
235, 625–634 (1994).
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2.3.  Materials and methods 
MD simulations were performed using the GROMACS (Groningen Machine for Chemical 
Simulation) engine (14) and Gromos54a7 united atom force field (15) for the simulation models 
described below. Each model was solvated in a dodecahedron water box using single point 
charge (SPC) type water molecules, retaining crystallographic water molecules and adding 
counter ions to neutralise the overall model. The dimensions of the box were chosen such that 
the minimum distance between the protein and the box wall was at least 1.2 nm. The twin-range 
method was used to evaluate nonbonded interactions. Interactions within the short-range cutoff 
of 0.9 nm were updated every step, whereas, the interactions within the long-range cutoff of 1.4 
nm were updated every three steps together with the pair list. To minimise the effect of 
truncating the electrostatic interactions beyond the 1.4 nm long-range cutoff, a reaction-field 
correction was applied using a relative dielectric constant of εr = 78.5.  The SETTLE algorithm 
was used to constrain the geometry of the water molecules. In addition, the explicit hydrogen 
atoms in the protein were replaced with dummy atoms, the positions of which were calculated in 
each step on the basis of the positions of the heavy atoms to which they were attached. This 
eliminated high-frequency degrees of freedom associated with the bond angle vibrations 
involving hydrogens, allowing a time step of 4 fs to be used to integrate the equations of motion 
without affecting thermodynamic properties of the system. Before equilibration, the models were 
energy minimised to eliminate any close contacts. For equilibration, the backbone atoms of the 
proteins were constrained to their crystal structure positions, reducing the force constant 
gradually from 1000 kJ mol−1 nm−2 to 0 over a period of 11 ns. Both equilibration and simulation 
were done using dodecahedron periodic boundary conditions, Berendsen coupling for 
temperature and pressure and simulation time step of 4 fs (16, 17). The simulations were carried 
out in the NPT ensemble at T = 300 K and P = 1 bar. The pressure coupling was isotropic. The 
temperature and pressure were maintained close to the reference values by weakly coupling the 
system to an external temperature and pressure bath using a relaxation time constant of 0.1 ps 
and 0.5 ps, respectively. The compressibility was 4.5 × 10−5 bar. The LINCS algorithm was used 
to convert all bonds to constraints and standard values were used for non-bonding interactions 
(18). All simulations were run in duplicated using different random number seedings to allocate 
initial velocities. Each simulation was run for 50 ns and conformations were saved every 20 ps. 
The analysis of the trajectories was done using the GROMACS analysis tools. VMD (19) and 
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PyMol (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.) were used 
to visualise the simulation trajectories and to generate images.  
 
To investigate the importance of protonation state of metal-binding histidines, His67 and His139, 
in the metal binding process of PsaA and other cluster A-I SBPs, MD simulations were 
performed using metal-free PsaA crystal structure (pdb: 3ZK7) as the starting conformation for 
the three simulation models. Model 1a, with both metal-binding histidines in the neutral state; 
Model 1b, with both metal-binding histidines in the protonated state; and Model 1c, with one 
histidine in neutral and other histidine in protonated state. This has been elaborated further in the 
next section. 
 
The estimation of the pKa values of His67 and His139 was performed using the PROPKA 3.0 
server. PROPKA is a structure-based empirical method for the pKa prediction of the ionisable 
residues in the proteins and is fully automated (24). pKa is the sum of two terms (pKa = pKa,model 
+ ΔpKa), where pKa,model is associated with the unperturbed value for each residue (for example 
6.5 for His), and the shift (ΔpKa) is treated as an environmental perturbation. Furthermore, for 
each ionisable group, ΔpKa is given as a sum of perturbations due to desolvation, hydrogen 
bonding, and charge−charge interactions (ΔpKa = ΔpKDesolvation + ΔpKHB + ΔpKChgChg) (25). A 
pdb file is used as input to the server, which provides pKa values for each residue in a fully 
automated fashion 
 
To understand the differential motion of the C-terminal domain of PsaA in three different 
simulation models, 1a, 1b and 1c, Principal Component Analysis (PCA) was performed (21, 22). 
PCA is a method which analyses a simulation trajectory and extract only the dominant modes 
from the entire motion of the molecule. The complex conformational space of the simulation 
trajectory is reconstructed using a simple linear transformation in a Cartesian coordinate space to 
generate a 3N x 3N covariance matrix. Following this, diagonalisation of the covariance matrix 
produces a set of eigenvectors that represent each component of the motion as well as the 
direction of motion. The eigenvector also has a corresponding eigenvalue, which represents the 
energetic contribution of that particular component to the global motion of the protein (23). 
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Gromacs tools, such as g_covar and g_anaeig were used to perform PCA analysis of the Cα 
atoms of the simulation trajectories. 
 
2.4.  Results and discussion 
2.4.1. Influence of pH conditions on the metal-binding process  
 
Metal binding has been established as a pH-dependent process in various metal-binding 
transporters, exhibiting metal uptake and transport at lower pH values (5, 9, 10). Metal-bound 
structures of Cluster A-1 metal-binding SBPs have been crystalised at different pH conditions, 
such as, PsaA metal-bound structures have been crystallised at pH 4.0 (Mn2+) (6), 7.5 (Zn2+) (7) 
and 8.0 (Cd2+). In addition, metal-free PsaA has been crystallised at pH 8.7 (8). These 
crystallographic pH differences are bound to affect the protonation states of the histidines 
involved in the metal binding site, which is evident from the pKa determination of the PsaA 
metal binding residues. The pKa of Glu205 and Asp280 indicated that they remain deprotonated 
in all the PsaA crystal structures, however, the two metal-binding histidine residues (His67 and 
His139) showed differential protonation states depending on the pH conditions (12, 13). In 
metal-free PsaA (pdb: 3ZK7), crystallised at pH 8.7, both His67 and His139 remain neutral with 
a pKa of 6.7 and 8.1, respectively, whereas, in Mn
2+-bound PsaA (pdb: 3ZTT), crystallised at pH 
4.0, both His67 and His139 were found to be protonated with a pKa of 6.7 and 8.6, respectively. 
Additionally, for the other two PsaA crystal structures, Zn2+-bound (pdb: 1PSZ; pH 7.5) and 
Cd2+-bound (pdb: 4UTP; pH 8.0), His67 remain neutral with a pKa of < 7, whereas, His139 is 
protonated with a pKa of > 8 in both the cases. The pKa of the two metal-binding histidines for 
each of these crystal structures was determined using PROPKA 3.0 server. It is to be noted that 
these pKa determinations were done in the absence of the metal ions in the metal binding pocket. 
This suggests that when pH is above pKa more than 50 % of each of His67 and His139 exists in 
unprotonated state, whereas, when pH is lower than pKa more than 50 % of each of these 
histidines in the system are protonated. This implies that neutral to basic pH conditions are 
required to keep both histidines majorly in unprotonated state, which in turn is important for 
metal binding in PsaA. In addition, unlike the standard pKa of ~6.5 for imidazole side chains of 
histidines, PsaA His139 has a pKa of ~8.5 and therefore, a highly basic pH condition is required 
to keep this residue in entirely neutral state. To further understand why protonation state of 
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histidines may have a crucial role in metal binding to PsaA and other similar SBPs, molecular 
dynamics simulations were performed using metal-free PsaA (pdb: 3ZK7) as a starting structure 
to three different simulation models. These three simulation models were without the metal-ion 
in the metal-binding pocket, similar to their starting structure 3ZK7 (metal-free PsaA), differing 
only in their metal-binding histidines protonation states: (a) simulation model 1a, representing 
the basic pH condition where both histidines are neutral as in metal-free PsaA crystal structure 
(pdb: 3ZK7), (b) simulation model 1b, representing acidic pH condition where both the 
histidines are protonated as in Mn2+-bound PsaA (pdb: 3ZTT) and (c) simulation model 1c, 
representing neutral pH condition where His67 is neutral and His139 is protonated as in Zn2+-
bound (pdb: 1PSZ) and Cd2+-bound (pdb: 4UTP) PsaA, as illustrated in figure 2.4.1. Simulating 
these three simulation models has given critical insights into (i) conformational flexibility of N- 
and C-terminal domain of apo-PsaA at different pH conditions and (ii) most interestingly, 
importance of metal-binding histidines protonation for metal binding.  
 
Neutral histidine residue represents imidazole ring with a protonated Nδ1 and a neutral NƐ2 
atom; whereas, protonated histidine residue represents imidazole ring with protonated NΔ1 and 
NƐ2 atoms. 
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Figure 2.4.1: Metal-binding histidines, His67 and His139, show different protonation states at different pH. Both 
histidines protonated are represented as His(+,+); His67 neutral and His139 protonated is represented as His(n,+); 
both histidines neutral are represented as His(n,n). Mn2+ (pdb: 3ZTT), Zn2+ (pdb: 1PSZ) and Cd2+ (pdb: 4UTP) 
bound PsaA was crystallised at pH 4, 7.5 and 8, respectively. Metal-free (apo) PsaA was crystallised at pH 8.7. 
Model 1a represents 3ZK7, Model 1b represents 3ZTT and Model 1c represents 1PSZ and 4UTP. 
 
2.4.2. Root-mean square deviation (R.M.S.D) analysis 
 
The three simulation models, model 1a, 1b and 1c, were simulated for 50 ns in two independent 
simulations each, with different sets of starting velocities. To evaluate the relative difference 
between trajectories, the root-mean square deviation (RMSD) was calculated using the method 
of Maiorov and Crippin (20) after first fitting the trajectory frames to a reference structure or 
domain. The Cα RMSD values of N-terminal (residues 32-117) domain were only 1.8 ± 0.2 Å, 
2.2 ± 0.2 Å and 1.8 ± 0.1 Å for simulation models 1a, 1b and 1c, respectively, 
indicatingstructural integrity of N-terminal lobe at all pH conditions and histidine protonation 
states  (Figure 2.4.2, panel a, c and e). However, Cα RMSD values of C-terminal (residues 194-
309) domain were 4.3 ± 0.3 Å, 2.2 ± 0.2 Å and 2.8 ± 0.2 Å for simulation models 1a, 1b and 1c, 
respectively, indicating that C-terminal lobe undergoes greater domain movement in Model 1a 
(with neutral histidines) as compared to the other two simulation models (1b and 1c) (Figure 
2.4.2, panel b, d and f). 
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Figure 2.4.2: RMSD of the Cα atoms from their initial coordinates (pdb: 3ZK7) as a function of time for 
Model 1a, 1b and 1c. (a, c, e) RMSD of the Cα atoms of N-terminal (residues 32-117) domain for simulation 
models 1a, 1b and 1c, respectively. (b, d, f) RMSD of the Cα atoms of C-terminal (residues 194-309) domain for 
simulation models 1a, 1b and 1c, respectively. 
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2.4.3. Principal component analysis (PCA) of open-state (apo) PsaA simulation models 
 
PCA of the C-terminal domain of the 3 models, i.e. model 1a, 1b and 1c, revealed that the first 
10 eigenvectors accounted for 87.4 % of the global motion of the protein and that the first 
eigenvector corresponded to 42.1 % of the total motion and the second to a further 14.3 % 
(Figure 2.4.3.1).  
 
 
Figure 2.4.3.1: Eigenvalue spectra of diagonalised covariance matrix, for simulation models 1a, 1b and 1c. The first 
eigenvector contributes 42.1 % to the total motion of protein, whereas second eigenvector contributes 14.3 %. 
 
Further analysis of C-terminal domain dynamics for the three simulation models was limited to 
the first two eigenvectors, and a projection of the trajectories of the three simulation models onto 
the first two eigenvectors was analyzed graphically (Figure 2.4.3.2, panel a). During the 50 ns 
simulation, Model 1a, with both histidines in a neutral protonation state, showed two distinct 
clusters for the backbone conformation of the C-terminal domain, with only a single transition 
from one to the other. In the first cluster, opening of the Model 1a structure occurred via a rigid 
body movement of the C-terminal domain with a hinge-angle of 23.7° between N- and C-
terminal domains in a plane orthogonal to the linking helix, whereas in the second cluster, this 
hinge-angle further increased to 66.1° (Figure 2.4.3.2, panel b) and remained at that level for the 
remainder of the simulation. On the other hand, simulations of both Model 1b and Model 1c 
showed only conformations which are similar to the first cluster of Model 1a (Figure 2.4.3.2, 
panel a). This indicates that apo-PsaA at basic pH, with both metal binding histidines in their 
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neutral state, undergoes extensive C-terminal domain movement causing further solvent 
exposure of metal binding pocket inhibiting metal binding. Changing the protonation state of one 
or both histidines to positive charged corresponding to neutral or acidic pH, maintains the 
structural integrity of the C-terminal domain, restricting its movement. Interestingly, this change 
of dynamic behaviour between different protonation states is limited to the C-terminal domain. 
Equivalent analysis of the N-terminal domain (32-117), using a PCA of the Cα atoms, showed all 
three models maintaining similar structural integrities and showing a single and similar 
conformational cluster (Figure 2.4.3.3). 
 
 
Figure 2.4.3.2: (a) Projections of the C-terminal domain Cα atoms trajectories of Model 1a, 1b and 1c onto the first 
(EV1) and second (EV2) eigenvectors. The red-colored projection represents Model 1a, green-colored projection 
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represents Model 1b and blue-colored projection represents Model 1c. Black dot represents metal-free PsaA crystal 
structure (pdb:3ZK7) and grey-colored dot represents Zn-bound PsaA crystal structure (pdb: 1PSZ). (b) 
Superposition of metal-free-PsaA crystal structure (pdb:3ZK7; grey), with average structure of Model 1a second 
conformational cluster (red). All the helices for both the structures are shown as cylinders. Residues in the metal 
binding site are shown in stick representation. The difference in the hinge-angles between the two structures is 
noted. 
 
 
 
Figure 2.4.3.3: Projections of the N-terminal Cα atoms trajectories of Model 1a, 1b and 1c onto the first (EV1) and 
second (EV2) eigenvectors. The red-colored projection represents Model 1a, green-colored projection represents 
Model 1b and blue-colored projection represents Model 1c. Black dot represents metal-free PsaA crystal structure 
(pdb: 3ZK7) and grey-colored dot represents Zn-bound PsaA crystal structure (pdb: 2PSZ). 
 
A closer look at the projection of Model 1b and Model 1c trajectories using a smaller scale for 
the presentation revealed that the C-terminal domain of Model 1b remains mainly within one 
conformational cluster, for both replica simulation of the model (Figure 2.4.3.4, panel a). Figure 
2.4.3.4, panel b shows the superposition of metal-free-PsaA crystal structure and the dominant 
cluster for Model 1b. It is evident that the N-terminal domain and the linking helix superimpose 
well with the crystal structure, while the C-terminal domain shows a shift in two of its helices 
(234-245; 259-269) creating space in between the two. However, the C-terminal domain does not 
undergo rigid body movement as in Model 1a, showing an increase of the hinge-angle of only 
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3.7° (Figure 2.4.3.4, panel b). Detailed analysis of the metal binding pocket over 50 ns of 
simulations revealed that the protonated histidines, His67 and His139, potentially contributed to 
the positively charged environment of the metal binding pocket which attracted both 
deprotonated metal-binding residues, Glu205 and Asp280 towards His139. The mobile metal 
binding residue Glu205, along with the static metal binding residue, Asp280, formed a H-bond 
contact with the protonated His139 (Figure 2.4.3.4, panel c). These strong H-bond contacts (< 
3.0 Å), in addition to the presence of protonated His67 in the metal binding pocket, seemed to 
regulate the movement of Glu205, which in turn contributed in controlling the hinge-bending 
motion of C-terminal domain. This suggests that at acidic pH with protonated histidines, apo-
PsaA maintains structural stability which is ideal for metal binding.  
 
 
Figure 2.4.3.4: (a) Closer view of C-terminal domain Cα atoms projections of the Model 1b trajectory onto the first 
(EV1) and second (EV2) eigenvectors. Black dot represents metal-free PsaA crystal structure (pdb: 3ZK7) and grey-
Chapter 2 
47 
 
colored dot represents Zn-bound PsaA crystal structure (pdb: 1PSZ). (b) Superposition of metal-free PsaA crystal 
structure (pdb: 3ZK7; grey) and middle structure of Model 1b 50 ns simulation (green). All the helices for both the 
structures are shown as cylinders. Residues in the metal binding site are shown in stick representation. The hinge-
angle between C-terminal domains of the two structures is noted. (c) View of the Model 1b middle structure’s metal 
binding pocket. The protein is shown in cartoon representation with metal-coordinating residues in sticks with 
following atom colors: carbon, green; nitrogen, blue; oxygen, red; and polar hydrogens, white. Metal-coordinating 
residues of metal-free PsaA crystal structure (pdb: 3ZK7) are shown in grey sticks for reference. The residues are in 
black labels and hydrogen-bonding interactions are shown in black-dotted lines. 
 
  In comparison, the C-terminal domain in Model 1c occupies two conformational clusters over 
50 ns of simulation and in both replica simulations, with frequent transitions from one to the 
other (Figure 2.4.3.5, panel a). In the first cluster, the hinge bending motion of the C-terminal 
domain was evident with a hinge-angle of 6.3° while the rest of the protein maintains its 
structural integrity. In the second cluster, this hinge-angle increased further to 15.2° suggesting 
that one protonated histidine in the metal binding pocket works better in regulating the opening 
of PsaA structure than a neutral pocket (Figure 2.4.3.5, panel b). Further analysis of metal 
binding pocket revealed that in the first cluster, the charged His139 is in H-bond distance to the 
metal binding residue, Glu205, similar to the cluster in Model 1b (Figure 2.4.3.5, panel c). 
However, in the second cluster, His139 moved away from Glu205 (increased its distance to 5.3 
Å) while moving closer to Asp280 with distance < 3.0 Å (Figure 2.4.3.5, panel d). The main 
difference between Model 1b and 1c is the protonation state of His67. Unlike Model 1b, the 
absence of an additional proton on His67 of Model 1c affected the positively charged 
environment of metal-binding pocket in Model 1c. This potentially resulted in differences in the 
H-bonding between metal-binding residues of Model 1b and Model 1c. Moreover, this indicates 
that in addition to His139, His67 contributes to the structural integrity of the binding site, by 
supporting the H-bond network in the site between, His139, Glu205 and Asp280 with an 
additional proton in case of Model 1b. However, in Model 1c missing the additional proton on 
His67 affected this behaviour causing Glu205 to display more mobility, thereby causing slightly 
more hinge-bending motion. Conclusively, at neutral pH, absence of protonated His67 
potentially affects the H-bonding between protonated His139 and Glu205, contributing to 
slightly more hinge-bending motion of C-terminal domain of apo-PsaA. However, the presence 
Chapter 2 
48 
 
of only one protonated histidine, His139, in the metal binding pocket still imparts the structural 
stability to the protein required for metal binding. 
 
 
 
Figure 2.4.3.5: (a) Closer view of C-terminal domain Cα atoms  projections of the Model 1c trajectory onto the first 
(EV1) and second (EV2) eigenvectors. Black dot represents metal-free  PsaA crystal structure (pdb: 3ZK7) and 
grey-colored dot represents Zn-bound PsaA crystal structure (pdb: 1PSZ). (b) Superposition of metal-free  PsaA 
crystal structure (pdb: 3ZK7; grey), with middle structures of Model 1c first conformational space (blue) and second 
conformational space (cyan).All the helices for both the structures are shown as cylinders. Residues in the metal 
binding site are shown in stick representation. The hinge-angle between C-terminal domains of the three structures is 
noted. (c) View of the Model 1c first conformational space middle structure’s metal binding pocket. (d) View of the 
Model 1c second conformational space middle structure’s metal binding pocket. In both (c) and (d), the protein is 
shown in cartoon representation with metal-coordinating residues in sticks with following atom colors: carbon, 
green; nitrogen, blue; oxygen, red; and polar hydrogens, white. Metal-coordinating residues of metal-free PsaA 
crystal structure (pdb: 3ZK7) are shown in grey sticks for reference. The residues are in black labels and hydrogen-
bonding interactions are shown in black-dotted lines.   
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2.4.4. Principal component analysis (PCA) of closed-state (Zn2+-bound) PsaA simulation 
models 
 
In addition to simulating apo-PsaA (metal-free, open) using different protonation states of metal-
coordinating histidines representing different pH conditions, Zn2+-bound closed PsaA structure 
(pdb:1PSZ) was used as a control for this study. The Zn2+ ion was constrained in the metal 
binding site using distance restraints between the ion and the metal binding residues (Model 2). 
The C-terminal domain PCA of the 50 ns simulation, using the same combined eigenvector 
projection as in Model 1, showed that the model maintained a high structural integrity, with only 
small conformational variations around its original starting conformation (Figure 2.4.4). 
Furthermore, Zn2+ was removed from the Zn2+ bound closed crystal structure of PsaA (pdb: 
1PSZ) to develop other simulation models, Model 3a with both metal-coordinating histidines as 
neutral representing basic pH conditions and Model 3b with both metal-coordinating histidines 
as protonated representing acidic pH conditions. These two simulation models (Model 3a and 
3b) were developed to understand if the open or closed form of the protein influences the effect 
caused by different pH conditions and corresponding histidines protonation states on PsaA 
conformational dynamics. PCA of the C-terminal domain Cα atoms of Model 3a revealed that it 
sampled two different conformational spaces during 50 ns of simulation similar to Model 1a and 
an extensive hinge-bending motion occurred leading to a maximal hinge-angle of 59.2° 
calculated from the average structure of second conformational space (Figure 2.4.4). However, 
PCA of the C-terminal domain Cα atoms of Model 3b showed that it explored a single 
conformational space similar to Model 1b clearly suggesting different protonation states of 
metal-coordinating histidines and pH conditions affect the conformational dynamics of PsaA 
irrespective of its closed or open state. 
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Figure 2.4.4: Projections of the C-terminal domain Cα atoms trajectories of Model 2, 3a and 3b onto first (EV1) and 
second (EV2) eigenvectors. The grey-colored projection represents Model 2, red-colored projection represents 
Model 3a and green-colored projection represents Model 3b. Grey dot represents Zn2+-bound crystal structure (pdb: 
1PSZ) and black dot represents metal-free PsaA crystal structure (pdb: 3ZK7). (a) Superposition of Zn2+-bound 
crystal structure (grey), with average structures of Model 3a (red) and 3b (green) first conformational space. All the 
structures are represented in cartoon representation. (b) Cartoon representation of the average structure of Model 3a 
second conformational space. The hinge-angle of the C-terminal domain is noted.   
 
2.5. Conclusion 
The study has highlighted the importance of pH required for metal binding in the substrate 
binding proteins (SBPs). It has now been established that N-terminal domain of PsaA imparts 
structural stability to the protein at all pH conditions, whereas, protonation states of metal-
binding histidines have a huge impact on conformational flexibility of the C-terminal domain of 
PsaA. The B-factor analysis of the metal-free crystal structures of PsaA (pdb: 3ZK7) and AdcA 
(pdb: 3CX3) shows that the C-terminal domain loop regions in both the structures have high B-
factors, thereby suggesting the higher degree of flexibility of these regions in both the SBPs 
Chapter 2 
51 
 
which belong to cluster A-I. In addition, the study has clearly suggested that the protonated 
forms of histidines, especially His139, play a pivotal role in the structural stability of PsaA, 
which is important for metal binding. Finally, the basic pH conditions and neutral metal-binding 
histidines cause extensive C-terminal domain rigid-body movement due to the unregulated 
hinge-bending motion. This leads to excessive solvent exposure of the metal binding pocket, 
therefore, inhibiting metal binding. Given that Cluster A-1 SBPs lack homologs in humans, have 
a role in bacterial virulence and are a potential drug targets against Gram-positive bacteria, these 
findings would help to further understand and devise newer ways to target these proteins and 
hence, the infection. 
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3.1. Introduction 
The work presented in this chapter is a continuation of the work presented in chapter 2 and 
involves the development of fragment-like small molecule inhibitors targeting PsaA. As 
mentioned in Chapter 1, Streptococcus pneumoniae is a leading cause of mortality worldwide 
and its treatment primarily involves traditional antibiotics such as β-lactams, which cure the 
infection by killing the bacteria. However, this approach has led to the rapid emergence of multi-
drug resistant (MDR) strains of the pneumococcus in the past two decades demanding 
researchers to look for newer strategies targeting pneumococcal infection, which would put less 
evolutionary pressure on target bacterium and hence, would control the development of MDR 
strains. One such strategy is to target substrate-binding proteins (SBPs) such as PsaA, as it 
functions as a surface adhesin as well as SBP binding Mn2+ and transporting it into the bacterial 
cell. Chapter 2 (section 2.2) presented the crystallised and published crystal structure of the 
open-state metal-free PsaA along with the novel mechanism of metal binding and release from 
the PsaA. These findings have been used in Chapter 3 to identify novel inhibitors for PsaA, using 
a combination of virtual screening and conventional fragment-based drug design approaches. 
The findings of this study are reported in the following manuscript that has been accepted for 
publication by ACS Chemical Biology “M. Bajaj, S.K. Mamidyala, J. Zuegg, S.L. Begg, M.P. 
Ween, J.X. Huang, B. Kobe, J.C. Paton, C.A. McDevitt and M.A. Cooper. Development of novel 
Pneumococcal surface antigen A (PsaA) inhibitors using a fragment-based drug design 
approach. ACS Chemical Biology Accepted 19th March 2015, Publication Date (Web): March 
19, 2015, DOI: 10.1021/cb501032x.” which forms section 3.2.  
   
3.2. M. Bajaj, S.K. Mamidyala, J. Zuegg, S.L. Begg, M.P. Ween, J.X. Huang, B. Kobe, J.C. 
Paton, C.A. McDevitt and M.A. Cooper. Development of novel Pneumococcal surface 
antigen A (PsaA) inhibitors using a fragment-based drug design approach. ACS Chemical 
Biology, DOI: 10.1021/cb501032x. The manuscript is in the form as published in ACS 
Chemical Biology. The supporting information of the manuscript is in the appendix section of 
this thesis (page 127). 
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ABSTRACT: Streptococcus pneumoniae is a leading cause of
life-threatening bacterial infections, especially in young
children in developing countries. Pneumococcal infections
can be treated with β-lactam antibiotics, but rapid emergence
of multidrug-resistant strains of S. pneumoniae over the past
two decades has emphasized the need to identify novel drug
targets. Pneumococcal surface antigen A (PsaA) is one such
target, found on the cell surface of S. pneumoniae. It functions as a high-affinity substrate-binding protein, facilitating acquisition
of Mn2+, which has an important role in protecting S. pneumoniae from reactive oxygen species and, hence, oxidative stress.
Consequently, PsaA is essential for bacterial survival and an important virulence factor, which makes it a promising target for
antibiotic drug development. To design novel PsaA inhibitors, we used a combination of de novo fragment-based drug discovery
and in silico virtual screening methods. We profiled a collection of low molecular weight compounds that were selected based on
their structural diversity and ability to bind to apo-PsaA in a virtual docking experiment. The screening resulted in two initial hits
that were further optimized by structural variation to improve their potency while maintaining their ligand efficiency and
favorable physicochemical properties. The optimized hits were validated using a cell-based assay and molecular dynamics
simulations. We found that virtual screening substantially augmented fragment-based drug design approaches, leading to the
identification of novel pneumococcal PsaA inhibitors.
■ INTRODUCTION
Streptococcus pneumoniae, a Gram-positive bacterium also known
as pneumococcus, is a leading cause of morbidity and mortality
worldwide, reportedly causing more than 1 million deaths per
year.1−3 The major burden of mortality, caused by invasive
pneumococcal disease, is shared by the youngest (<5 years of
age) and oldest (>60 years of age) segments of the population in
developing countries.3−5 In developed countries, deaths due to
pneumococcal infection remain high despite the availability of
vaccines and antimicrobial therapies. This is, in part, due to the
lack of a universal pneumococcal vaccine, as the current
conjugate vaccines provide protection against up to 23 of the
91 known serotypes of S. pneumoniae.6,7 Although the pneumo-
coccus is asymptomatically carried in the nasopharynx of many
individuals, it has a high capacity to escape this niche and cause
both localized and systemic diseases such as pneumonia,
bacteremia, meningitis, otitis media, and conjunctivitis, depend-
ing on the immune status of the host.2,6 The emergence of
clinically significant multidrug resistance in S. pneumoniae has
highlighted the need to identify new approaches that can combat
the infections.8,9 Virulence factors are not usually essential for the
viability or growth of bacteria but are crucial for establishing and
maintaining an infection in a host. Targeting S. pneumoniae
virulence factors rather than its growth would apply minimal
evolutionary pressure and, hence, would control infection and
potentially reduce the incidence of the resistant strains.10
Pneumococcal surface antigen A (PsaA) is a strictly conserved
surface-exposed lipoprotein expressed by all known pneumo-
coccal serotypes and is essential for colonization and patho-
genesis.11,12 Loss of PsaA has been found to perturb growth and
attenuate the in vivo virulence of S. pneumoniae in murine
models.13,14 PsaA is an integral part of an ATP-binding cassette
(ABC) transporter protein complex known as the PsaBCA
permease, which is involved in manganese (Mn2+) transport
across the bacterial cell membrane. The Mn2+ ion serves as an
essential trace element for S. pneumoniae, and it has a prominent
role in the management of oxidative stress, where it serves as a
cofactor for superoxide dismutase (SOD), catalyzing the
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dismutation of superoxide to oxygen and hydrogen peroxide.15,16
Given this role of PsaA, where it is essential for bacterial survival
and an important virulence factor, it is a promising target for
antibiotic drug development against S. pneumoniae.17
This study describes the identification of novel ligand-efficient
compounds targeting PsaA, using a combination of fragment
based drug design (FBDD) and in silico virtual screening
methods, representing an effective and resource-efficient path for
the identification of novel hits at the early stage of a drug
discovery process. Fragments, or small molecules (MW usually
<350 Da), can be used to extensively explore the chemical space
in the binding site of proteins, as they have a limited number of
functional groups. Subsequently, lead candidates are generated
by growing, expanding, or linking these fragments while
maintaining physiochemical properties and ligand efficiency.18
Herein, we report a fragment-based approach combined with in
silico methods to (a) preselect a fragment library by virtual
screening using the apo-PsaA structure, (b) evaluate the activity
of the library in a PsaA competitive metal-binding assay, (c)
optimize the initial hits by structural variation guided by the
virtual screening, and (d) evaluate the binding orientation of the
optimized hits by molecular dynamics simulations.
■ RESULTS AND DISCUSSION
Identification of PsaA Inhibitors by Fragment Screen-
ing. The high-resolution structure of apo-PsaA (PDB ID
3ZK7)19 was used to perform virtual screening of a fragment
library developed in-house using the FlexX (BiosolveIT) docking
software.19,20 The details of fragment library construction are
provided in the Supporting Information. The 1519 fragment-like
small molecules (with an average molecular weight of 214.9 Da)
were docked into the PsaAmetal-binding site, based on 3D shape
and electrostatic surface similarity to the pocket, followed by
scoring of all fragments using the in-built FlexX scoring function.
PsaA has a two-lobed structure with N- and C-terminal domains
linked together by a rigid helix.19,21,22 The Mn2+-binding pocket
is located at the bisection of the two domains and is coordinated
by two side-chain N atoms fromHis67 and His139 and two side-
chain O atoms from Glu205 and Asp280 (Supporting
Information Figure 1, panel a).19,21 The Nε2 atom of His139
was selected as the center of the binding pocket, and residues
within a 10 Å radius of the center were considered as part of a
binding site. The protonation state for each of the metal-binding
residues was determined at pH 7.0, predicting Glu205 and
Asp280 to be deprotonated, His67 to be neutral, and His139 to
be protonated. Virtual screening of the fragment library into the
PsaA metal-binding site was followed by selection of the top 300
fragment-like small molecules based on their FlexX score.
Subsequent visual inspection of their docked poses allowed
acceptance or rejection of the proposed binding modes. The 300
selected fragments were further filtered by cluster analysis using
Pipeline Pilot (Accelrys), selecting a diverse set of 60
molecules,23 which were tested with PsaA in a competitive
Zn2+-binding assay.
Zinc ions have previously been shown to compete with Mn2+
ions for binding to PsaA, despite having a KD that is nearly 2
orders of magnitude lower than that of the cognate ligand.22
Zn2+, being an irreversible natural inhibitor of PsaA, was used to
develop a PsaA competitive Zn2+-binding assay in which
FluoZin-3, a Zn2+-specific probe, produced a fluorescence signal
upon binding to Zn2+ (Ex, 494 nm; Em, 516 nm).22,24 Titrating
apo-PsaA protein from a concentration of 0 to 1000 nM, while
keeping a constant concentration of ZnCl2 (500 nM) and
FluoZin-3 (600 nM), showed a reduction of fluorescence signal
(Supporting Information Figure 1, panel b). At a protein
concentration of 100 nM, the fluorescence signal dropped by
95% after 10 min of incubation. At this concentration, PsaA is
able to compete for Zn2+ binding, thereby reducing the
concentration of the Zn2+−FluoZin-3 complex and quenching
its fluorescence readout. Conversely, inhibition of PsaA binding
Figure 1.A total of 60 fragments tested at a single concentration of 100 μM in the PsaA competitive Zn2+-binding assay. Error bars are standard deviation
of the mean for n = 5. Fragments 15 and 58 (structures shown) showed more than 50% PsaA inhibition at 1 mM concentration in individual titrations in
the PsaA competitive Zn2+-binding assay. The bars corresponding to fragments showing over 15 % inhibition are highlighted in green (the rest shown in
red).
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Zn2+ would result in a higher fluorescence signal due to increased
FluoZin-3 binding to Zn2+.
The 60 small molecules selected from virtual docking were first
tested at a single concentration (100 μM) in this assay, with PsaA
at 100 nM, ZnCl2 at 500 nM, and FluoZin-3 at 600 nM. For the
raw data of all 60 fragments in the PsaA competitive Zn2+-binding
assay, refer to Supporting Information Table 1. Interference of
the compounds with FluoZin-3 was also evaluated, and none of
the compounds showed a direct interaction with FluoZin-3. Of
the 60 fragments, 10 exhibited ≥15% inhibition of PsaA at a 100
μM concentration (Figure 1). These 10 compounds were tested
at different concentrations ranging from 0 to 1000 μM. Two
compounds, 15 and 58, showed more than a 50% inhibition of
Zn2+ binding by PsaA at a 1 mM concentration and were pursued
further.
Characterization of Fragments Binding Mode in PsaA
Metal-binding Pocket. The structures of both active
compounds 15 and 58 indicate potential hydrogen-bond donors
and acceptors that could have important roles in interacting with
the metal-binding site of PsaA (Figure 2, panel a and b). Insight
into the binding mode will provide valuable information for
guiding structure-based optimization and, thereby, further
improve activity. The metal-ion binding site of PsaA consists of
four residues, His67, His139, Glu205, and Asp280.21,22 In
addition, Pro66, Leu92, Pro138, and Trp141 of the N-terminal
lobe form a “hydrophobic pocket N” adjacent to the metal-
binding site, while the carbonyl backbone of Gln64 and side-
chain oxygen atoms of Asp65 are potential acceptor sites to form
hydrogen bonds. On the C-terminal lobe, Ala207, Phe208, and
Thr279 yield a hydrophobic surface in the binding pocket,
forming “hydrophobic pocket C,” while Asn226, Thr227, and
Glu230 could potentially be involved in hydrogen bonding with
prospective PsaA inhibitors forming “hydrophilic pocket C”
(Supporting Information Figure 2).
Structural analysis of the virtual docking pose of 15 within the
binding pocket of PsaA showed the amine forming a hydrogen
bond with the metal-binding residue Asp280 and the backbone
carbonyl of Gln64, while the amide formed an H-bond with
Asp280. The phenyl ring “A” of 15 filled the “hydrophobic
pocket N”, with the nitro group orientated toward the inside of
the protein and the methoxy-group occupying the “hydrophobic
pocket C” (Figure 2, panel c). The structural analysis indicates
that while 15 occupies most of the PsaA binding site, there are
regions around ring A that could expand to form additional H-
bond interactions with either metal-binding residue Glu205 or
other polar residues, such as Asp65, Asn226, Thr227, and
Glu230.
The virtual docking pose of 58 showed a strong H-bond
network with the PsaA binding site. The amine and hydroxyl
groups formed H-bonds with side-chain oxygen atoms of Asp65
on theN-terminal lobe, while the sulfonamide group formed aH-
bond network with “hydrophilic pocket C” (Figure 2, panel d).
The virtual docking poses were then used as references to further
optimize both compounds.
Optimization of Fragment 15. Based on the docking
studies of fragment 15 in the PsaA metal-ion binding site, 13
different phenyl ring A substituents were selected and screened
in PsaA competitive Zn2+-binding assays at 500 μM concen-
tration (Table 1). To ascertain whether any electronic factors or
steric factors influenced the affinity for PsaA, we used phenyl ring
A substituents such as electron withdrawing groups, donating
groups, and bulky groups.
Among the analogues tested, compound 15h with the
hydroxyl group at the ortho position of phenyl ring A showed
Figure 2. Proposed binding modes of fragment 15 and fragment 58 in the PsaA metal-binding pocket determined by in silico docking studies. (a)
Fragment 15 structure. The phenyl rings are labeled as A and B for distinction. (b) Fragment 58 structure. H-bond acceptor sites of the fragments are in
red circles, and H-bond donor sites of the fragments are in blue circles. (c) View of the fragment 15 binding mode. (d) View of the fragment 58 binding
mode. Fragments in the PsaA metal-binding site are shown in stick representation and colored in the following atom colors: carbon, orange; nitrogen,
blue; oxygen, red; sulfur, yellow; and polar hydrogens, white. PsaA protein is shown in surface representation, and binding site residues are shown in stick
representation with the following atom colors: carbon, cyan; nitrogen, blue; oxygen, red; and polar hydrogens, white. Metal-binding residues have blue
labels, whereas all other residues have black labels. Hydrogen-bonding interactions are shown as black dotted lines.
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the best activity with 100% PsaA inhibition at 500 μM. A dose−
response assay revealed an IC50 of 28.1 μM (Figure 3, panel a),
giving a ligand efficiency of 0.37 (using pIC50 divided by number
of heavy atoms), which is regarded as a good starting point for
further optimization.25,26 The PsaA−15h docked complex is
quite similar to fragment 15 in the previously proposed binding
mode in the PsaA metal-binding pocket (Figure 3, panel b). The
amine of phenyl ring B forms similar hydrogen-bond contacts
with the carbonyl group of Gln64 and the side-chain oxygen of
Asp280. Additionally, the amide also formed a H-bond with
Asp280 while the phenyl ring A occupies the “hydrophobic
pocket N” formed by the N-terminal lobe residues. An additional
strong hydrogen bond interaction is also formed between the
side-chain oxygen atom of polar residue Asp65 and the hydroxyl
attached to phenyl ring A of 15h. This could potentially
contribute to the improved activity of 15h compared to fragment
15. To obtain the crystal structure of the 15h−PsaA complex,
soaking of apo-PsaA crystals with the compound and
cocrystallization experiments of the compound with apo-PsaA
were attempted; however, all attempts were unsuccessful, most
likely due to the limited solubility of the compound and the
limited affinity for the protein. High concentrations of the
compound in a DMSO solution resulted in crystals with poor
diffraction quality, while using lower concentrations of the
compound, X-ray data could be collected, but the ligand could
not be located in the crystals.
In addition to the screening of phenyl ring A substituents,
seven modifications were tested on phenyl ring B, which again
included electron withdrawing groups, donating groups, and
bulky groups (see Supporting Information Table 2). However,
none of these substituents showed any inhibitory activity against
PsaA. Following this, 31 different substitutions were tried on
both the phenyl rings A and B simultaneously, which were again
found to be inactive in PsaA competitive Zn2+-binding assays
(see Supporting Information Table 3).
Optimization of Fragment 58. Table 2 shows the chemical
structures and PsaA inhibition data for all the phenyl ring
substitutions tested in the process of fragment 58 optimization.
To ascertain whether any substituents affected PsaA
inhibition, we assessed several different commercially available
sulfonamide fragments. Of the entire set of fragment 58
analogues tested, 58f exhibited the best activity with 100%
PsaA inhibition at 500 μM in single point screening experiments,
and an IC50 of 71.8 μM, resulting in a ligand efficiency of 0.48
(Figure 3, panel a). The PsaA−58f docked pose analysis revealed
two different binding modes for the analogue. The first potential
binding pose is similar to the PsaA-fragment 58 docked pose
where a sulfonamide group on the phenyl ring forms an extensive
polar contact network with the hydrophilic pocket C on the C-
terminal lobe. However, the ortho-amine group forms a strong H-
bond with the metal-binding residue Glu205, which may be a
factor in the improved activity of 58f (Figure 3, panel c). The
Table 1. Derivatives of Fragment 15a
aDerivatives tested at single point concentration (500 μM) in PsaA competitive Zn2+-binding assays (n = 6).
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second possible binding pose of 58f shows H-bond interactions
that are similar to fragment 15 in the PsaA metal-binding site.
The sulfonamide group forms strong polar contacts with Asp65,
Ser256, Thr279, and metal-binding residue Asp280, while the
ortho-amine group forms H-bonds with the side-chain O atom of
Asp280 and the carbonyl of Gln64 (Figure 3, panel d).
Collectively, the docked poses of 58f, in combination with its
activity and ligand efficiency, indicate potential for further
optimization of this hit into a lead molecule targeting PsaA.
In addition to testing different substitutions on the phenyl ring
while keeping the sulfonamide moiety consistent, a number of
other modifications were also tried during fragment 58
optimization, where sulfonamide was substituted with groups
such as SO2NHCH3, SO2CH3, CONH2, CONHCH3,
NHCONH2, and COOH (see Supporting Information Table
5). However, none of these sulfonamide substitutions conserved
or showed improved activity compared with fragment 58 in PsaA
competitive Zn2+-binding assays.
Molecular Dynamics Simulations of 15h. Given that we
were unable to determine the crystal structure of the PsaA−15h
complex, molecular dynamics (MD) simulations were performed
to analyze the structural dynamics of 15h in the metal-binding
site of PsaA and the effect the compound has on the binding site
conformation, compared to the apo-form of the protein. MD
simulations of two different models were performed: PsaA−15h,
using the docking pose (see Figure 3, panel b) as the starting
conformation, and apo-PsaA, using the crystal structure (PDB ID
3ZK7) without any ligand or metal as the starting conformation.
Each model was simulated in duplicate to increase the statistical
significance of the results. Detailed results and further discussion
of the overall conformational changes and interdomain move-
ment of apo-PsaA and l5h-bound PsaA models over 100 ns of
simulation are presented in the Supporting Information.
Structural analysis of PsaA−15h simulation trajectories
showed 15h remaining in the metal-binding pocket of PsaA for
a period of 100 ns. However, compared to the initial docked pose
(Figure 3, panel b), 15h changed the interaction network with
Figure 3. (a) Dose response curve of fragment 15h and fragment 58f along with their structures, IC50, and ligand efficiency (LE). Error bars are standard
deviation of the mean for n = 12. (b) Proposed binding mode of fragment 15h in the PsaA metal-binding site. (c) First proposed binding mode of
fragment 58f in the PsaAmetal-binding site. (d) Second proposed bindingmode of fragment 58f in the PsaAmetal-binding site. Fragments are shown in
stick representation and colored in the following atom colors: carbon, orange; nitrogen, blue; oxygen, red; sulfur, yellow; and polar hydrogens, white.
The PsaA protein is shown in surface representation, and binding site residues are shown in stick representation with the following atom colors: carbon,
cyan; nitrogen, blue; oxygen, red; and polar hydrogens, white. Metal-binding residues have blue labels, whereas all other residues have black labels.
Hydrogen-bonding interactions are shown as black dotted lines.
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the binding site. While all the initial H-bonds to Gln64, Asp65,
and Asp280 are lost within the first 10 ns of simulation, new H-
bonds were formed with Trp141, Phe278, and Thr279 in the first
PsaA−15h trajectory and with Thr279 in the second PsaA−15h
trajectory (Figure 4). Moreover, the metal-binding pocket
underwent conformational change over a period of 100 ns
causing hydrophobic pocket N to open further. This led to the
formation of new hydrophobic contacts between the phenyl ring
B of 15h and Ile41, Phe278, Ile282, Tyr292, and Met295 in
addition to the already existing hydrophobic contacts with Pro66
and Trp141. Further structural analysis of 15h MD binding
orientation in the PsaA metal-binding pocket revealed that while
its phenyl ring A oriented itself toward hydrophobic pocket C,
there are regions around ring A that could be explored to capture
additional interactions in the metal-binding pocket (Figure 4,
panel e and f).
Collectively, the PsaA−15h MD simulations suggested that
15h had reduced polar interactions and increased hydrophobic
interactions in the metal-binding site, compared to the initial
docked pose. This suggests that docking programs overestimate
polar interactions compared to hydrophobic interactions, as
reported previously.27 Additionally, the new MD-derived
binding poses of 15h give us vital information to design further
optimization of 15h around the ortho-, meta-, and para positions
of phenyl ring A.
Cell-based Metal Competition Assay. The antimicrobial
activities of the aforementioned compounds were assessed using
wild-type S. pneumoniae D39, wherein PsaA has an essential role
recruiting Mn2+ ions. Cultures were grown in cation-defined
media, supplemented with a minimal Mn2+ concentration (1
μM), to allow inhibitor-induced growth perturbation to be
analyzed. Compound 15h showed the highest degree of
antimicrobial activity with bacterial growth significantly
perturbed at 195 μg/mL and completely inhibited at 779 μg/
mL. Compound 58 showed a lesser degree of inhibition, with
bacterial growth perturbed at 625 μg/mL and completely
inhibited at 1250 μg/mL (Figure 5). Although compound 58f
demonstrated a greater capacity to inhibit PsaA in vitro, this was
not reflected in the growth assays where it perturbed growth at
1250 μg/mL and inhibited growth at 2500 μg/mL. This may be
due to the inhibitors not efficiently outcompeting the Mn2+ ions,
given that PsaA has very high affinity for Mn2+ with a KD of 3.3±
1 nM.22 It is also possible that there may be unanticipated
interactions between the inhibitor compounds and the
structurally related Zn2+-binding proteins AdcA and AdcAII,
also found on the pneumococcal cell surface.28 The other
compound 58 derivatives (58a, 58b, 58p) also showed reduced
perturbation of S. pneumoniae growth by comparison with the
parent compound. This highlights the challenges associated with
optimizing the compound hits against PsaA in the context of the
whole organism.
Optimization of Fragment 15h. In order to improve the
activity of 15h further, we tried a second round of modifications
of 15h based on the structural insights from PsaA−15h MD
simulations and evaluated their inhibitory effect on PsaA.
Unfortunately, any modification on the para position of the
phenol ring either lowered or completely abolished the inhibitory
activity (Table 3).
Compound 61i, with the methoxy-substitution at the para
position showed 44.7% PsaA inhibition at 1 mM concentration,
whereas compound 61 with a nitro substitution at the para
position showed an improved activity of 69.2% PsaA inhibition at
1 mM concentration when compared to its derivative with 2-
methoxy substituent 15 (Table 1). This suggests that nitro and
methoxy substitutions in 15h maintain its inhibition property at
higher concentrations and potentially capture polar contacts with
the metal-binding pocket in the MD-derived 15h binding poses
(refer to Figure 4e and f). Structural analyses of these binding
poses reveal that nitro and methoxy substituents could
potentially interact with metal-binding residues His139 and
Glu205. Compounds 61g and 61k, with the methyl substituent
or chloro substitutions at the para position, respectively, and 61j,
with naphthalene substitution, did not show any affinity with
PsaA at any concentration tested (up to 1 mM). This suggests
that electron-withdrawing groups, bulky groups, and hydro-
phobic groups are inappropriate substituents at this position. All
the compounds were also tested for their cytotoxic effects against
HepG2 and HEK293 mammalian cell lines and were found to be
non-cytotoxic (>1 mM) with the exception of compound 61j,
which showed a cytotoxic effect on HEK293 cells at 503.5 μM
(see Supporting Information Table 6).
In addition to trying different substitutions at the para position
of 15h phenyl ring A, the amide linker of 15h was substituted
with triazole or sulfonamide (see Supporting Information Table
4), which did not improve its activity, indicating the importance
of the amide bond linker.
Table 2. Derivatives of Fragment 58a
compound R1 R2 R3 R4 R5 % PsaA inhibition
58 NH2 OH 39.5
58a NH2 F 28.6
58b NH2 F 29.4
58c NH2 F 5.4
58d F NH2 1.5
58e F NH2 12.6
58f NH2 F 100
58g NH2 6.4
58h NH2 CONH2 6.3
58i NH2 OCH3 7.3
58j NH2 CH3 5
58k CH3 NH2 3.7
58l Cl NH2 Cl ≤0
58m NHCH3 6
58n NH2 OCH3 ≤0
58o OH NH2 ≤0
58p OH NH2 36.4
58q OH ≤0
58r F 14.7
58s CH3 F 6.5
58t NO2 F 5.3
58u F CH3 ≤0
58v H H H H H 7.1
58w CH3 CH3 ≤0
58x CH3 ≤0
58y Cl ≤0
58z Cl OCH3 ≤0
aDerivatives tested at single point concentration (500 μM) in PsaA
competitive Zn2+-binding assays (n = 6).
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Figure 4.H-bonding distances between PsaA metal-binding site residues and fragment 15h over a period of 100 ns: (a) backbone carbonyl of Thr279
and amide of 15h, (b) backbone carbonyl of Thr279 and phenyl ring B amine of fragment 15h, (c) indole ring NH of Trp141 and carbonyl of 15h, (d)
backbone carbonyl of Phe278 and phenyl ring B amine of fragment 15h. (e-f) Binding mode of fragment 15h in the PsaA metal-binding pocket at the
end of 100 ns ofMD simulation. (e) First simulation trajectory shows 15hH-bonding with Trp141, Phe278, and Thr279 at the end of 100 ns. (f) Second
simulation trajectory shows 15h H-bonding with Thr279 at the end of 100 ns. In addition, hydrophobic contacts are formed with both N- and C-
terminal residues. Fragments are shown in stick representation and are colored in the following atom colors: carbon, orange; nitrogen, blue; oxygen, red;
and polar hydrogens, white. PsaA protein is shown in surface representation, and binding site residues are shown in stick representation with the
following atom colors: carbon, cyan; nitrogen, blue; oxygen, red; and polar hydrogens, white. Metal-binding residues have blue labels, whereas all other
residues have black labels. Hydrogen-bonding interactions are shown as black dotted lines.
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■ CONCLUSIONS
Identification of PsaA inhibitors using a combination of virtual
screening and fragment-based drug design approaches produced
two fragment hits, 15h and 58f. The initial virtual screening and
clustering of the in-house fragment library yielded 60 diverse and
low-molecular-weight fragments which were screened in the
PsaA competitive Zn2+-binding assay giving two starting points,
fragments 15 and 58, for further optimization. These initial hits
were further optimized to produce potent and ligand-efficient
hits, 15h and 58f, with IC50 values of 28.1 μM and 71.8 μM,
respectively. Furthermore, MD simulations were performed on
the docked complex of 15h with PsaA, which highlighted the
dynamic behavior of 15h in the metal-binding pocket over 100
ns. A cell-based, metal competition assay further validated the
potency of 15h as it exhibited perturbation of pneumococcal
growth at 195 μg/mL, and complete growth inhibition at 779
μg/mL. In contrast, 58f perturbed bacterial growth at a
concentration of 1250 μg/mL and complete growth inhibition
only at 2500 μg/mL. As 15h emerged as the more promising hit,
further optimization was designed around its scaffold, but any
modification to the para position of the phenolic ring did not
improve the potency of 15h.
In conclusion, 15h and 58f have been developed from the
initial hits identified from a fragment-based library. Developing a
series of active compounds with the same scaffold indicate that
the behavior of the compounds is not due to the promiscuous or
adventitious interactions with the protein, which is a potential
risk for fragment-sized molecules. Both 15h and 58f are able to
inhibit the metal-binding function of PsaA in biochemical and
cell-based assays with good ligand-efficiency. As small molecules
with aMWof <250 Da, both have significant potential for further
optimization and development into a novel anti-pneumococcal
agent.
Figure 5. Cell-based metal competition assay. S. pneumoniae grown in
CDM supplemented with inhibitor fragments as indicated. The data
correspond to mean (±s.e.m.) absorbance measurements at 600 nm
from three independent biological experiments. Errors bars, where not
visible, are overlapped by the representative symbols.
Table 3. Derivatives of Fragment 15ha
aDerivatives tested at concentrations 1 mM and 500 μM in PsaA competitive Zn2+-binding assays (n = 6).
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■ MATERIALS AND METHODS
In Silico Virtual Screening Using FlexX. Apo-PsaA (PDB ID
3ZK7) was used to perform virtual docking of our fragment library to
select compounds able to bind in the metal-binding pocket of the
protein. Refer to the Supporting Information for details about fragment
library preparation. FlexX (BioSolveIT, Germany)20 was used for the
docking using the in-built scoring function. For a given protein and a
ligand, FlexX predicts the geometry of the complex as well as an estimate
for the strength of binding with the help of binding score. First, atomic
coordinates of the apo-PsaA protein were uploaded as a new project.
This was followed by defining the binding site where His139-Nε2 was
selected as the center of the binding pocket and residues within 10 Å of
the radius to the center were considered as part of the binding site. All
the chemical ambiguities were then resolved, including the protonation
and tautomeric states of the residues considered as part of the docking
site. Finally, this binding pocket information was saved as a project and
fragment library was uploaded and was docked to the site of interest.
FlexX uses CORINA, which is a 3D structure generator to produce ring
conformations and clean up ligand molecule structures.20
PsaA Competitive Zn2+-binding Assay. In this assay, Zn2+ binds
to the Zn2+-specific fluorescent probe, FluoZin-3 (Life Technologies),
producing a fluorescence signal (494/516 nm). Apo-PsaA added to this
complex competes with FluoZin-3 to bind Zn2+ in its metal-binding
pocket causing reduction in fluorescence signal. Therefore, a prospective
PsaA inhibitor would reduce this chelating action of PsaA, which would
inhibit dissociation of the Zn2+−FluoZin3 complex, and an elevated
fluorescence signal would be seen. The concentrations of apo-PsaA,
ZnCl2, and FluoZin-3 used in the assay to screen fragments were
optimized to 100, 500, and 600 nM, respectively, according to the
maximum fluorescence signal obtained. Positive and negative controls
consisted of ZnCl2 and FluoZin-3 without and with PsaA, respectively.
Ninety-six-well black Optiplates were used to conduct the experiment
and were read using a BMG Polarstar having a 490−10 excitation filter
and 520−10 emission filter. % PsaA inhibition was calculated using (FI/
FImax × 100) where FI is the fluorescence intensity.
Molecular Dynamics Simulations. Both simulations, apo-PsaA
and 15h-bound PsaA, were performed using the GROMACS
(Groningen Machine for Chemical Simulations) engine29 in con-
junction with the GROMOS 54a7 force field for proteins.30 Refer to the
Supporting Information for details.
Chemical Synthesis. The synthesis of designed compounds 61,
61g, and 61i−k is illustrated in the Supporting Information. The
aromatic acids with various substituents were reacted with amine using
standard amide bond coupling using HBTU to obtain corresponding
products 16i−z in good yields (see the Supporting Information). The
methoxy group was deprotected using BBr3 to obtain the corresponding
phenolic compounds 61, 61g, and 61i−k (Supporting Information
Figure 4).
Cell-based Metal Competition Assay. S. pneumoniae D39
bacteria were grown in cation-defined media (CDM) without transition
metal-ion supplementation. The base ion content of CDM was
ascertained by inductively coupled plasma mass spectrometry (ICP-
MS) on an Agilent 7500cx ICP-MS (AdelaideMicroscopy, University of
Adelaide), as described previously.22 Growth experiments were
conducted in CDM supplemented with 1 μM MnSO4. All chemicals
used in the cell-based assay were purchased from Sigma-Aldrich, unless
otherwise specified. Minimal Inhibitory Concentration (MIC) deter-
mination was conducted as described in ref 31. Briefly, an inoculum was
prepared from an overnight grown culture on a blood-agar plate in CDM
and grown to an absorbance at 600 nm (A600) of 0.4 (1 × 10
8 cfu mL−1).
The inoculum was then diluted 1:100 in sterile CDM to give a
concentration of 1 × 106 cfu mL−1. A total of 100 μL of inoculum was
added to a 96-well flat bottom plate (Greiner Bio One), and 100 μL of
inhibitor compound, which was solubilized in DMSO and diluted in
CDM, was serially diluted 1:2, giving a final inoculum of 5 × 105 cfu
mL−1. The plate was then sealed with a gas-permeable seal (Breathe-
Easy, Diversified Biotech) and incubated in a FLUOStar Omega
spectrophotometer with an ACU gas controller (BMG Labtech) at 310
K in 5% CO2. A600 readings were recorded using the well-scan function
every 30 min, and growth data were analyzed using Prism software.
Expression and Purification of apo-PsaA, Crystallographic
Studies, and Cytotoxicity Assay. Refer to the Supporting
Information for details.
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3.3. Conclusions 
 
This study identified the novel inhibitors for PsaA, using virtual screening and fragment-based 
drug design approaches. The open-state (metal-free) PsaA crystal structure (pdb: 3ZK7) was 
used to perform virtual screening of the in-house fragment library, which was followed by the 
clustering of the top ranking compounds based on their structural diversity. This helped derive 
60 diverse and low-molecular weight molecules, which were further screened in the competitive 
Zn2+  binding assay to test the ability of the selected 60 compounds for competitive inhibition of 
Zn2+ binding to PsaA. This resulted in 2 active fragments, 15 and 58, which were further 
optimised by various chemical modifications, helping identify two compounds, 15h and 58f, 
with IC50 values for PsaA inhibition of 28.1 µM and 71.8 µM, respectively. A cell-based metal 
competition assay was performed in Dr. Christopher A. McDevitt’s laboratory in The University 
of Adelaide, which further validated the potency of 15h as it exhibited perturbation of 
pneumococcal growth at 195 µg/mL. Further chemical modifications were synthesised by Dr. 
Sreeman Mamidyala in the Cooper group, which were again tested in the competitive Zn2+  
binding assay, however, none of these showed higher potency than 15h. Therefore, with 15h 
being the most promising hit, MD simulations were performed on PsaA-15h docked complex to 
validate its stability in the metal binding pocket over 100 ns and explore further chemical 
modifications that could be attempted to potentially increase its potency. 
In conclusion, 15h has shown its ability to inhibit the metal-binding function of PsaA in 
biochemical and cell-based assays with good ligand-efficiency. Therefore, as a small molecule 
with MW of 228.2 Da it has a significant potential for further optimisation and development into 
a novel anti-pneumococcal agent. 
 
Contribution summary: I was involved with conception and design of this study. I performed 
the virtual screening of the in-house fragment library using metal-free PsaA crystal structure 
(pdb: 3ZK7). Following this, I performed the clustering of the top ranked compounds based on 
their structural diversity, which helped me achieve 60 diverse and low-molecular weight 
compounds for further screening in the competitive Zn2+ binding assay. I was involved in 
development and optimization of the PsaA competitive Zn2+ binding assay used to screen the 
virtually identified diverse fragment-like small molecules. Testing the 60 diverse fragments in 
the experimental assay gave me 2 active fragments, 15 and 58, which were further optimized and 
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helped me identify two compounds, 15h and 58f, with IC50 values for PsaA inhibition of 28.1 
µM and 71.8 µM, respectively. I tested further chemical modifications of 15h synthesized by Dr. 
Sreeman Mamidyala in the PsaA competitive Zn2+ binding assay, but none of these showed 
higher potency than 15h. Finally, I performed MD simulations on PsaA-15h docked complex to 
validate its stability in the metal binding pocket over 100 ns. 
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Targeting Cryptococcus neoformans IMPDH to inhibit fungal purine 
metabolic pathway 
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4.1. Introduction 
Inosine monophosphate dehydrogenase (IMPDH), part of the purine metabolic pathway, is the 
key enzyme involved in the de novo GTP biosynthesis, which is essential for cell survival and 
replication (1-3). Targeting Cryptococcus neoformans IMPDH would therefore inhibit fungal 
growth and control diseases like cryptococcal meningitis caused by fungal infections (3-5). 
IMPDH  structural analysis revealed that it has two binding pockets, IMP (substrate) binding site 
and NAD+ (cofactor) binding site (1, 2, 4, 6-8). While the IMP site is highly conserved across the 
species, the NAD+-binding site shows wider diversity between the species, and has hence been 
selected for the design of selective antifungal inhibitors. Chapter 4 illustrates the use of 
homology modelling and molecular dynamics simulation (MD) techniques for modelling the key 
regions of the human and C. neoformans IMPDH structures which are unresolved in any of the 
crystal structures, and for simulating the homo-tetrameric structure of the IMPDH, which forms 
the bioactive assembly. The MD-derived IMPDH conformations were used as a template for 
using virtual docking of IMPDH inhibitors. This chapter also elucidates novel strategies that 
could be used to design selective C. neoformans IMPDH inhibitors, and in silico structure 
activity relationship (SAR) studies of the experimentally identified antifungal hits, MCC_005985 
and MCC_006189. 
 
4.2. Prior unpublished work 
A screening library of 114,000 compounds were tested at Walter and Eliza Hall of Medical 
Research (WEHI) for their inhibitory activity against the IMPDH of C. neoformans. This study 
was funded by Therapeutic Innovation Australia (TIA). This screening was performed at a single 
concentration of 10 µM, producing 704 compounds with inhibition greater than 50%. Following 
this, Dr. Avril Robertson (post-doc in Cooper Group) filtered the selected 704 compounds for 
known IMPDH inhibitors and common toxicophoric features, and finally clustered by structural 
diversity using topological fingerprints, selecting 200 compounds for further hit confirmation by 
dose response assays. Of these 200 compounds, 118 compounds were selected with IC50 values 
less than 15 µM and sourced from commercial vendors for further validation. 94 of these 118 
compounds could be grouped into 26 structural clusters, leaving 24 with unique structures 
(singleton). 
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4.3. IMPDH crystal structures 
 
To date, 47 IMPDH crystal structures have been reported in the Protein Databank (PDB) at 
Research Collaboratory for Structural Bioinformatics (RCSB), belonging to different organisms 
and species. So far, only one structure has been reported for C. neoformans (pdb: 4AF0), co-
crystallised with IMP and MPA (4). For the human isoforms one structure has been reported for 
IMPDH I (563 residues) while three structures have been reported for IMPDH II (514 residues) 
(9, 10). Out of these four, the IMPDH II co-crystal structure (pdb: 1NF7) has been found to have 
the highest resolution of 2.65 Å and the least unresolved regions. The C. neoformans IMPDH 
(pdb: 4AF0) and human IMPDH I (pdb: 1JCN) and IMPDH II (pdb: 1NF7, 1NFB and 1B3O) 
structures have been found to have an unresolved active site flap region (Figure 4.3.1, panel b 
and c). In addition, human IMPDH I (pdb: 1JCN) and IMPDH II (pdb: 1NFB and 1B3O) have an 
unresolved active site loops. Therefore, C. neoformans IMPDH (pdb: 4AF0) and human IMPDH 
II (pdb: 1NF7) were selected for further comparative studies (Figure 4.3.1, panel b and c).  
 
Sequence analysis shows only 59.7 % sequence identity between the IMPDH of C. neoformans 
and human IMPDH II (4, 11, 12), however, both the IMP and NAD+ binding sites are highly 
conserved (Figure 4.3.2). While the IMP binding site is completely conserved, smalldifferences 
can found in the NAD+ binding sites, especially Arg267(C. neoformans) / His253(human) at the 
centre of the NAD+ binding site (Figure 4.3.1, panel a). In addition, other key structural 
differences can identified between the enzymes, including the presence of a unique cavity close 
to the NAD+ binding site of C. neoformans IMPDH, absent in human IMPDH II. This cavity is 
formed by differences in the active site loop (C. neoformans Cys345-Val353) conformation 
between the two enzymes (4). The second region of interest is the active site flap (C. neoformans 
Met428-Gln470), which is located adjacent to the NAD+ binding site and is fully or partially 
unresolved in all the IMPDH X-ray structures. In human IMPDH II the active site flap comprises 
16 residues, while in C. neoformans the flap consists of 32 amino acids, making it the longest 
flap reported for an IMPDH structure. This flap is a crucial structure for the mode of action of 
the enzyme, as its conformational change brings an arginine (C. neoformans Arg458 / human 
Arg429) residue (present in flap) into the correct position to initiate the final hydrolysis step of 
the mechanism (6). In the IMPDH structure of C. neoformans, the flap is partially resolved 
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leaving 12 amino acids unresolved (Figure 4.3, panel b). In comparison, the human IMPDH II 
structure has most of its flap (16 residues) unresolved (Figure 4.3, panel c). Superposition of the 
two structures (pdb: 4AF0 and 1NF7) indicated that the open conformation of the active site flap 
of C. neoformans is folded outwards as compared to unfolded open conformation in human 
IMPDH II.  
 
IMPDH enzymes exist as a homo tetramer in a biological system, while most crystal structures 
have only one monomer in their asymmetric unit (25). The tetrameric assembly is important as 
the C-terminal part (19 residues) of one monomer interacts with the active site loop of the 
adjacent monomer, indicating that the tetrameric structure could adopt a different conformation 
compared to the monomeric crystal structure, and could influence the binding of IMPDH 
inhibitors. 
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Figure 4.3.1: (a) Superposition of IMP and NAD+ binding sites of C. neoformans IMPDH (cyan, pdb: 4AF0) and 
human IMPDH II (red, pdb: 1NF7). The difference in residues, Arg267 (C. neoformans) and His253 (human) has 
been highlighted by a black circle. The structure is shown as cartoon representation, whereas, the binding site 
residues are shown in stick representation. The IMP (yellow) and MPA (pink) are present in the IMP-binding site 
and NAD+-binding site, respectively, and are shown in stick representation. (b) C. neoformans IMPDH (pdb: 4AF0) 
with IMP (cyan) and MPA (orange) bound to substrate-binding and NAD+-binding site, respectively. Active-site 
loop represented in red and partially resolved active-site flap represented in green. (c) Human IMPDH (pdb: 1NF7) 
with IMP (cyan) and MPA (orange) bound to substrate-binding and NAD+-binding site, respectively. Active-site 
loop represented in red and partially resolved active-site flap represented in green. 
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Figure 4.3.2: Sequence alignment of C. neoformans IMPDH and Human IMPDH II using CLUSTALW2. Active-
site loop and active-site flap is highlighted in pink and purple color, respectively. 
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4.4. Materials and methods 
 
4.4.1. Homology modelling of the unresolved regions in C. neoformans and human IMPDH 
The available IMPDH crystal structures are not completely resolved; therefore, a bioactive 
homo-tetrameric form of fungal and human IMPDH enzyme with all the unresolved regions was 
modeled. To do this, tetrameric biological assembly of both fungal and human IMPDH enzyme 
(pdb: 4AF0 and 1NF7, respectively) were obtained from RCSB (4, 11). This tetrameric assembly 
was built using the PISA program, which used the crystallised tetrameric IMPDH structure from 
Tritichomanas foetus as reference (13). Further, the CBS (cystathionine β-synthase) domain from 
each of the IMPDH monomer was removed, as it has been established previously that this 
domain has no significant role in the IMPDH catalytic activity (4). This was followed by 
homology modelling of the unresolved regions using swiss-pdb viewer (26) and Modeller 
version 9.10 program (14, 15). This included homology modelling of the active-site flap of both 
C. neoformans IMPDH and human IMPDH II structures. The loop database of swiss-pdb viewer 
was used to build loops in the missing regions for each of these crystal structures (26). The “Scan 
loop” item of the Build menu was used, which prompted to pick two residues serving as the 
anchor points. A window appeared with the list of the possible loops. It showed the desired loop 
sequence, aligned with the sequence of a fragment selected from the database of folds. The most 
suitable loop was selected for each of the crystal structures based on the similarity score 
(computed from the PAM200 matrix), clash score, force field score and the number of residues 
from the source loop that have bad phi/psi angles. Following this, the loops forming the 
unresolved region of active-site flaps in the C. neoformans and human IMPDH crystal structures 
were optimised using loop optimisation module of Modeller version 9.10 program. The loop 
regions were defined for refinement using the “loopmodel” class. The set of atoms that were to 
be optimised were selected using loopmodel.select_loop_atoms routine in the loop model script. 
This helped in the final optimisation of the loops modelled using loop database of swiss-pdb 
viewer, thereby forming the complete tetrameric IMPDH structures for both C. neoformans and 
human which was further used for MD simulations.  
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4.4.2. MD simulations of C. neoformans and human IMPDH homo-tetrameric structures 
 
The simulations were performed using the Gromacs (Groningen Machine for Chemical 
Simulation) 4.0.5 engine (16) and Gromos54a7 united atom force field (17). 150 mM KCl was 
added to each of the model, before solvating the models in a dodecahedron water box using 
single point charge (SPC) type water molecules, retaining crystallographic water molecules and 
adding counter ions to neutralise the overall model. Each of the simulation models was a large 
system with ~381,000 atoms. Before equilibration, the models were energy minimised to 
eliminate any close contacts. All the tetrameric models were equilibrated for 10 ns by slowly 
releasing the position restraints from 1000 kJ mol−1nm−2 to 10 kJ mol−1nm−2 followed by 
unrestrained simulation of 100 ns. Both equilibration and simulation were done at 300 K, using 
dodecahedron periodic boundary conditions, Berendsen coupling for temperature and pressure 
and simulation time step of 4 fs (18, 19). LINCS algorithm was used to constrain all bonds and 
standard values were used for non-bonding interactions (20). The models were run in triplicates 
using different random number seedings for the allocation of their initial velocities. Each 
simulation was run for 100 ns and conformations were saved every 20 ps. The analysis of the 
trajectories was done using the GROMACS analysis tools, VMD (21) and PyMol (The PyMOL 
Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.). 
RMSD Analysis: To evaluate the relative difference between trajectories, the root-mean square 
deviation (RMSD) was calculated using the method of Maiorov and Crippin after first fitting the 
trajectory frames to a reference structure or domain (22).  
Cluster Analysis: To categorise trajectories into clusters using Cα atoms, with each cluster having 
RMSD > 1.2 Å compared to the other. Single linkage method was used to cluster the structures 
or the snapshots in the trajectory. This method adds a structure to a cluster when its distance to 
any element of the cluster is less than cut-off. The cut-off used was 1.2 Å. 
 
4.4.3. IMPDH inhibitor library preparation and virtual screening 
 
The IMPDH inhibitor library for virtual screening consisted of 953 IMPDH inhibitors from 
ChEMBL database (version 17), 704 WEHI hits from hit-confirmation (section 4.2.), 1,500 small 
molecules from our in-house fragment-based screening library and 426 non-active compounds 
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against C. neoformans IMPDH to form negative dataset, thereby forming a combined library of 
3,927 inhibitors. Compounds similar to IMP were identified by calculating the extended-
connectivity fingerprints, ECFP_4 and similarity by the tanimoto distance equation. Applying a 
threshold of 0.7 similarity to IMP, 100 structures were removed from the library. Therefore, 
IMPDH virtual screening library comprising of 3,827 structures was used for docking 
experiments to determine the conformations of C. neoformans and human IMPDH, which had 
the best predictive power in differentiating between the true positives and true negatives. These 
3,827 ligands were prepared for the docking experiments using the default Ligand Prep 
workflow, with the protonation state of the ligand at pH 7.0. 
 
The in silico docking was done using Schrödinger software package, Glide version 5.9, Prime 
version 3.2, Schrödinger, LLC, New York, NY, 2013 (23, 24). For the docking studies, the 53 
MD-derived conformations of monomeric IMPDH bound with both IMP and MPA in their 
respective binding sites were used. IMP is bound to the IMP-binding site and MPA is bound to 
the NAD+ binding site. Default parameters for the protein preparation and Glide docking 
workflow were used, using the bound MPA molecule as ligand for the definition of the receptor 
site (box size of 40 Å around the ligand). All residues of the binding pocket were kept rigid, 
however, the ligands were made flexible. In addition, the crystallographic water molecules were 
retained in the docking experiments. The docking was performed with SP precision and using the 
in-built Glide scoring function.  
 
4.4.4. Virtual Structure Activity Relationship (SAR) studies 
 
The molecules were drawn, converted into 3D and optimised using ChemOffice 15.0 software, 
ChemDraw (Perkin Elmer, CambridgeSoft). The optimised molecules were then docked into the 
NAD+ binding pocket of C. neoformans (pdb: 4AF0) and human (pdb: 1NF7) IMPDH crystal 
structures using Schrödinger software package, Glide version 5.9, Prime version 3.2, 
Schrödinger, LLC, New York, NY, 2013 as described in section 4.2.3 (23, 24), using the same 
parameter and setup as descript previously. 
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4.5. Results and discussion 
 
4.5.1. Homology modelling of the unresolved regions in C. neoformans and human IMPDH 
The aim of the work was to develop novel selective IMPDH inhibitors using structure-based 
drug design approaches. However, available IMPDH crystal structures are not completely 
resolved; therefore, a bioactive homo-tetrameric form of fungal and human IMPDH enzyme with 
all the unresolved regions was modeled. To do this, the tetrameric biological assembly of both 
fungal and human IMPDH enzyme (pdb: 4AF0 and 1NF7, respectively) were obtained from 
RCSB (4, 11). This tetrameric assembly was built using the PISA program, which used the 
crystallised tetrameric IMPDH structure from Tritichomanas foetus as reference (13). This was 
followed by homology modelling of the unresolved regions using swiss-pdb viewer and 
Modeller version 9.10 program as described in materials and methods section (14, 15). This 
included homology modelling of the active-site flap of both C. neoformans IMPDH and human 
IMPDH II structures. Two different tetrameric starting models were built for the fungal IMPDH. 
In the first model, 12 unresolved residues of the 32 residue long active site flap were modelled in 
the folded open conformation (Figure 4.5.1, panel b). This model constitutes the closest to the 
crystal structure of crypto IMPDH. In the second fungal IMPDH model, the structure was 
modeled similar to the human IMPDH II structure, with the entire active site flap of 32 residues 
remodelled in an unfolded open conformation using human IMPDH II active site flap as template 
(Figure 4.5.1, panel c). In comparison, the human IMPDH structure with unresolved active site 
flap (16 residues) also was modelled using the loop modelling module of Modeller  version 9.10 
program and then using loop database of swiss-pdb viewer (Figure 4.5.1, panel a). The C. 
neoformans IMPDH structure (pdb 4AF0) has been crystallised with IMP and MPA in IMP-
binding and NAD+-binding pocket, respectively. Human IMPDH II crystal structure (pdb 1NF7) 
has been reported with RVP (Ribavirin monophosphate) in the IMP-binding pocket and MYD 
(Mycophenolic adenine dinucleotide) in the NAD+-binding pocket, however both ligands are 
very similar in structure and binding orientation to IMP and MPA, allowing simple replacement. 
For the comparative study, superposition of C. neoformans IMPDH and human IMPDH II was 
performed to replace RVP and MYD in human IMPDH II structure with IMP and MPA, as 
found in the C. neoformans IMPD.   
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MD simulations for conformational equilibrium were performed for each of the 3 tetrameric 
structures (i.e., human model, C. neoformans model 1 (with open-folded flap) and C. neoformans 
model 2 (with open-unfolded flap), allowing to adjust any structural uncertainty during the 
modelling of the unresolved region, and to sample the conformational space.  
 
 
Figure 4.5.1: (a) Human IMPDH model with IMP (cyan) and MPA (orange) bound to substrate-binding and NAD+-
binding site, respectively. Active-site loop represented in red and modelled active-site flap represented in green. (b) 
C. neoformans IMPDH with IMP (cyan) and MPA (orange) bound to substrate-binding and NAD+-binding site, 
respectively. Active-site loop represented in red and modelled active-site flap in open-folded conformation 
represented in green. (c) C. neoformans IMPDH with IMP (cyan) and MPA (orange) bound to substrate-binding and 
NAD+-binding site, respectively. Active-site loop represented in red and modelled active-site flap in open-unfolded 
conformation (resembling human IMPDH modelled active-site flap) represented in green. 
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4.5.2. MD simulations of C. neoformans and human IMPDH homo-tetrameric structures 
MD simulations were used to investigate the conformational equilibrium and changes of 
tetrameric fungal and human IMPDH structure in particular for the modelled regions. The aim 
was to explore the conformational space and flexibility of the entire structure, particularly the 
modelled active site flap, and their influence on the binding of the MPA inhibitor.  
 
RMSD of Cα atoms for each simulation model to their corresponding starting conformations 
showed that the models were stable after 20 ns of simulation. The Cα RMSD values for the last 
30 ns were only 2.1 ± 0.2 Å, 2.5 ± 0.2 Å and 1.8 ± 0.1 Å for the Cryptococcus model 1, 
Cryptococcus model 2 and human model, respectively, indicating their structural integrity.  
Further, the GROMACS analysis tool, g_cluster, was used to categorise trajectories into clusters 
using Cα atoms, with each cluster having RMSD > 1.2 Å compared to the other, as described in 
materials and methods section 4.4.2. This classified Crytococcus model 1 simulation trajectories 
into 8 clusters and Crytococcus model 2 trajectories into 25 clusters. Similarly, snap-shots of 
human model trajectories were grouped into 20 different clusters.  Finally, the middle structures 
of each of these clusters were selected as the representative conformations of C. neoformans and 
human IMPDH. Thus, 53 conformations in total were selected for both C. neoformans and 
human IMPDH, which were further used to perform virtual docking of all known human and 
fungal inhibitors and select the conformations which had the best predictive power to 
differentiate between the true positives and true negatives. 
 
4.5.3. Identification of MD conformations with best predictive power 
The library for virtual screening consisted of 953 IMPDH inhibitors from the ChEMBL database, 
704 WEHI hits from hit-confirmation (section 4.2), 1,500 small molecules from our in-house 
fragment-based screening library and 426 non-active compounds against C. neoformans IMPDH 
to form a negative dataset. Finally, 100 structures similar to IMP were removed from the library 
using Tanimoto equation as described in materials and methods section. All these together 
formed an IMPDH virtual screening library comprising 3,827 structures, which were used for 
virtual docking experiments to determine the conformations of C. neoformans and human 
IMPDH, which had the best predictive power in differentiating between the true positives and 
  Chapter 4 
79 
 
true negatives. Of the 3,827 compounds, 704 have been reported to have activity against C. 
neoformans IMPDH and 681 compounds have shown activity against human IMPDH II. The rest 
of the compounds have been found to be actives against Mus musculus IMPDH, E. coli IMPDH, 
Crytosporidium parvum IMPDH or human IMPDH I, or are non-actives (27). 
 
Unlike the IMP-binding site, NAD+-binding site of C. neoformans is not completely conserved 
across species (as discussed in section 4.3), therefore, targeting this site has a better ability to 
develop a selective antifungal inhibitor. The virtual docking of the compound library was 
performed on the NAD+-binding site using Glide docking software (23, 24). The 3,827 
compounds were docked into the NAD+ binding site of the 53 selected conformations of C. 
neoformans and human IMPDH to:  (a) determine which of these conformations show the best 
correlation of the experimental activity (IC50) with the predicted docking score, and (b) derive 
information regarding potential selective inhibitors for C. neoformans IMPDH vs. human 
IMPDH, which could to further experimentally verified (Figure 4.5.3.1). 
 
 
Figure 4.5.3.1: Flowchart of IMPDH inhibitor library construction. 
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Unfortunately, no correlation could be found between experimental activity, expressed as –log 
IC50 (pIC50) against IMPDH, and the docking score of the compounds, for each of the 53 
different conformations (Figure 4.3.5.2, panel a). The plot shows similar docking scores for 
compounds with different experimental activity, showing little to no quantitative prediction 
power from the virtual docking. Even a qualitative approach, classifying actives and non-active 
using IC50 cut-off of 20 µM, did not improve the predictive power of the docking score. Receiver 
operating characteristic (ROC) curves, which compare the specificity and sensitivity of the 
predictive model using true positive rates (TPR) and false positive rates (FPR), indicated only 
poor model properties, with accuracy (AUC) below 0.7 for all 53 conformations (AUC >0.7 and 
<0.8 is an average model and AUC >0.8 is a good model) (Figure 4.3.5.2, panel b). In summary, 
none of the 53 docking experiments were able to distinguish between actives and non-actives, 
suggesting that no correct bioactive conformation was among the 53 conformations, or that the 
activity of inhibitors might be affected by an ensemble of different active site flap conformations 
rather than a single one. The aim of using homology modelling and MD simulations to derive C. 
neoformans conformations that could be further used to design novel and selective antifungal 
inhibitors was unsuccessful.  
 
Given that MD conformations were not useful to perform structure-based drug design of 
selective anti-fungal inhibitors, the MD trajectories of C. neoformans and human IMPDHs could 
be used in future to further understand the conformational flexibility of the tetrameric IMPDH 
structure, particularly the unresolved active-site flap, to establish the importance and biological 
relevance of the tetramer and the role of the active-site flap in ligand binding to NAD+-binding 
pocket.  
 
 
  Chapter 4 
81 
 
 
Figure 4.5.3.2: (a) Graph showing experimental activity (-log IC50) vs. predicted docking score (Glide score) 
correlation for 1st MD-derived conformation of C. neoformans Model 1. (b) Graph showing ROC curve, estimating 
the sensitivity and specificity of the 1st MD-derived conformation of C. neoformans Model 1 based on the 
experimental and virtual screening data. Plots were generated using Pipeline Pilot (Accelrys) and its build in 
function for the analysis of ROC curves. 
 
 
4.5.4. Strategies to design selective C. neoformans IMPDH inhibitors 
The crystal structures of C. neoformans and human IMPDH with the modelled flap regions, and 
the 53 MD derived conformations were found to be incapable of distinguishing between the 
active and non-active compounds of the in-house IMPDH inhibitor library and hence, did not 
yield predictive models for the design of selective antifungal inhibitors. This was potentially due 
to the fact that the modelled flap region near the NAD+ binding site, was not able to achieve its 
lowest energy state even after 100 ns of MD simulation in both C. neoformans and human 
IMPDH. Therefore, the crystal structures of both C. neoformans (pdb: 4AF0) and human 
IMPDH II (pdb: 1NF7) (without modelled flap regions) were used for comparative analysis to 
identify regions in NAD+ binding site that could potentially be used to gain inhibitor selectivity. 
The sequence and structural comparison of the NAD+ binding sites of C. neoformans and human 
IMPDH showed some key differences: (a) a cavity near the NAD+ binding site present in the C. 
neoformans IMPDH, but absent in human IMPDH II, due to the difference in the active site loop 
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conformation (4), (b) arginine residue (Arg267) in C. neoformans IMPDH, but histidine residue 
(His253) in the human IMPDH II, and (c) a secondary pocket in the NAD+ binding site that 
could not be explored in human IMPDH II due to different conformation of Lys438 (Figure 
4.5.4, panel a and b). These differences could allow the design of fungal specific inhibitors.   
 
  Chapter 4 
83 
 
 
Figure 4.5.4: (a) Surface representation of the C. neoformans IMPDH, and (b) surface representation of the human 
IMPDH II. The key differences between the two IMPDH structures are highlights with the pointers as illustrated in 
the text of section 4.5.4. 
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4.5.5. Selection of compounds for structure-activity relationship (SAR) studies 
As mentioned in section 4.2, 118 compounds forming 26 hit clusters and 24 unique structures 
were identified to have IC50 values less than 15 µM in an in vitro C. neoformans IMPDH 
inhibition assay. In addition, fungal broth micro dilution assay (performed by Emily Furlong, an 
honours student in the Cooper Group) of these 118 compounds identified several compound 
clusters with promising antifungal activity in the cell-based assay. Two of these clusters, 
aminothiazoles and dihydroindenyl acetamides, were selected for further investigation based on 
their data of the in vitro enzymatic and cell-based assays (performed by WEHI and Emily 
Furlong). The aminothiazole cluster consisted of 10 compounds, whereas, the dihydroindenyl 
acetamide cluster consisted of 15 compounds. The best compounds within these two clusters 
were MCC_005985 (aminothiazoles) and MCC_006189 (dihydroindenyl acetamides), as they  
were found to have the lowest MIC values and IC50 of <10 µM in the in vitro high-throughput 
screen. In addition, both of these compounds were found to have 9.4-fold (MCC_005985) and 
7.7-fold (MCC_006189) selectivity for C. neoformans IMPDH against human IMPDH in the in 
vitro enzymatic assay. In comparison, mycophenolic acid (MPA) was found to be merely 0.25-
fold selective (performed by Emily Furlong, honours student in Cooper Group) (Table 4.5.5). 
Given this data, both MCC_005985 and MCC_006189 were selected for further exploration 
using structure-based drug design approaches and in silico docking studies. This could 
potentially help develop an effective structure-activity relationship (SAR) of the compounds, 
thereby, producing highly potent antifungal inhibitors. 
 
Table 4.5.5: The selected compounds for further in silico SAR studies based on their activities from the in vitro 
enzyme assay and MIC assay (data generated by Emily Furlong). 
Compound ID Structure 
MIC (μg/mL) 
C. neoformans/ 
C. albicans 
C. neoformans 
IMPDH 
IC50 (µM) 
Human IMPDH 
type II IC50 (µM) 
Selectivity 
MCC_005985 
 
25, 50 1.40±0.07 13.1±2.1 9.4 
MCC_006189 
 
12.5, 50 2.67±0.29 20.6±3.9 7.7 
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4.5.6. In silico docking studies of MCC_005985  
The monomer of C. neoformans IMPDH (pdb: 4AF0) and human IMPDH (pdb: 1NF7) was used 
to perform virtual docking of MCC_005985 into the NAD+ binding site of both the IMPDHs. 
The docking was performed using the Glide program (23, 24) of the Schrodinger package and 
analysis of docked poses was done using PyMol (The PyMOL Molecular Graphics System, 
Version 1.5.0.4 Schrödinger, LLC.). The docked pose of MCC_005985 in the NAD+ binding site 
of C. neoformans IMPDH and human IMPDH showed similar binding pattern (Figure 4.5.6, 
panel a and b). Both orientations showed the methoxy group of the compound forming a H-bond 
with the side-chain of an asparagine residue (Asn317/Asn303). An additional weak H-bond was 
formed by the pyridine moiety of MCC_005985 with the backbone carbonyl group of Met428 in 
C. neoformans IMPDH with a distance of 3.4 Ǻ, whereas in human IMPDH backbone carbonyl 
of Met414 formed H-bonding with the thiazole moiety of MCC_005985. Apart from this, the 
binding orientation of MCC_005985 was found to be similar in the two structures and the 
docking score produced by the Glide program was in the same range. This suggests that 9.4-fold 
difference in the potency MCC_005985 against C. neoformans IMPDH vs. human IMPDH II is 
too small to be efficiently captured by the in silico docking. Therefore, a virtual SAR of 
MCC_005985 was performed to identify regions of the compound which could affect the 
selectivity. Derivatives of MCC_005985 exploring the previously identified differences between 
cryptococcus and human IMPDHs have been suggested for synthesis. These derivatives have 
been discussed in sections below. The designed derivatives were tested in the in silico docking 
experiments and will later be validated experimentally in both in vitro enzymatic and cell-based 
assays. 
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Figure 4.5.6: (a) Proposed binding mode of MCC_005985 in the NAD+-binding site of C. neoformans IMPDH (b) 
Proposed binding mode of MCC_005985 in the NAD+-binding site of human IMPDH II. Compound is shown in 
stick representation and colored in the following atom colors: carbon, orange; nitrogen, blue; oxygen, red; sulfur, 
yellow; and polar hydrogens, white. The IMPDH structures are shown in surface representation and binding site 
residues are shown in stick representation with the following atom colors: carbon, cyan (in a)/pink (in b); nitrogen, 
blue; oxygen, red; and polar hydrogens, white.  Residues have black labels and hydrogen-bonding interactions are 
shown in black dotted lines. 
 
 
 
 
4.5.7. In silico SAR studies of MCC_005985 
As mentioned in section 4.5.5, MCC_005985 was the most potent compound of the 
aminothiazole cluster, which consisted of 10 compounds in total. All the derivatives designed for 
the in silico SAR studies of MCC_005985 were in addition to these already existing members of 
aminothiazole cluster. 
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1) Establishing importance of the MCC_005985 moieties using in silico docking (suggested by 
Dr. Avril Roberson, Post-doc in the Cooper group) (Figure 4.5.7.1).  
 
 
 
 
Figure 4.5.7.1: The picture illustrates the importance of each of the moieties in MCC_005985 based on the 
virtual docking data (suggestions by Dr. Avril Robertson). 
 
 
2) Substituting amide linker with a sulfonamide linker in MCC_005985 (Figure 4.5.7.2, panel 
a). The sulfonamide linker in C. neoformans IMPDH oriented the compound towards the 
selective residue Arg267, which could potentially help to explore this key difference and 
improve the potency of MCC_005985 derivatives (Figure 4.5.7.2, panel b and c). 
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Figure 4.5.7.2: (a) Structure of MCC_005985 sulfonamide linker derivative, highlighting the difference with the 
MCC_005985 compound (b) Proposed binding mode of MCC_005985 sulfonamide derivative in the NAD+-binding 
site of C. neoformans IMPDH (c) Proposed binding mode of MCC_005985 sulfonamide derivative in the NAD+-
binding site of human IMPDH. Compound is shown in stick representation and colored in the following atom 
colors: carbon, orange; nitrogen, blue; oxygen, red; sulfur, yellow; and polar hydrogens, white. The IMPDH 
structures are shown in surface representation and binding site residues are shown in stick representation with the 
following atom colors: carbon, cyan (in a)/red (in b); nitrogen, blue; oxygen, red; and polar hydrogens, white.  
Residues have black labels and hydrogen-bonding interactions are shown in black dotted lines. 
 
 
Addition of an amide group (-CONH2) or a carboxylic acid (-COOH) to the left-side pyridine 
either at R1 or R2 position could potentially improve the potency of MCC_005985 derivative, as 
this would possibly form H-bonding interaction with Arg267 in C. neoformans IMPDH. In 
addition, the size of the pyridine on left-side could be reduced to a 3-membered ring or a 5-
membered ring to allow this interaction work (Figure 4.5.7.3).  
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Figure 4.5.7.3: Structural representation of potential substitutions on the left-side pyridine ring.  
 
Addition of an amide group at the para position on the left side pyridine of MCC_005985 
reversed the orientation of the molecule in both C. neoformans and human IMPDH NAD+ 
binding site (Figure 4.5.7.4).  
 
a  
b   c   
Figure 4.5.7.4: (a) Structure of MCC_005985 sulfonamide linker derivative with amide group attached to the para 
position on the left side pyridine ring (b) Proposed binding mode of the molecule in the NAD+-binding site of C. 
neoformans IMPDH (c) Proposed binding mode of the molecule in the NAD+-binding site of human IMPDH. 
Compound is shown in stick representation and colored in the following atom colors: carbon, orange; nitrogen, blue; 
oxygen, red; sulfur, yellow; and polar hydrogens, white. The IMPDH structures are shown in surface representation 
and binding site residues are shown in stick representation with the following atom colors: carbon, cyan (in a)/red 
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(in b); nitrogen, blue; oxygen, red; and polar hydrogens, white.  Residues have black labels and hydrogen-bonding 
interactions are shown in black dotted lines. 
 
Addition of the carboxylic acid at the para position on the left side pyridine of MCC_005985 
displayed the formation of H-bonding interaction with Thr266 in C. neoformans IMPDH NAD+ 
binding site, whereas in human IMPDH, the molecule was docked in reverse orientation (Figure 
4.5.7.5).   
 
 
a  
b c   
Figure 4.5.7.5: (a) Structure of MCC_005985 sulfonamide linker derivative with carboxylic acid attached to the 
para position on the left side pyridine ring (b) Proposed binding mode of the molecule in the NAD+-binding site of 
C. neoformans IMPDH (c) Proposed binding mode of the molecule in the NAD+-binding site of human IMPDH. 
Compound is shown in stick representation and colored in the following atom colors: carbon, orange; nitrogen, blue; 
oxygen, red; sulfur, yellow; and polar hydrogens, white. The IMPDH structures are shown in surface representation 
and binding site residues are shown in stick representation with the following atom colors: carbon, cyan (in a)/red 
(in b); nitrogen, blue; oxygen, red; and polar hydrogens, white.  Residues have black labels and hydrogen-bonding 
interactions are shown in black dotted lines. 
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MCC_005985 derivative with amide group at the meta position on the left side pyridine 
displayed reverse docked orientation in C. neoformans IMPDH and loss of important H-bonding 
interactions in the human IMPDH NAD+ binding site (Figure 4.5.7.6). 
 
 
a  
b  c   
Figure 4.5.7.6: (a) Structure of MCC_005985 sulfonamide linker derivative with amide group attached to the meta 
position on the left side pyridine ring (b) Proposed binding mode of the molecule in the NAD+-binding site of C. 
neoformans IMPDH (c) Proposed binding mode of the molecule in the NAD+-binding site of human IMPDH. 
Compound is shown in stick representation and colored in the following atom colors: carbon, orange; nitrogen, blue; 
oxygen, red; sulfur, yellow; and polar hydrogens, white. The IMPDH structures are shown in surface representation 
and binding site residues are shown in stick representation with the following atom colors: carbon, cyan (in a)/red 
(in b); nitrogen, blue; oxygen, red; and polar hydrogens, white.  Residues have black labels and hydrogen-bonding 
interactions are shown in black dotted lines. 
 
 
MCC_005985 derivative with carboxylic acid at the meta position on the left side pyridine 
showed H-bond formation with the selective residue Arg267 in C. neoformans IMPDH NAD+ 
binding site. In addition, more H-bonds were formed with Pro87, His111, Ser290 and Asp378. In 
comparison, human IMPDH showed two h-bonding interactions with the derivative (Figure 
4.5.7.7). 
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a  
b    c  
Figure 4.5.7.7: (a) Structure of MCC_005985 sulfonamide linker derivative with carboxylic acid attached to the 
meta position on the left side pyridine ring (b) Proposed binding mode of the molecule in the NAD+-binding site of 
C. neoformans IMPDH (c) Proposed binding mode of the molecule in the NAD+-binding site of human IMPDH. 
Compound is shown in stick representation and colored in the following atom colors: carbon, orange; nitrogen, blue; 
oxygen, red; sulfur, yellow; and polar hydrogens, white. The IMPDH structures are shown in surface representation 
and binding site residues are shown in stick representation with the following atom colors: carbon, cyan (in a)/red 
(in b); nitrogen, blue; oxygen, red; and polar hydrogens, white.  Residues have black labels and hydrogen-bonding 
interactions are shown in black dotted lines. 
 
 
 
3) Addition of a methoxy group to the right-side pyridine could help to gain an additional H-
bond with the active site loop in both C. neoformans IMPDH and human IMPDH. This 
suggests the substituting an additional methoxy group to MCC_005985 would improve the 
potency of the compound for both IMPDHs (Figure 4.5.7.8).    
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Figure 4.5.7.8: (a) Structure of MCC_005985 methoxy derivative, highlighting the addition to the MCC_005985 
compound (b) Proposed binding mode of MCC_005985 methoxy derivative in the NAD+-binding site of C. 
neoformans IMPDH (b) Proposed binding mode of MCC_005985 methoxy derivative in the NAD+-binding site of 
human IMPDH.  
 
 
4) A number of bicyclic or tricyclic rings or similarly synthesisable moieties could be tried in 
place of right-side pyridine to achieve higher potency and selectivity of MCC_005985 
derivatives for C. neoformans IMPDH (Figure 4.5.7.9).    
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Figure 4.5.7.9: Structural representation of the bicyclic and tricyclic rings substitutions that could potentially 
replace right-side pyridine to improve the potency of MCC_005985. 
 
The docking score of the 116 derivatives (Figure 4.5.7.9) of MCC_005985 for human and the C. 
neoformans IMPDH is listed in appendix pages 170-187 (supporting information for chapter 4). 
It shows that the potency of these derivatives could potentially be higher than the parent 
molecule, MCC_005985. However, the selectivity for C. neoformans IMPDH could probably be 
achieved only by few derivatives such as derivative 19, 22, 26, 45, 51, 53 and 57 as the docking 
score of each of these derivatives is about 2-fold higher for C. neoformans IMPDH as compared 
to human IMPDH. 
 
 
4.5.8. In silico docking studies of MCC_006189  
Similar to the in silico docking of MCC_005985, the monomer of C. neoformans IMPDH (pdb: 
4AF0) and human IMPDH (pdb: 1NF7) was used to perform virtual docking of MCC_006189 
into the NAD+ binding site of both the IMPDHs. The docked pose MCC_006189 in the NAD+ 
binding site of C. neoformans IMPDH and human IMPDH showed almost identical binding pose 
(Figure 4.5.8, panel a and b). The dioxolane moiety on the right-side of the molecule formed H-
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bond with the asparagine residue (Asn317/Asn303) in both the IMPDHs. Apart from this, the 
binding orientation of MCC_006189 was found to be similar in the two structures and the 
docking score produced by Glide was in the same range. This suggests that the 7.7-fold 
difference in the potency MCC_006189 against C. neoformans IMPDH vs. human IMPDH is too 
small to be efficiently captured by the in silico docking. Therefore, similar to MCC_005985 in 
the previous section, the virtual SAR of MCC_006189 was performed to identify regions of 
importance in the compound and modify the compound further to explore the key differences 
between C. neoformans IMPDH and human IMPDH mentioned in section 4.5.4. Derivatives of 
MCC_006189 exploring the previously identified differences have a great potential to be highly 
selective for C. neoformans IMPDH. The designed derivatives were tested in the in silico 
docking experiments and will later be validated experimentally in both in vitro enzymatic and 
cell-based assays. 
 
 
 
Figure 4.5.8: (a) Proposed binding mode of MCC_006189 in the NAD+-binding site of C. neoformans IMPDH (b) 
Proposed binding mode of MCC_006189 in the NAD+-binding site of human IMPDH. Compound is shown in stick 
representation and colored in the following atom colors: carbon, orange; nitrogen, blue; oxygen, red; sulfur, yellow; 
and polar hydrogens, white. The IMPDH structures are shown in surface representation and binding site residues are 
shown in stick representation with the following atom colors: carbon, cyan (in a)/red (in b); nitrogen, blue; oxygen, 
red; and polar hydrogens, white.  Residues have black labels and hydrogen-bonding interactions are shown in black 
dotted lines. 
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4.5.9. In silico SAR studies of MCC_006189  
 
As mentioned in section 4.5.5, MCC_006189 was the most potent compound of the  
dihydroindenyl acetamide cluster, which consisted of 15 compounds in total. All the derivatives 
designed for the in silico SAR studies of MCC_006189 were in addition to these already existing 
members of dihydroindenyl acetamide cluster. 
 
Indane moiety in the left-side of MCC_006189 was replaced with 1,3-benzodioxole (Figure 
4.5.9.1, panel a). The docked poses suggest that this substitution would have no additional effect, 
as it could not capture any additional contacts (Figure 4.5.9.1, panel b and c). The docking score 
was also in the same range (-5.956 for C. neoformans and -5.268 for Human IMPDH), 
suggesting that the activity of this derivative would be comparable to that of MCC_006189. 
 
 
Figure 4.5.9.1: (a) Structure of MCC_006189 1,3-benzodioxole derivative (b) Proposed binding mode of 
MCC_006189 1,3-Benzodioxole derivative in the NAD+-binding site of C. neoformans IMPDH (b) Proposed 
binding mode of MCC_006189 1,3-benzodioxole derivative in the NAD+-binding site of human IMPDH. 
Compound is shown in stick representation and colored in the following atom colors: carbon, orange; nitrogen, blue; 
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oxygen, red; sulfur, yellow; and polar hydrogens, white. The IMPDH structures are shown in surface representation 
and binding site residues are shown in stick representation with the following atom colors: carbon, cyan (in a)/red 
(in b); nitrogen, blue; oxygen, red; and polar hydrogens, white.  Residues have black labels and hydrogen-bonding 
interactions are shown in black dotted lines. 
 
 
1) The amide linker of MCC_006189 was flipped (Figure 4.5.9.2, panel a). The docked 
poses suggest that flipping the linker should not affect the binding mode of MCC_006189 
in both C. neoformans IMPDH and human IMPDH (Figure 4.5.9.2, panel b and c). 
 
 
 
Figure 4.5.9.2: (a) Structure of MCC_006189 ‘flipped linker’ derivative (b) Proposed binding mode of 
MCC_006189 ‘flipped linker’ derivative in the NAD+-binding site of C. neoformans IMPDH (b) Proposed 
binding mode of MCC_006189 ‘flipped linker’ derivative in the NAD+-binding site of human IMPDH. 
Compound is shown in stick representation and colored in the following atom colors: carbon, orange; nitrogen, 
blue; oxygen, red; sulfur, yellow; and polar hydrogens, white. The IMPDH structures are shown in surface 
representation and binding site residues are shown in stick representation with the following atom colors: 
carbon, cyan (in a)/red (in b); nitrogen, blue; oxygen, red; and polar hydrogens, white.  Residues have black 
labels and hydrogen-bonding interactions are shown in black dotted lines. 
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2) Removing pentane moiety from left-side and addition of an amide group (-CONH2) or a 
carboxylic acid (-COOH) to the left-side benzene ring either at R1 or R2 position could 
potentially improve the potency of MCC_006189 derivative, as this would possibly form 
H-bonding interaction with H-bonding residues in that region (Figure 4.5.9.3). 
 
 
Figure 4.5.9.3: Structural representation of potential substitutions on the left-side benzene ring.  
 
The docking score of the four derivatives of MCC_006189 for human and the C. neoformans 
IMPDH (discussed in figure 4.5.9.3) listed below in Table 4.5.9.1 shows that the potency of 
these derivatives could potentially be higher than the parent molecule, MCC_006189. However, 
the selectivity for C. neoformans IMPDH could probably not be achieved, as the docking score 
of each of the derivatives for the two IMPDHs is similar. 
 
 
Table 4.5.9.1: Docking score of the left-side benzene ring MCC_006189 derivatives for the C. neoformans and 
human IMPDHs 
S. No. Compound 
Cryptococcus 
docking score 
Human 
docking score 
1 
 
-6.856 -7.649 
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2 
 
-6.439 -7.248 
3 
 
-6.865 -6.963 
4 
 
-6.865 -7.561 
 
 
3) A number of bicyclic or tricyclic rings or similarly synthesisable moieties could be tried 
in the place of right-side 1,3-Benzodioxole to achieve higher potency and selectivity of 
MCC_006189 derivatives for C. neoformans IMPDH (Figure 4.5.9.4). 
 
 
 
Figure 4.5.9.4: Structural representation of the bicyclic and tricyclic rings substitutions that could potentially 
replace right-side 1,3-Benzodioxole to improve the potency of MCC_006189. 
 
The docking score of the 17 derivatives of MCC_006189 for human and the C. neoformans 
IMPDH (discussed in figure 4.5.9.4) listed below in Table 4.5.9.2 shows that the potency of 
these derivatives could potentially be higher than the parent molecule, MCC_006189. However, 
the selectivity for C. neoformans IMPDH could probably be achieved only by derivatives 6 and 
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17, as the docking score of each of these two derivatives is slightly higher for C. neoformans 
IMPDH as compared to human IMPDH. 
 
 
 
Table 4.5.9.2: Docking score of the right-side 1,3-Benzodioxale MCC_006189 derivatives for the C. neoformans 
and human IMPDHs 
S. No. Compound 
Cryptococcus 
docking score 
Human docking 
score 
1 
 
-6.865 -7.561 
2 
 
-5.722 -6.493 
3 
 
-6.111 -6.284 
4 
 
-6.367 -6.276 
5 
 
-7.121 -6.599 
6 
 
-7.099 -5.271 
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7 
 
-5.556 -6.513 
8 
 
-6.676 -6.694 
9 
 
-6.757 -7.083 
10 
 
-5.628 -6.321 
11 
 
-6.01 -6.021 
12 
 
-6.516 -6.187 
13 
 
-6.487 -6.671 
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14 
 
-6.218 -5.62 
15 
 
-6.0 -6.685 
16 
 
-5.872 -6.814 
17 
 
-8.099 -6.212 
 
 
4.6. Conclusions 
 
The study described targeting the IMPDH of Cryptococcus neoformans to develop selective 
antifungal inhibitors. The structure of the IMPDH enzyme contains two binding pockets, one for 
IMP (substrate) and the other for NAD+ (cofactor), with IMP binding-site highly conserved 
across the species as described in section 4.3. On the other hand, the NAD+-binding site varied 
between the different species and was therefore selected as the target site for designing selective 
antifungal inhibitors. Homology modelling techniques were used to build the missing regions in 
both human and C. neformans IMPDH structures, particularly the binding site flap regions. MD 
simulations were performed with the tetrameric complex of the IMPDH’s which represents the 
bioactive form of the enzyme. However, any of the different conformations from the MD 
simulation did not improve the predictive power of any subsequent virtual docking experiment, 
beyond the conformation found in the crystal structure.  
  Chapter 4 
103 
 
The primary aim of the work was to design selective anti-fungal inhibitors, therefore, detailed 
sequence and structural comparison of cryptococcal and human IMPDH crystal structures was 
performed. This helped to identify key differences between the two structures, described in 
section 4.5.4. The screening of compound library in an in vitro enzyme assay and in a cell-based 
fungal growth inhibition assay was performed at WEHI, which identified 118 compounds 
forming 26 structurally diverse clusters and 24 unique singleton. Out of these, the best 
compounds, MCC_005985 and MCC_006189, belonging to clusters aminothiazoles and 
dihydroindenyl acetamides, respectively, were selected for further in silico docking studies, as 
they had the lowest MIC values in their corresponding cluster and IC50 of <10 µM in the in vitro 
screen. The in silico SAR studies of MCC_005985 has identified novel substitutions, such as 
replacing amide linker with sulfonamide linker and substituting right-side pyridine with the 
suggested bicyclic and tricyclic rings. Similarly, in silico SAR studies of MCC_006189 helped 
designing substitutions, such as replacing left-side pentane ring with amide or carboxylic acid 
group and substituting right-side 1,3-Benzodioxole with bicyclic and tricyclic rings. Virtual 
docking of these substitutions suggest that they have the potential to improve the activity against 
C. neoformans IMPDH by picking up additional interactions with the NAD+ binding pocket, 
while maintaining or reducing their activity against human IMPDH due to steric overlap or lack 
of additional interactions. In addition, virtual screening could be performed for the compound 
libraries targeting NAD+ binding site of C. neoformans to select more compounds that could 
potentially form the selective antifungal inhibitors.   
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5.1. Conclusions and future directions 
Streptococcus pneumoniae is one of the leading causes of morbidity and mortality worldwide, 
reportedly causing more than a million deaths per year (25). Despite the availability of β-lactam 
antibiotics and conjugate vaccines to cure or control pneumococcal infections, pneumococcus 
continues to remain the leading cause of infant and elderly population mortality, especially in the 
developing world (26, 27). This is due to the rapid emergence of MDR strains of S. pneumoniae, 
which are increasingly unresponsive to the existing last line of antibiotics (28-31). Chapter 1 of 
this thesis described various virulence factors found on the surface of the S. pneumoniae, which 
play a crucial role in establishing the pneumococcal infection in the host cell.  The virulence 
factors form ideal therapeutic drug targets, as they are not essential for the viability of the 
bacteria, but are crucial for establishing and maintaining an infection in its pathogenic state with 
a host cell (32). Therefore, targeting pneumococcal virulence factors would control the infection 
and potentially reduce the incidence of the resistant strains. Chapter 1 of this thesis exemplifies 
Pneumococcal surface antigen A (PsaA) as a therapeutic drug target of great importance due to 
its dual role of a virulence factor as well as a Mn2+-transporter (33, 34). The Mn2+ is essential for 
the pneumococcal cell as it protects the bacteria from oxidative stress. The three-dimensional 
structure of PsaA contains two lobes, with N- and C-terminal domains linked together by a rigid 
helix and forming a Mn2+-binding site in between by the side-chains of residues His67, His139, 
Glu205 and Asp280 (35-37). Chapter 1 concluded that targeting the metal-binding pocket of 
PsaA has the potential of preventing Mn2+ uptake and thereby inhibiting pneumococcal growth. 
 
Before targeting the metal-binding pocket of PsaA for structure-based drug design, the 
conformational flexibility of its N- and C-terminal domains was determined to understand the 
conformational variation affecting the binding site. Chapter 2 illustrates the structural differences 
between the open (metal-free) and closed (metal-bound) conformation of the PsaA. The 
transition from the closed metal-bound structure to the open (metal free) conformation has been 
found to be achieved by a rigid-body movement of the C-terminal domain with a hinge-bending 
angle between N- and C-terminal domains of 13° (35). Whereas, the N-terminal domain of PsaA 
in both open and closed states remains nearly static. In addition, chapter 2 elucidates the 
mechanism of metal binding to PsaA as a ‘spring-hammer’ mechanism, where the mobile metal 
binding residue Glu205 (‘the hammer’), on the C-terminal domain, captures the metal ion and 
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pushes it onto the static metal-binding site, formed by His67, His139 and Asp280 (‘the anvil’) 
(35). Furthermore, MD simulations were used to analyse the stability of the open state and to 
understand the dynamic transition from the closed to open state. 
In addition to understanding the transition from the closed to open state and the mechanism of 
metal-binding and release, chapter 2 highlighted the importance of the local pH environment for 
metal binding in PsaA. Using MD simulations at different pH values (i.e. protonation states of 
binding site histidine residues), the N-terminal domain of PsaA has been identified as structural 
stabilizer  to the protein at all pH conditions, whereas, protonation states of metal-binding 
histidines have been to found to have a huge impact on conformational flexibility of the C-
terminal domain of PsaA. The chapter identifies that the protonated forms of histidines, 
especially His139, play a pivotal role in the structural stability of PsaA, and their importance for 
metal binding. At basic pH conditions the uncharged metal-binding histidines induce an 
extensive C-terminal domain rigid-body movement and an extended hinge-bending motion. This 
leads to excessive solvent exposure of the metal binding pocket, thereby, disabling any metal 
binding. Given that PsaA lacks homologs in humans, the protein is a potential drug target for 
compounds against S. pneumonia infections, these findings will help to further understand the 
mechanism of metal binding and help identify new approaches to target the function of PsaA. 
 
Chapter 3 involved the identification of novel inhibitors for PsaA, using virtual screening in 
combination with fragment-based drug design approaches. Virtual docking experiments of an in-
house fragment library, into the metal-binding site of the open-state (metal-free) PsaA were 
carried out, followed by structural diversity clustering the top ranking compounds. This 
workflow yielded 60 diverse, low-molecular-weight (≤350 Da) molecules, which were screened 
for competitive inhibition of Zn2+-binding to PsaA. The biochemical assay resulted in 2 active 
fragments, 15 and 58, which were used as starting points for further optimisation by chemical 
modification, resulting in two compounds, 15h and 58f, with IC50 values for PsaA inhibition of 
28.1 µM and 71.8µM, respectively, and good ligand-efficiency. A cell-based, metal competition 
assay further validated the potency of 15h as it exhibited perturbation of pneumococcal growth at 
195 µg/ml, and complete growth inhibition at 779 µg/ml. In contrast, 58f perturbed bacterial 
growth at a concentration of 1,250 µg/ml and complete growth inhibition only at 2,500 µg/ml. 
With 15h as the more promising hit, further MD simulations were performed (for 100 ns) on the 
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complex of PsaA with docked 15h, to investigate any structural behavior of inhibitor-protein 
complex and indicate any further optimisation option. The MD simulations were used as any co-
crystallisation or crystal soaking attempts failed with 15h. Using the structural information from 
the MD simulation, further chemical modifications were designed around the scaffold of 15h, 
however, any modification to the para-position of the phenolic ring did not improve the potency 
of 15h.  
In conclusion, 15h is able to inhibit the metal-binding function of PsaA in biochemical and 
cell-based assays with good ligand-efficiency. As a small molecule with MW of 228.2 Da it has 
significant potential for further optimisation and development into a novel anti-pneumococcal 
agent. Therefore, the future scope of this work would be to develop a more extensive structure-
activity relationship (SAR) around 15h and 58f, thereby improving the overall activity and 
changes for structural investigation by X-ray. The developed molecules could further be tested 
for their activity against other substrate-binding proteins (SBPs) belonging to the same cluster, 
sub-cluster A-I, such as AdcA.   
 
Chapter 4 of this thesis describes the effort to target the IMPDH of Cryptococcus neoformans 
to develop selective antifungal inhibitors. The yeast C. neoformans is the primary cause of 
cryptococcal meningitis, which has been found to be one of the leading causes of mortality in the 
immune-compromised individuals, such as HIV-infected and transplant patients (38, 39). 
IMPDH is a key enzyme in the de novo GTP biosynthesis pathway and is involved in GTP 
production, by catalyzing the oxidation of IMP to XMP. GTP is essential for fungal cell survival 
and replication, therefore, inhibition of IMPDH controls the growth and, thereby, the infection 
by C. neoformans (1, 2). The structure of the IMPDH enzyme contains two binding pockets, one 
for IMP (substrate) and the other for NAD+ (cofactor) (4), with the IMP binding-site highly 
conserved across species. On the other hand, the NAD+-binding site displays variations between 
different species and has therefore been selected as the target site for designing selective 
antifungal inhibitors. Chapter 4 describes using homology modelling and MD simulations to 
investigate different conformations of the IMPDH’s of C. neoformans and human, to be used for 
the design of novel and selective antifungal inhibitors. In particular, the MD simulations were 
done with the tetrameric complex of the IMPDH’s which represents the bioactive form of the 
enzyme. In comparison, crystal structures only displayed the IMPDH in the monomeric form. 
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However, any of the different conformations from the MD simulation did not improve the 
predictive power of any subsequent virtual docking experiment, beyond the conformation found 
in the crystal structure. In conclusion, MD trajectories of C. neoformans and human IMPDHs 
could further be used in future to determine and understand conformational flexibility of the 
tetrameric IMPDH structure, particularly the active-site loop and unresolved active-site flap.  
Given that the primary aim of the work was to design selective anti-fungal inhibitors, detailed 
sequence and structural comparison of cryptococcal and human IMPDH crystal structures was 
performed. This helped to identify three key differences that could be exploited to design 
selective antifungal compounds. These are: (a) a cavity near the NAD+ binding site in the C. 
neoformans IMPDH, which is missing in human IMPDH due to the difference in the active site 
loop conformation (4), (b) an arginine residue (Arg267) in the NAD+ binding site of C. 
neoformans IMPDH, instead of a histidine residue (His253) in the human form, and (c) a second 
pocket in the NAD+ binding site of C. neoformans IMPDH, not present in  human IMPDH due to 
the different conformation of Lys438. The screening of compound library in an in vitro enzyme 
assay and in a cell-based fungal growth inhibition assay performed at WEHI and by Emily 
Furlong and Dr. Avril Robertson identified 118 compounds, which form 26 structurally diverse 
clusters and 24 unique singletons. Two of the clusters, aminothiazoles and dihydroindenyl 
acetamides, were selected for further investigation based on their chemical accessibility. The best 
compounds within these two clusters were MCC_005985 (aminothiazoles) and MCC_006189 
(dihydroindenyl acetamides), as they had the lowest MIC values in their corresponding cluster 
and IC50 of <10 µM in the in vitro screen. Both, MCC_005985 and MCC_006189 were selected 
for further exploration using structure-based drug design approach and in silico docking studies. 
The in silico SAR studies of MCC_005985 helped to design novel substitutions, such as 
replacing the amide linker with a sulfonamide linker and substituting right-side pyridine with the 
suggested bicyclic and tricyclic rings. Similarly, in silico SAR studies of MCC_006189 helped to 
design substitutions, such as replacing left-side pentane ring with amide or carboxylic acid group 
and substituting right-side 1,3-Benzodioxole with bicyclic and tricyclic rings. Virtual docking of 
all these substitutions suggested that they have the potential to improve the activity against C. 
neoformans IMPDH by picking up additional interactions with the NAD+ binding pocket, while 
maintaining or reducing their activity against human IMPDH due to steric overlap or lack of 
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additional interactions. Future scope of this work would include screening the identified IMPDH 
inhibitors, against other fungal pathogens IMPDHs, such as Candida and Cryptosporidium. 
 
In summary, the conventional method of searching the hit molecules for a protein target is to use 
the experimental screening approach. However, using the high-throughput screening (HTS) 
approach suffers several challenges such as limited throughput, cost of instruments and 
equipment, high protein and compounds concentration requirements (41). Moreover, sometimes 
the lack of biophysical techniques needed to detect the weakly interacting ligands limits this 
approach (40, 41). Therefore, virtual screening approach is an emerging alternative to the 
conventional HTS approach, as it samples large chemical space at practically zero cost compared 
to HTS (40,41). The success of the virtual screening of libraries heavily rely on the 3-
dimensional structure of the target protein and the ability of the docking algorithm to predict 
binding mode and energy (40). In chapter 3, the aim was to identify fragment-like small 
molecules targeting the metal binding pocket of PsaA and the PsaA crystal structure used for 
virtual screening was a complete structure with high resolution. The virtual screening and 
fragment-based drug design approaches successfully helped to identify PsaA inhibitors. This 
implies that similar approaches could be used identify inhibitors for other substrate-binding 
proteins.  In comparison, the aim of chapter 4 was to identify the MD-derived conformations of 
IMPDH which have the best predictive power to differentiate between actives and non-actives, 
but, the crystal structures used for docking had missing regions. Homology modelling of the 
highly flexible binding site flap regions (32 residues in C. neoformans and 16 residues in human 
IMPDH) in the monomers, followed by MD simulations of the tetrameric structures, potentially 
limited the scope of success of virtual screening approach in IMPDH. 
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Supplementary Tables 
 
Supplementary Table 1. Effect of Mn2+ and Zn2+ on the melting temperature shifts of PsaA 
variants 
Sample Tm (°C)a ΔTm (°C)b 
apo-PsaA 52.70 ± 1.57 - 
PsaA 10:1 Mn2+ 63.97 ± 1.94 +11.27 
PsaA 10:1 Zn2+ 70.86 ± 2.06 +18.16 
apo-PsaA-E205Q 56.26 ± 0.67 - 
PsaA-E205Q 10:1 Mn2+ 57.57 ± 1.08 +1.31 
PsaA-E205Q 10:1 Zn2+ 60.97 ± 5.24 +4.71 
apo-PsaA-D280N 55.45 ± 0.35 - 
PsaA-D280N 10:1 Mn2+ 56.07 ± 1.17 +0.61 
PsaA-D280N 10:1 Zn2+ 56.35 ± 3.50 +0.90 
a Values shown represent the mean and standard deviation from at least 6 independent 
measurements. 
b Values shown represent the difference in means between the apo-isoform and the metal-bound 
isoform. 
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Supplementary Table 2. X-ray data collection and refinement statistics for PsaA crystals 
 Wild-type apo-PsaA PsaA-D280N PsaA-E205Q PsaA-D280N-Mn2+ 
Data collection     
Space group P1 P1 P1 P1 
Cell dimensions       
   a, b, c (Å) 41.0, 60.0, 62.7 41.0, 59.8, 62.4 39.8, 59.1, 62.2 39.5, 59.0, 62.1 
  a, b, g  (°)  107.0, 103.9, 96.9 106.9, 103.9, 97.4 106.4, 105.1, 93.5 106.2, 104.5, 94.4 
Resolution (Å) 19.55-1.69 (1.72-1.69) 
* 
19.46-1.45 (1.47-
1.45) 
19.65-1.65 (1.68-1.65) 22.70-1.55 (1.57-
1.55) 
Rmerge 0.05 (0.74) 0.027 (0.20) 0.034 (0.12) 0.038 (0.46) 
< I / σ(I)> 14.7 (1.6) 21.1 (4.8) 17.6 (5.7) 16.2 (2.1) 
Completeness (%) 96.3 (86.6) 95.5 (85.5) 92.4 (60.5) 95.4 (86.8) 
Multiplicity 3.9 (3.5) 3.0 (2.9) 2.4 (2.5) 3.7 (3.1) 
     
Refinement     
Resolution (Å) 17.0-1.69 (1.73-1.69) 19.46-1.45 (1.45-
1.49) 
19.65-1.65 (1.69-1.65) 22.70-1.55 (1.55-
1.59) 
No. reflections 57,796 (4,069) 91,166 (6,255) 57,680 (2,871) 71,639 (5,267) 
Rwork/ Rfree (%) 16.1 / 19.2 13.9 / 16.5 14.9 / 18.2 16.5 / 19.8 
No. atoms     
    Protein 8,834 8,863 8,834 8,846 
    Ligand / ion 80 / 0 40 / 0 40 / 0 40 / 2 
    Water 667 877 690 543 
B-factors (Å2)     
    Protein 27.2 17.2 21.3 24.9 
    Ligand/ion 30.0 12.7 20.7 27.5 / 33.6 
    Waters 38.2 31.0 35.4 38.5 
R.m.s. deviations     
    Bond lengths (Å)  0.010 0.010 0.010 0.010 
    Bond angles (°) 1.07 1.07 1.05 1.08 
All datasets collected from single crystals.  
*Highest resolution shell is shown in parenthesis.  
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Supplementary Table 3. Effect of Mn2+ and Zn2+ on the melting temperature shifts of the Cys-
PsaARed variant 
Sample Tm (°C)a ΔTm (°C)b 
PsaA 10:1 Mn2+ 63.97 ± 1.94 - 
PsaA 10:1 Zn2+ 70.86 ± 2.06 - 
PsaARed 10:1 Mn2+ 64.65 ± 0.16 - 
PsaARed 10:1 Zn2+ 72.33 ± 0.27 - 
Cys-PsaARed 10:1 Mn2+ 62.94 ± 0.01 - 1.71 
Cys-PsaARed 10:1 Zn2+ 67.17 ± 0.01 - 5.16 
a Values shown represent the mean and standard deviation from at least 3 independent 
measurements. 
b Values shown represent the difference in the mean Tm values between wild-type PsaARed and the 
Cys-PsaARed variant. 
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Supplementary Table 4. Oligonucleotide primers used in this study 
Primer Sequence (5’→3’) Comment 
PsaA_LIC1F TGGGTGGTGGATTTCCTGGAAAAAAAGATACAACTTCT Ligation-
independent cloning 
sequence underlined 
PsaA_LIC1R TTGGAAGTATAAATTTCCTTTTGCCAATCCTTCAGCAAT Ligation-
independent cloning 
sequence underlined 
E205Q_F GAAAAGAAACTCATTGTAACCAGCCAGGGAGCATTCAAAT
ACTTCTCTAAA 
For E205→Q205 
mutation 
E205Q_R TTTAGAGAAGTATTTGAATGCTCCCTGGCTGGTTACAATG
AGTTTCTTTTC 
For E205→Q205 
mutation 
D280N_F CCCAATCTACGCACAAATCTTTACTAACTCTATCGCAGA For D280→N280 
mutation 
D280N_R TCTGCGATAGAGTTAGTAAAGATTTGTGCGTAGATTGGG For D280→N280 
mutation 
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Supplementary Movie Legend 
 
Supplementary Movie 1. Spring-hammer model of metal-ion binding by PsaA. The movie 
shows the conformational changes in PsaA as the cognate physiological ligand Mn2+ binds to the 
protein as revealed by the crystal structures of metal free, open state PsaA (3ZK7); open state Mn2+-
D280N-PsaA (3ZKA); and closed state Mn2+-PsaA (3ZTT). Changes in secondary structure and 
backbone hydrogen bonding that occur in the flexible (‘spring’) helix of PsaA during binding are 
highlighted. The movie also shows the conformational differences between closed state Mn2+-PsaA 
(3ZTT) and closed state Zn2+-PsaA (1PSZ).  
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Supplementary Figures 
 
 
 
Supplementary Figure 1. The structure of metal-free wild-type PsaA reveals an open metal-
binding site. (a) Cartoon representation of open, metal-free PsaA, showing N- and C-terminal lobes 
(this view is rotated 90° about a horizontal axis relative to the view in Fig. 1). Metal-coordinating 
residues are shown in stick representation. (b) Cross-section view of the molecular surface in open, 
metal-free PsaA showing that the metal-binding site of the protein is exposed to the solvent. The 
expected position for the metal ion, as in the Zn2+-bound protein (PDB ID 1PSZ), is shown as a 
dotted sphere. Protein backbone of open, metal-free PsaA is shown in green cartoon representation. 
(c) Cross-section view of the closed, Zn2+-bound PsaA structure showing that the metal ion is 
completely buried within the molecular surface. The protein backbone of Zn2+-bound PsaA is 
shown in purple cartoon representation and metal-binding residues are shown in stick 
representation. Molecular surfaces shown are colored by electrostatic potential (blue - positive; red 
- negative). (d) Details of the metal-binding site of PsaA in the presence (PDB ID 1PSZ, purple) 
and absence (open, metal free, green) of ligand (Zn2+, grey sphere). Metal-coordinating residues are 
shown in stick representation. Metal-ion coordination in the metal-bound protein is shown as 
dashed lines and conforms to a tetrahedral geometry. 
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Supplementary Figure 2. Loop movements in the crystal structures of open and closed-state 
wild-type PsaA. (a and b) Composite images depicting the individual superpositions of N- and C-
terminal lobes of the closed, Zn-bound (PDB ID 1PSZ - purple) and the open, metal-free (green) 
PsaA structures; the linking helix is only shown for the latter structure. The metal ion present in the 
Zn-bound structure is shown as a grey sphere. Metal-binding residues are depicted in stick 
representation. Asterisks denote loops that display significant differences following the 
superposition of open and closed proteins. Loop 1 - residues 223-230; loop 2 - residues 93-99; loop 
3 - residues 278-298; loop 4 - residues 125-136. View in (b) is rotated 90° about a horizontal axis 
relative to the view in (a).  
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Supplementary Figure 3. The structural stability of open-state PsaA in MD simulations. (a) 
Superposition of the conformation of PsaA after 50 ns of MD simulation from the six independent 
simulations (grey) and the conformation of the open state PsaA structure (green) (PDB ID: 3ZK7). 
(b, c, d and e) The Cα RMSD of the N-terminal [residues 32-309, (b) and (d)] and C-terminal 
[residues 194-221 and residues 248-309, (c) and (e)] domains calculated with respect to the open, 
metal-free crystal structure. His67 and His139 were either singly protonated [(b) and (c)], or doubly 
protonated [(d) and (e)].  
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Supplementary Figure 4. Superposition of metal-free wild-type, E205Q and D280N PsaA 
structures. (a and b) Superposition based on residues 32-309 from both protein chains found in the 
asymmetric units of metal-free wild-type (light/dark green), E205Q (light/dark yellow), and D280N 
(light/dark blue) protein crystals. Backbone atoms are depicted in cartoon representation. Metal-
binding residues are shown in stick representation. The side-chain group from His67 in one of the 
chains from the metal-free, open D280N structure was best modeled as having two conformations 
with partial occupancies. Asterisks denote loops that display significant differences following the 
superposition of open and closed proteins as shown in Supplementary Figure 2. View in (b) is 
rotated 90° about a horizontal axis relative to the view in (a). 
 
  
Nature Chemical Biology: doi:10.1038/nchembio.1382
11 
 
 
 
Supplementary Figure 5. Location of introduced cysteine residues in the metal-free PsaA. (a) 
Overall structure of metal-free PsaA. Residues in the metal-binding site and main-chain atoms for 
residues in the flexible helical turn of the linking helix are shown in stick representation. Main-
chain hydrogen bonding for residues in the flexible helical turn are shown as dashed lines. Side-
chains for introduced cysteine residues are shown in stick representation and putative disulfide 
bonds are depicted as dashed lines (within the dotted circles). (b and c) Distance between the Cα 
atoms of (b) residues 190 and 304, and (c) 194 and 308 from 50 ns MD simulations of metal-free 
PsaA. The individual simulation runs are colored in blue, red, and black.  
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Supplementary Figure 6. Zinc-ion binding and extraction. Time-course metal binding 
experiments of apo-PsaA with EDTA-Zn2+, and Zn2+-PsaA with EDTA. EDTA-Zn2+ (3 mM EDTA 
+ 300 µM ZnSO4) was incubated with apo-PsaA (30 µM) for 1 to 4 hours as indicated. The 
concentration of Zn2+ associated with apo-PsaA after incubation with EDTA-Zn2+ was determined 
by ICP-MS. Zn2+-PsaA (30 µM) was incubated with EDTA (3 mM) for 1 to 4 hours as indicated 
with the concentration of Zn2+ associated with Zn2+-PsaA after incubation determined by ICP-MS. 
The molar ratio of metal ion-to-protein for all samples was determined and data shown correspond 
to mean values of at least 3 independent biological samples. Statistical significance between the 
means was determined by a two-tailed unpaired t-test (n.s. corresponds to not significant). 
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Results and Discussion 
 
Molecular dynamics simulations. In both models, apo-PsaA and 15h-bound PsaA, the N-
terminal lobe (residues 32-189) maintained similar structural integrity during the 100 ns 
simulations, showing similar RMSD ± standard deviation (s.d.) values of the corresponding Cα 
atoms of 2.9 ± 0.2 Å and 2.7 ± 0.1 Å for PsaA-15h and apo-PsaA, respectively, compared to the 
starting structure. The C-terminal lobe (residues 194-221 and 248-309) showed a slightly 
increased flexibility for the PsaA-15h model with RMSD ± s.d. values of 3.1 ± 0.6 Å, compared 
to 2.1 ± 0.1 Å for the apo-PsaA model. Apart from global movement of the domains, the inter-
domain angle ± s.d. between Cα atoms of His67, His139 and Glu205 showed similar increase 
with 13.8 ± 6.0° and 15.6 ± 6.5° for PsaA-15h and apo-PsaA, respectively, compared to the 
metal bound PsaA crystal structure (PDB ID 3ZK7).  
While the overall structure for both models remained similar throughout the simulations, the 
metal-binding site showed significantly different behaviors. For PsaA-15h, the binding site 
showed a slight uniform enlargement compared to the starting conformation (PDB ID 3ZK7), 
with distances ± s.d. between the metal-binding residues increasing by 3.7 ± 0.4 Å (between Cβ 
atoms of His139 and Asp280) and 3.0 ± 0.9 Å (between Cβ atoms of His67 and Glu205). In 
comparison, for the apo-PsaA the distance ± s.d. between Cβ atoms of His139 and Asp280 
remained similar (only increasing by 0.6 ± 0.4 Å compared to the crystal structure) while 
distance ± s.d. between Cβ atoms of His67 and Glu205 widened significantly by 7.1 ± 2.5 Å 
compared to the starting conformation (PDB ID 3ZK7). This suggests that apo-PsaA undergoes 
extensive rigid body movement of the C-terminal domain over 100 ns of simulation causing 
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further opening and solvent exposure of the metal-binding site. The presence of a ligand in the 
metal-binding site, on the other hand, restricts this type of behavior, as shown by PsaA-15h 
simulations.  
Materials and Methods 
 
Fragment library. The in-house fragment library was developed by analyzing active 
molecules from public databases (ChEMBL and PubChem) and selecting molecules with activity 
(KI, KD, IC50, EC50, etc.) below 0.1 µM and classifying them according to 9 type of targets, 
comprising of aminergic, peptidic and other GPCRs, ion channels, transporters, nuclear 
receptors, proteases, kinases and other enzymes. The molecules were fragmented and the 
fragments filtered by an extended rule-of-3 (1) using the following thresholds: MW between 
150-350 Da, H-bond acceptor ≤ 3, H-bond donor ≤ 3, rotatable bonds ≤ 3, logP ≤ 3 and solubility 
≥ 100 µM. In order to focus only on relevant fragments, all those fragments found in less than 30 
active molecules were filtered out. Also, in order to filter out promiscuous fragments, all those 
fragments found in more than 3 target classes were filtered out. The selected fragments were 
mapped against the catalog of commercially available compounds, retrieving compounds with 
exact or closely similar structures. To optimize the purchase process, only two vendors were 
selected, which had the largest collection at the time. In addition, the final size of the library was 
further limited to 2,000 compounds selecting a chemically and biologically diverse sub-set. From 
the 1,986 selected compounds, 1,623 could be purchased at the time from Enamine (Ukraine) 
and Princeton Biomolecular (USA), and dissolved in DMSO at a target concentration of 200, 100 
or 50 mM, eliminating 104 compounds with DMSO solubility below 50 mM. The final fragment 
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library consisted of 1,519 samples. The selection of the fragment library was done as fee-for-
service by ChemoTargets S.L. (Spain).    
 
Expression and purification of apo-PsaA. Recombinant PsaA was expressed in E. coli 
LEMO21(DE3) from the pCAMcLIC01-PsaA construct as described previously (2). The 
dodecahistidine tag was removed from affinity-purified PsaA by enzymatic digestion by the 
human rhinovirus 3C protease and the protein purified further on a HisTrap HP column. Apo-
PsaA was prepared by dialyzing the dodecahistidine tag-cleaved protein in a 20-kDa molecular-
weight-cutoff membrane (Slide-A-Lyzer, Pierce) against 4 L of sodium acetate buffer, pH 4.0, 
with 20 mM EDTA at 300 K. The sample was then dialyzed against 4 L of 20 mM Tris-HCl, pH 
7.2, 100 mM NaCl, at 277 K and centrifuged at 18,000 × g for 10 min to remove any insoluble 
material. Protein samples were analyzed for metal content by heating 5 μM protein at 370 K for 
15 min in 3.5% HNO3 and the metal-ion content was measured by ICP-MS (3). 
 
Molecular dynamics simulations. Both simulations, apo-PsaA and 15h-bound PsaA, were 
performed using GROMACS (Groningen Machine for Chemical Simulations) engine (4) in 
conjunction with the GROMOS 54a7 force field for proteins (5). The crystallographic water 
molecules were retained. Water was described using the simple point charge (SPC) water model. 
All of the simulations were performed under periodic boundary conditions using a rectangular 
box. The dimensions of the box were chosen such that the minimum distance between the protein 
and the box wall was at least 1.2 nm. The non-bonded interactions were evaluated using a twin-
range method. Interactions within the short-range cutoff of 0.9 nm were updated every step. 
Interactions within the long-range cutoff of 1.4 nm were updated every three steps together with 
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the pair list. To minimize the effect of truncating the electrostatic interactions beyond the 1.4-nm 
long-range cutoff, a reaction-field correction was applied using a relative dielectric constant of Ɛr 
= 78.5 (6). The SHAKE algorithm (7) was used to constrain the lengths of the covalent bonds. 
The SETTLE algorithm (8) was used to constrain the geometry of the water molecules. To 
extend the timescale that could be simulated, explicit hydrogen atoms in the protein were 
replaced with dummy atoms, the positions of which were calculated in each step on the basis of 
the positions of the heavy atoms to which they were attached. Doing so eliminated high-
frequency degrees of freedom associated with the bond angle vibrations involving hydrogens, 
allowing a time step of 4 fs to be used to integrate the equations of motion without affecting 
thermodynamic properties of the system (9). The simulations were carried out in the NPT 
ensemble at T = 300 K and P = 1 bar. The pressure coupling was isotropic. The temperature and 
pressure were maintained close to the reference values by weakly coupling the system to an 
external temperature and pressure bath using a relaxation time constant of 0.1 ps (10) and 0.5 ps, 
respectively. The compressibility was 4.5*10
-5
 bar. Configurations were saved every 40 ps for 
analysis. Images were produced using VMD (11) and PyMol (The PyMOL Molecular Graphics 
System, Version 1.5.0.4 Schrödinger, LLC). 
The system was equilibrated as follows: 500 steps of steepest descent energy minimization 
were performed to relax the solvent atoms with the initial protein conformations restrained using 
harmonic potential with a force constant of 1,000 kJ mol
-1
nm
-1
. Then, a series of 1 ns simulations 
was performed, in which the force constant was progressively relaxed from 1,000 kJ mol
-1
nm
-1
 to 
10 kJ mol
-1
nm
-1
 over 10 ns equilibration period. New velocities were then assigned and each 
system was simulated for 100 ns without restraints. Two independent simulations with different 
sets of starting velocities were performed for each apo-PsaA and 15h-bound PsaA simulations. 
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In all MD simulations, the error is the standard deviation calculated from the last frames of the 
simulations. 
 
MD analysis. R.m.s. deviation:  To compare the relative difference between trajectories or 
clusters, the r.m.s. deviation was calculated using the method of Maiorov and Crippin (12) after 
first fitting the trajectory frames to a reference structure or domain. 
Interdomain angles: To identify the domain motion associated with the change in angle 
between the C-terminal and N-terminal domain associated with the bending of the hinge 
residues, the angle between the Cα atoms of His67, His139 and Glu205 was calculated. 
Inter-residue distances: To determine the flexibility of the PsaA metal-binding site, the 
distance between the center of mass of the Cβ atoms of the residues His67 and Glu205, and the 
center of mass of the Cβ atoms of residues His139 and Asp280 was measured.   
 
Crystallographic studies. Crystals of the apo-state of both wild-type and the D280N mutant 
of PsaA were obtained using the hanging drop vapor diffusion method in 12.5 % (w/v) 
polyethylene glycol (PEG) 1000, 12.5% (w/v) PEG 3350, 12.5% (v/v) 2-methyl-2, 4-pentanediol 
(MPD) and 0.1 M Trizma-Bicine, pH 8.7, as previously described (2). For soaking experiments, 
the crystals were soaked with the compound 15h at various concentrations (5 to 20 mM) for 15 
minutes before being flash-cooled by rapid dipping into liquid nitrogen prior to data collection. 
For co-crystallization, the compound 15h (5 to 20 mM) was incubated with the protein at room 
temperature for 30 minutes before setting up crystallization trays. The diffraction quality of the 
crystals was tested and diffraction data collected on single crystals at the Australian Synchrotron. 
The structures were determined by molecular replacement using the available structures of apo-
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PsaA (PDB ID 3ZK7) or the D280N mutant (PDB ID 3ZK9) (2) as a template, following 
structure refinement by Phenix.Refine (13) with manual model fitting in Coot (14). 
 
Cytotoxicity assay. Hepatocellular carcinoma (HepG2, ATCC HB-8065) and human 
embryonic kidney cells (HEK293, ATCC CRL-1573) cells were seeded as 3000 cells per well in 
a 384-well plate in DMEM medium (GIBCO-Invitrogen #11995-073), in which 1% of FBS was 
added. Cells were incubated for 24 hours at 37 
o
C, 5% CO2 to allow cells to attach to the plates. 
Compounds were prepared in DMSO at 200 mM and were diluted 100-fold in culture media, 
giving a final concentration of 2000 µM with 1% DMSO. It was then diluted from 2000 µM to 
0.91 µM in 3-fold dilutions. The cells were incubated with the compounds for 24 hours at 37 
o
C, 
5% CO2. After the incubation, 10 µM resazurin (Sigma-Aldrich) (15) was added to each well and 
then incubated for 2 hours at 37 
o
C, 5% CO2. Then the fluorescence intensity (FI) was read using 
a Polarstar Omega plate reader with excitation/emission 560/590. The data was then analysed by 
Prism software. Results were calculated using the following equation: percent viability = (FITEST 
– FINEGATIVE/ FI1%DMSO –FINEGATIVE)*100%.  
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Supplementary Figures  
 
 
 
Supplementary Figure 1. (a) Cartoon representation of Mn
2+
-bound PsaA (pdb:3ZTT), showing 
N- and C-terminal domains connected by the linking helix. Metal-coordinating residues are 
shown in stick representation with the following color scheme: carbon, green; nitrogen, blue and 
oxygen, red. Mn
2+
 ion is shown as a sphere. (b) PsaA protein titration curve from 0 to 1000 nM 
concentration to measure the decrease in fluorescent intensity with increasing protein 
concentration, while keeping the concentrations of ZnCl2 and FluoZin-3 constant at 500 nM and 
600 nM, respectively. Error bars are standard deviation of the mean for n=6. 
 
9 
 
 
 
Supplementary Figure 2. PsaA metal-binding pocket. PsaA protein is in shown in surface 
representation and binding site residues are shown as sticks with following atom colors: carbon, 
cyan; nitrogen, blue; oxygen, red; and polar hydrogens, white. Metal binding residues are in blue 
labels whereas all other residues are in black labels. Right circle highlights ‘Hydrophobic pocket 
N’ formed by Pro66, Leu92, Pro138 and Trp14. Left circle highlights ‘Hydrophobic pocket C’ 
formed by Ala207, Phe208 and Thr279. ‘Hydrophilic pocket C’ is also highlighted on the top-
left corner.  
10 
 
 
Supplementary Figure 3. The structural stability of open state apo-PsaA and 15h-bound PsaA 
in MD simulations. (a) Open state apo-PsaA and (b) 15h-bound PsaA: Cα RMSD of the N-
terminal (residues 32-189, left panel) and C-terminal (residues 194-221 and residues 248-309, 
right panel) domains calculated with respect to the 3ZK7 crystal structure.  
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Supplementary Figure 4. Scaffold chemical synthesis route and structures for 15h derivatives. 
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Supplementary Tables  
 
Supplementary Table 1. 60 fragments tested at single concentration of 100 µM in PsaA 
competitive Zn
2+
-binding fluorescence assay (n=5). 
Fragment % PsaA Inhibition Standard Deviation 
1. 6.3 1.0 
2. -1.3 0.5 
3. 0.4 0.8 
4. 15.9 0.8 
5. 4.3 0.5 
6. 1.3 0.8 
7. -5.1 1.0 
8. 5.9 1.2 
9. -11.9 0.5 
10. 8.0 1.0 
11. 2.1 0.8 
12. 3.0 1.2 
13. -3.9 0.8 
14. -6.2 2.0 
15. 19.1 1.7 
16. 1.9 1.0 
17. 6.5 0.5 
18. 6.4 1.2 
19. 3.1 0.8 
20. -6.7 2.0 
21. -7.4 0.5 
22. -1.2 1.0 
23. 8.6 1.0 
24. 8.3 0.5 
25. -12.3 1.2 
26. 15.7 1.0 
27. -3.2 2.0 
28. 6.1 0.8 
29. 4.4 1.0 
30. -0.3 0.5 
31. 0.4 2.1 
32. 7.4 1.2 
33. -3.8 2.0 
34. 4.2 3.0 
35. 1.2 0.8 
36. 15.3 2.0 
37. 5.2 0.5 
38. 5.4 1.2 
39. 7.9 1.0 
40. 18.0 0.8 
41. 2.5 3.0 
42. -3.2 1.0 
43. 1.0 2.0 
44. 1.1 1.0 
45. 2.2 1.2 
46. -3.9 1.0 
47. 2.0 2.0 
48. 16.0 0.5 
49. 7.2 0.8 
50. 8.9 1.0 
51. -9.8 2.0 
52. 4.2 0.5 
53. 16.1 1.0 
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54. 3.5 1.0 
55. 15.2 3.0 
56. 15.1 1.0 
57. 2.2 1.0 
58. 26.3 1.2 
59. 9.5 0.8 
60. 6.5 2.0 
 
Supplementary Table 2. The phenyl ring B modified derivatives of fragment 15 tested at single 
point concentration (500 µM) in PsaA competitive Zn
2+
-binding fluorescence assay (n=6). 
                                                                           
 
R % PsaA Inhibition R % PsaA Inhibition 
 
3.3 
 
≤0 
 
≤0 
 
≤0 
 
≤0 
 
≤0 
 
≤0   
 
Supplementary Table 3. The phenyl ring A and B modified derivatives of fragment 15 tested at 
single point concentration (500 µM) in PsaA competitive Zn
2+
-binding fluorescence assay (n=6). 
 
R1 R2 % PsaA Inhibition R1 R2 % PsaA Inhibition 
  
4.1 
  
≤0 
  
≤0 
  
≤0 
  
≤0 
  
≤0 
 
C2H5 ≤0 
  
≤0 
14 
 
  
≤0 
  
≤0 
  
≤0 
  
≤0 
  
≤0 
  
≤0 
  
3.8 
 
 
7.0 
  
≤0 NH2 
 
≤0 
  
≤0 
  
2.0 
  
≤0 
  
11.0 
  
≤0 
  
8.0 
  
≤0 
  
≤0 
  
≤0 
  
≤0 
  
≤0 
  
≤0 
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Supplementary Table 4a. Linker modified with sulfonamide derivatives of fragment 15 tested 
at single point concentration (500 µM) in PsaA competitive Zn
2+
-binding fluorescence assay 
(n=6). 
 
R1      R2 % PsaA Inhibition R1      R2 % PsaA Inhibition 
  
≤0 
  
≤0 
  
≤0 
  
≤0 
     
≤0 
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Supplementary Table 4b.  Linker modified with triazole derivative of fragment 15 tested at 
single point concentration (500 µM) in PsaA competitive Zn
2+
-binding fluorescence assay (n=6). 
 
R1 R2 % PsaA Inhibition 
  
≤0 
 
Supplementary Table 5. Derivatives of fragment 58 tested at single point concentration (500 
µM) in PsaA competitive Zn
2+
-binding fluorescence assay. (n=6) 
 
R1 R2 R3 R4 R5 R6 % PsaA Inhibition 
SO2NHCH3 NH2         ≤0 
SO2NHCH3  F        OCH3 ≤0 
SO2NHCH3 Cl Cl    2.5 
SO2CH3 NH2  CH3   ≤0 
SO2CH3  Br NH2   ≤0 
SO2CH3   F   ≤0 
CONH2  F F   1.7 
CONH2 F   NH2  ≤0 
CONH2 F  F NH2  4.3 
CONH2 NH2    CH3 ≤0 
CONH2  CH3 NH2   2.0 
CONH2 NH2 CH3    ≤0 
CONH2  Br    ≤0 
CONHCH3 Cl  NH2   ≤0 
NHCONH2  Br    ≤0 
NHCONHCH3   F   ≤0 
NHCONHCH3  Cl CH3   ≤0 
COOH  NH2 Cl   13.0 
COOH   Br   1.5 
COOH F   NH2  ≤0 
COOH Cl  Cl   ≤0 
COOH  F   CH3 8.0 
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COOCH3 F     ≤0 
COOCH3 Cl  NH2   ≤0 
NHSO2CH3   Br   ≤0 
NHCOCH3  NH2 Cl   7.3 
 
 
Supplementary Table 6. The derivatives of 15h and 58f were tested on HepG2 and 293 
mammalian cell lines to determine their cytotoxic effects.  
Compound Structure CC50 [µM] HepG2 CC50 [µM] 293 
15h 
     
>1,000 >1,000 
58 
 
>1,000 >1,000 
58a 
 
>1,000 >1,000 
58b 
 
>1,000 >1,000 
58f 
 
>1,000 >1,000 
58p 
 
>1,000 >1,000 
61 
 
>1,000 >1,000 
61g 
 
>1,000 >1,000 
61i 
 
>1,000 >1,000 
61j 
 
>1,000 503.5 
61k 
 
>1,000 >1,000 
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Chemical synthesis of 15h derivatives 
 
General. Reagents and anhydrous solvents (THF, dichloromethane, and acetonitrile) were used 
as purchased. Triphenylphosphine, polymer-bound (100-200 mesh, 1.6 mmol/g) was purchased 
from Sigma-Aldrich. Reaction progress was monitored by TLC using Merck silica gel 60 F-254 
with UV detection. Silica gel 60 (Merck 40–63 μm) was used for column chromatography. The 
following stain solutions have been used in addition to UV light with fluorescent TLC plates: 
phosphomolybdic acid, anisaldehyde/EtOH. Reactions requiring anhydrous conditions were 
performed under nitrogen. NMR data were collected and calibrated in d4-MeOH or CDCl3 at 
298K on a Varian Unity 400 MHz Hz spectrometer. HPLC and routine mass spectra were 
acquired on an Agilent Technologies 1200 Series instrument, fitted with a G1316A UV-Vis 
detector, 1200 Series ELSD and 6110 quadrupole ESI-MS. High resolution mass spectrometry 
(HRMS) was performed on the Bruker MicroTOF mass spectrometer. 
 
Experimental procedures for the synthesis of R1 modified analogues 
 
 
 
 
General procedure for amide bond formation 
To a solution of acid (200 mg, 1 eq.) in DMF (10 mL), diamine (2 eq.), HBTU (1.5 eq.) and 
DIPEA (1.5 eq.) were added. The reaction mixture was stirred at RT for 3 h, and was monitored 
by TLC. After completion of the reaction, the mixture was diluted with EtOAc (30 mL), washed 
with H2O (20 mL) and brine (20 mL). The organic layer was separated, dried over MgSO4, 
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filtered, and concentrated in vacuo. The crude product was purified by column chromatography 
to obtain the pure products. 
 
Compound Product 
Yield 
% 
Molecular 
Formula 
HRMS 
Calcd. Found 
  
97 
C14H15N2O2 
(M+H)
+
 
NA NA 
 
 
82 
C15H17N2O3 
(M+H)
+
 
273.1234 273.1228 
  
70 
C15H17N2O2 
(M+H)
+
 
257.1285 257.1296 
  
82 
C14H14ClN2O2 
(M+H)
+
 277.0738 277.0727 
  
82 
C14H14N3O4 
(M+H)
+
 
288.0979 288.0968 
  
88 
C18H17N2O2 
(M+H)
+
 
293.1285 293.1277 
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Procedure for the synthesis of anti triazole (anti-) 
To a solution of azide (1 mol.eq) and alkyne (1.0 mol. eq) in MeCN (1.0 mL), a solution of 
CuSO4 (5 mol %) was added and treated with an aqueous sodium ascorbate (10 mol%). The 
reaction was vigorously stirred for 12 h. and after completion of the reaction as indicated by 
TLC, the solvent was concentrated under vacuum. The crude product thus obtained was purified 
by column chromatography to isolate the desired product (89%). HRMS: calcd for C15H15N4O, 
267.1240 found: 267.1238. 
 
 
 
 
Procedure for the synthesis of sulfonamide  
To a solution of amine (1 eq.) in dry DMF, Et3N (1.5 eq.) was added. After stirring for 15 min, 
sulfonyl chloride (0.5 eq.) in dry DMF was added and the stirring continued for 2 h. The reaction 
was monitored by LCMS. After completion of the reaction, the solution was diluted with EtOAc 
(30 mL) washed with H2O (20 mL) and brine (20 mL). The organic layer was separated, dried 
(MgSO4) and evaporated to give the crude product. The crude product was purified by column 
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chromatography to isolate the pure product (69%). HRMS: calcd for C13H15N2O3S, 279.0798 
found: 279.09810. 
 
 
 
General procedure for the demethylation reaction (16) 
A solution of compound (20 mg, 0.06 mmol) in CH2Cl2 (10 mL) at 0 
o
C was treated with BBr3 
(1.0 M in CH2Cl2, 0.18 mmol). The mixture was stirred at RT for 2 h, and then quenched with 
saturated aq. NH4Cl (5 mL). The mixture was allowed to warm up to room temperature and 
diluted with CH2Cl2 (20 mL). The organic layer was washed with brine (10 mL), dried over 
MgSO4, filtered, and concentrated in vacuo.  
 
Compound Product 
Yield 
% 
Mol. 
Formula 
HRMS 
Calculated Found 
 
         
15h 
65 
C13H13N2O2 
(M+H)
+
 
229.0972 229.0982 
 
    
61i 
92 
C14H15N2O3 
(M+H)
+
 
259.1077 259.1085 
 
    
61k                
74 
C13H12ClN2O2 
(M+H)
+
 
263.0582 263.0581 
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61g 
70 
C14H15N2O2 
(M+H)
+
 
243.1128 243.1139 
 
   
61 
86 
C13H12N3O4 
(M+H)
+
 
274.0822 274.08223 
 
       
61j 
81 
C17H15N2O2 
(M+H)
+
 
279.1128 279.1135 
  
66 
C14H13N4O 
(M+H)
+
 
253.1084 253.1088 
  
0    
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S. No. Compound 
Cryptococcus 
docking score 
Human 
docking score 
1 
 
-6.695 -5.791 
2 
 
-6.059 -6.236 
3 
 
-7.589 -6.816 
4 
 
-5.519 -5.302 
5 
 
-7.41 -7.031 
6 
 
-7.652 -6.305 
7 
 
-6.389 -6.716 
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8 
 
-5.415 -5.237 
9 
 
-6.708 -6.025 
10 
 
-6.857 -5.914 
11 
 
-6.987 -6.426 
12 
 
-6.565 -5.875 
13 
 
-7.589 -6.034 
14 
 
-7.784 -5.045 
  Appendices 
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15 
 
-8.218 -7.34 
16 
 
-7.897 -5.271 
17 
 
-7.707 -6.525 
18 
 
-8.048 -6.291 
19 
 
-7.959 -4.608 
20 
 
-8.093 -6.822 
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21 
 
-8.23 -6.243 
22 
 
-8.384 -5.13 
23 
 
-8-212 -7.438 
24 
 
-7.959 -6.566 
25 
 
--7.335 -5.941 
26 
 
-8.024 -5.941 
27 
 
-7.973 -6.979 
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28 
 
-8.153 -5.88 
29 
 
-7.482 -6.452 
30 
 
-5.695 -5.381 
31 
 
-7.334 -5.13 
32 
 
-7.784 -6.625 
33 
 
-7.791 -5.615 
34 
 
-7.57 -5.555 
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35 
 
-7.92 -6.277 
36 
 
-6.635 -6.881 
37 
 
-7.219 -5.778 
38 
 
-6.713 -5.988 
39 
 
-7.035 -6.382 
40 
 
-7.224 -6.282 
41 
 
-7.359 -5.818 
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42 
 
-7.746 -6.14 
43 
 
-7.727 -6.282 
44 
 
-8.242 -7.259 
45 
 
-8.07 -5.716 
46 
 
-7.874 -6.474 
47 
 
-8.137 -6.304 
48 
 
-7.774 -5.597 
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49 
 
-7.804 -6.69 
50 
 
-8.061 -6.215 
51 
 
-8.537 -5.266 
52 
 
-5.167 -6.549 
53 
 
-8.135 -5.187 
54 
 
-8.273 -6.049 
55 
 
-8.198 -7.059 
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56 
 
-8.114 -7.055 
57 
 
-8.302 -5.83 
58 
 
-7.719 -6.824 
59 
 
-4.914 -7.239 
60 
 
-6.949 -7.153 
61 
 
-5.35 -5.794 
62 
 
-4.54 -7.547 
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63 
 
-6.389 -7.314 
64 
 
-6.159 7.645 
65 
 
-6.571 -7.032 
66 
 
-7.899 -8.084 
67 
 
-7.64 -7.981 
68 
 
-6.638 -6.718 
69 
 
-6.541 -7.194 
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70 
 
-6.587 -7.234 
71 
 
-6.528 -6.934 
72 
 
-7.399 -5.903 
73 
 
-6.352 -7.51 
74 
 
-7.108 -5.29 
75 
 
-6.655 -7.761 
76 
 
-6.574 -7.018 
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77 
 
-7.602 -6.57 
78 
 
-6.47 -7.85 
79 
 
-6.727 -7.194 
80 
 
-4.915 -5.127 
81 
 
-6.229 -8.076 
82 
 
-5.874 -6.504 
83 
 
-7.872 -5.256 
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84 
 
-6.765 -6.968 
85 
 
-6.776 -6.821 
86 
 
-6.987 -5.306 
87 
 
-6.962 -7.962 
88 
 
-6.734 -6.614 
89 
 
-6.697 -7.198 
90 
 
-4.757 -7.314 
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91 
 
-4.867 -6.035 
92 
 
-6.839 -6.482 
93 
 
-6.656 -7.239 
94 
 
-7.228 -7.112 
95 
 
-7.807 -7.824 
96 
 
-7.567 -7.011 
97 
 
-6.751 -6.341 
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98 
 
-6.78 -6.332 
99 
 
-6.391 -6.449 
100 
 
-6.399 -5.973 
101 
 
-7.246 -5.212 
102 
 
-6.571 -7.059 
103 
 
-6.867 -4.405 
104 
 
-6.264 -6.454 
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105 
 
-6.826 -6.467 
106 
 
-6.696 -6.289 
107 
 
-7.573 -6.65 
108 
 
-7.216 -5.782 
109 
 
-6.692 -4.77 
110 
 
-6.972 -5.344 
111 
 
-7.265 -6.23 
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112 
 
-6.345 -4.89 
113 
 
-6.806 -6.568 
114 
 
-7.005 -6.618 
115 
 
-6.923 -5.106 
116 
 
-6.786 -6.633 
 
